



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 215/48, 295/13 C07C 311/46, 311/47, 317/50 C07C 323/60, 275/14</p>	A1	<p>(11) International Publication Number: WO 92/08688</p> <p>(43) International Publication Date: 29 May 1992 (29.05.92)</p>
<p>(21) International Application Number: PCT/US91/08617</p> <p>(22) International Filing Date: 18 November 1991 (18.11.91)</p> <p>(30) Priority data: 615,210 19 November 1990 (19.11.90) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 615,210 (CIP) Filed on 19 November 1990 (19.11.90)</p> <p>(71) Applicant (for all designated States except US): MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : BERTENSHAW, Deborah, Elizabeth [US/US]; 8758 Pine Avenue, Brentwood, MO 63144 (US). FRESKOS, John, Nicholas [US/US]; 7572 York, Clayton, MO 63105 (US). GETMAN, Daniel, Paul [US/US]; 12944 Summit Ridge Drive, St. Louis, MO 63146 (US). HEINTZ, Robert, Martin [US/US]; 603 Nancy Place, Ballwin, MO 63021 (US). LIN, Ko-Chung [CN/US]; 12790 Polo Parc Drive, St. Louis, MO 63146 (US). ROGIER, Donald, Joseph, Jr. [US/US]; 2346 Halfmoon Drive, Apartment 1, St. Louis, MO 63114 (US). TALLEY, John, Jeffrey [US/US]; 1510 Amisk Court, Chesterfield, MO 63017 (US).</p>		
<p>(74) Agent: BOLDING, James, Clifton; Monsanto Company, 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BJ (OAPI patent), CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL (European patent), NO, PL, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		
<p>(54) Title: RETROVIRAL PROTEASE INHIBITORS</p> <div style="display: flex; justify-content: space-around; align-items: flex-start; margin-top: 20px;"> <div style="text-align: center;"> <p>(I)</p> </div> <div style="text-align: center;"> <p>(A1)</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: flex-start; margin-top: 20px;"> <div style="text-align: center;"> <p>(A2)</p> </div> <div style="text-align: center;"> <p>(A3)</p> </div> <div style="text-align: center;"> <p>(II)</p> </div> </div>		
<p>(57) Abstract</p> <p>Compounds represented by formula (I), wherein A represents R, R¹³ and radicals represented by formulas (A1, A2, A3), B represents radicals represented by formula (II), (values for the variables given herein), are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.</p>		

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

RETROVIRAL PROTEASE INHIBITORS

This application is a continuation-in-part of
5 U. S. Patent Application Serial No. 07/615,210, filed
November 19, 1990.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to retroviral
10 protease inhibitors and, more particularly, relates to
novel compounds and a composition and method for
inhibiting retroviral proteases. This invention, in
particular, relates to urea-containing hydroxyethylamine
protease inhibitor compounds, a composition and method
15 for inhibiting retroviral proteases such as human
immunodeficiency virus (HIV) protease and for treating a
retroviral infection, e.g., an HIV infection. The
subject invention also relates to processes for making
such compounds as well as to intermediates useful in
20 such processes.

2. Related Art

During the replication cycle of retroviruses,
gag and gag-pol gene products are translated as
proteins. These proteins are subsequently processed by
25 a virally encoded protease (or proteinase) to yield
viral enzymes and structural proteins of the virus core.
Most commonly, the gag precursor proteins are processed
into the core proteins and the pol precursor proteins
are processed into the viral enzymes, e.g., reverse
30 transcriptase and retroviral protease. It has been
shown that correct processing of the precursor proteins
by the retroviral protease is necessary for assembly of
infectious virions. For example, it has been shown that
frameshift mutations in the protease region of the pol
35 gene of HIV prevents processing of the gag precursor
protein. Thus, attempts have been made to inhibit viral
replication by inhibiting the action of retroviral
proteases.

Retroviral protease inhibition typically involves a transition-state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds (typically in a reversible manner) to the enzyme in competition with the gag and gag-pol proteins to thereby inhibit replication of structural proteins and, more importantly, the retroviral protease itself. In this manner, retroviral proteases can be effectively inhibited.

Several classes of mimetic compounds have been proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such mimetics include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP O 346 847; EP O 342,541; Roberts et al, "Rational Design of Peptide-Based Proteinase Inhibitors, "Science, 248, 358 (1990); and Erickson et al, "Design Activity, and 2.8Å Crystal Structure of a C₂ Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 (1990).

Several classes of mimetic compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. No. 4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115, GB 2,209,752, EP O 264,795, U.S. SIR H725 and U.S. 4,599,198 disclose urea-containing hydroxyethylamine renin inhibitors. However, it is known that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally cannot be predicted to be effective HIV protease inhibitors.


BRIEF DESCRIPTION OF THE INVENTION

The present invention is directed to virus inhibiting compounds and compositions. More particularly, the present invention is directed to retroviral protease inhibiting compounds and compositions, to a method of inhibiting retroviral proteases, to processes for preparing the compounds and

to intermediates useful in such processes. The subject compounds are characterized as urea-containing hydroxyethylamine inhibitor compounds.

DETAILED DESCRIPTION OF THE INVENTION


In accordance with the present invention, there is provided a retroviral protease inhibiting compound of the formula:




(Formula I)

or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:


A represents radicals represented by the formulas:



(A1)



(A2)




(A3)

wher in

- R represents hydrogen and alkoxy carbonyl,
- 5 aralkoxy carbonyl, alkyl carbonyl, cycloalkyl carbonyl, cycloalkyl alkoxy carbonyl, cycloalkyl alkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbonyl, aryloxy alkanoyl, heterocyclyl carbonyl, heterocyclyloxy carbonyl, heterocyclyl alkanoyl,
- 10 heterocyclyl alkoxy carbonyl, heteroaralkoxy carbonyl, heteroaryloxy carbonyl, heteroaroyl, alkyl, aryl, aralkyl, aryloxy alkyl, heteroaryloxy alkyl, hydroxy alkyl, alkyl amino carbonyl, aryl amino carbonyl, aralkyl amino alkyl carbonyl, amino alkanoyl radicals,
- 15 alkyl amino alkyl carbonyl and mono- and disubstituted amino alkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkyl alkyl, heteroaryl, heteroaralkyl, heteroalkyl, heterocycloalkyl alkyl radicals;
- 20 R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteraryl radical;
- t represents either 0 or 1;
- 25 R¹ represents hydrogen, -CH₂SO₂NH₂, CO₂CH₃, CONH₂, alkyl, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine,
- 30 tert-leucine, phenylalanine, ornithine, alanine, histidine, norleucine, glutamine, valine, threonine, serine, aspartic acid, beta-cyano alanine, and allo-threonine side chains;
- R^{1'} and R^{1''} independently represent hydrogen and radicals
- 35 as defined for R¹;
- R² represents alkyl, aryl, cycloalkyl, cycloalkyl alkyl and aralkyl radicals, which radicals are optionally substituted with a group selected

from $-\text{NO}_2$, $-\text{OR}^9$, $-\text{SR}^9$, and halogen radicals, wherein R^9 represents hydrogen and alkyl radicals;
 R^3 represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;
 X' represents O, $\text{C}(\text{R}^{17})$ where R^{17} represents hydrogen and alkyl radicals, and N;
 Y , Y' , and Y'' independently represent O, S and NR^{15} wherein R^{15} represents hydrogen and radicals as defined for R^3 ;
 B represents radicals represented by the formula:

15



20

wherein


n represents an integer of from 0 to 6, R^7 and $\text{R}^{7'}$ independently represent radicals as defined for R^3 and amino acid side chains selected from the group consisting of valine, isoleucine, glycine, alanine, allo-isoleucine, asparagine, leucine, glutamine, and t-butylglycine or R^7 and $\text{R}^{7'}$ together with the carbon atom to which they are attached form a cycloalkyl radical; and R^8 represents cyano, hydroxyl, alkyl, alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl and heteroaryl radicals and radicals represented by the formulas $\text{C}(\text{O})\text{R}^{16}$, CO_2R^{16} , SO_2R^{16} , SR^{16} , $\text{CONR}^{16}\text{R}^{17}$, OR^{16} , CF_3 and $\text{NR}^{16}\text{R}^{17}$ wherein R^{16} and R^{17} independently represent hydrogen and radicals as defined for R^3 or R^{16} and R^{17} together with a nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radicals.
 R^4 independently represents hydrogen and radicals as defined by R^3 ;

R^6 represents hydrogen and radicals as defined for R^3 ;
 R^{20} , R^{21} , R^{30} , R^{31} and R^{32} represent radicals as defined for
 R^1 , or one of R^1 and R^{30} together with one of R^{31} and
 R^{32} and the carbon atoms to which they are attached
 5 form a cycloalkyl radical; and
 R^{33} and R^{34} independently represent hydrogen and radicals
 as defined for R^3 , or R^{33} and R^{34} together with X
 represent cycloalkyl, aryl, heterocyclyl and
 heteroaryl radicals, provided that when X' is O, R^{34}
 10 is absent.

A preferred class of retroviral inhibitor
 compounds of the present invention are those represented
 by the formula:

15

20



or a pharmaceutically acceptable salt, prodrug or ester
 25 thereof, preferably wherein the stereochemistry about
 the hydroxy group is designated as (R);
 R represents hydrogen and alkoxycarbonyl,
 aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
 cycloalkylalkoxycarbonyl, cycloalkylalkanoyl,
 30 alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,
 aryloxyalkanoyl, heterocyclylcarbonyl,
 heterocyclyloxycarbonyl, heterocyclylalkanoyl,
 heterocyclylalkoxycarbonyl, heteroaralkoxycarbonyl,
 heteroaryloxycarbonyl, heteroaroyl, alkyl, aryl,
 35 aralkyl, aryloxyalkyl, heteroaryloxyalkyl,
 hydroxyalkyl, alkylaminocarbonyl, arylaminocarbonyl,
 aralkylaminoalkylcarbonyl, aminoalkanoyl radicals,
 alkylaminoalkylcarbonyl and mono- and disubstituted
 aminoalkanoyl radicals wherein the substituents are
 40 selected from alkyl, aryl, aralkyl, cycloalkyl,

cycloalkylalkyl, heteroaryl, heteroaralkyl,
heteroalkyl, heterocycloalkyl radicals;

R' represents hydrogen and radicals as defined for R³ or R
and R' together with the nitrogen to which they are
5 attached represent heterocycloalkyl and heteroaryl
radical;

R¹ represents hydrogen, -CH₂SO₂NH₂, CO₂CH₃, CONH₂, alkyl
and cycloalkyl radicals, and amino acid side chains
selected from asparagine, S-methyl cysteine and the
10 sulfoxide (SO) and sulfone (SO₂) derivatives thereof,
isoleucine, allo-isoleucine, alanine, leucine, tert-
leucine, phenylalanine, ornithine, histidine,
norleucine glutamine, threonine, glycine, allo-
threonine, serine, aspartic acid, beta-cyano alanine
15 and valine side chains;

R^{1'} and R^{1''} independently represent hydrogen and radicals
as defined for R¹;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl,
and aralkyl radicals, which radicals are
20 optionally substituted with a group selected from
alkyl radicals, -NO₂, OR⁹ and SR⁹ wherein R⁹
represents hydrogen and alkyl radicals, and
halogen radicals;

R³ represents alkyl, alkenyl, cycloalkyl,
25 cycloalkylalkyl, heterocycloalkyl,
heterocycloalkylalkyl, aryl, heteroaryl, aralkyl and
heteroaralkyl radicals; and

R⁴ represents hydrogen and radicals as defined for R³;

B represents radicals represented by the formula:
30




40 wherein n represents an integer of from 0 to 6, R⁷ and
R^{7'} independently represent radicals as defined for R³ and

- amino acid side chains selected from the group consisting of valine, isoleucine, glycine, alanine, allo-isoleucine, asparagine, leucine, glutamine, and t-butylglycine or R^7 and $R^{7'}$ together with the carbon atom to which they are attached form a cycloalkyl radical; and R^8 represents cyano, hydroxyl, alkyl, alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl and heteroaryl radicals and radicals represented by the formulas $C(O)R^{16}$, CO_2R^{16} , SO_2R^{16} , SR^{16} , $CONR^{16}R^{17}$, CF_3 and $NR^{16}R^{17}$ wherein R^{16} and R^{17} independently represent hydrogen and radicals as defined for R^3 or R^{16} and R^{17} together with a nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radicals.
- t represents 0 or 1; and
- 15 Y represents O, S, and NR^{15} wherein R^{15} represents hydrogen and radicals as defined for R^3 . Preferably, Y and Y' represent O.

Preferably, R^3 represents radicals as defined above which contain no α -branching, e.g., as in an isopropyl radical or a t-butyl radical. The preferred radicals are those which contain a $-CH_2-$ moiety between the nitrogen of the urea and the remaining portion of the radical. Such preferred groups include, but are not limited to, benzyl, isoamyl, cyclohexylmethyl, 4-pyridylmethyl and the like.


Another preferred class of compounds are those represented by the formula:



(Formula III)

- 40 or a pharmaceutically acceptable salt, prodrug or ester thereof wherein B, Y, Y' , R^1 , R^1 , R^2 , R^3 , R^4 , R^{20} and R^{21} are as defined above.

Yet another preferred class of compounds are those represented by the formula:



5

(Formula IV)

or a pharmaceutically acceptable salt, prodrug or ester thereof wherein t, B, X', Y, Y', Y'', R¹, R², R³, R⁴, R³⁰,
 10 R³¹, R³², R³³ and R³⁴ are as defined above.

As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing from 1 to about 10, preferably from 1 to about 8, carbon atoms. Examples of such
 15 radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octyl and the like. The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of
 20 suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. The term "cycloalkyl" means an alkyl radical which contains from about 3 to about 8 carbon atoms and is cyclic. The term "cycloalkylalkyl"
 25 means an alkyl radical as defined above which is substituted by a cycloalkyl radical containing from about 3 to about 8, preferably from about 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl
 30 and the like. The term "aryl", alone or in combination, means a phenyl or naphthyl radical which optionally

carries one or more substituents selected from alkyl, alkyl, halogen, hydroxy, amino and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like. The term "aralkyl", alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like. The term "aralkoxy carbonyl", alone or in combination, means a radical of the formula $-C(O)-O-$ aralkyl in which the term "aralkyl" has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl. The term "aryloxy" means a radical of the formula aryl-o- in which the term aryl has the significance given above. The term "alkanoyl", alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term "cycloalkylcarbonyl" means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid which is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The term "aralkanoyl" means an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl, and the like. The term "aroyl" means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-

carboxy-2 naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like. The heterocyclyl or heterocycloalkyl portion of a

5 heterocyclylcarbonyl, heterocyclylloxycarbonyl, heterocyclylalkoxycarbonyl, or heterocyclylalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle which contains one or more hetero atoms selected from

10 nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., -NH-) by alkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary

15 nitrogen atom (i.e. = N-) by oxido and which is attached via a carbon atom. The heteroaryl portion of a heteroaryl, heteroarylloxycarbonyl, or a heteroarylalkoxy carbonyl group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle which contains the

20 hetero atoms and is optionally substituted as defined above with respect to the definition of heterocyclyl. Examples of such heterocyclyl and heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol-4-

25 yl, 1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, thienyl, triazolyl, oxazolyl, thiazolyl, indolyl (e.g., 2-indolyl, etc.), quinolyl (e.g., 2-quinolyl, 3-quinolyl, 1-oxido-2-quinolyl, etc.), isoquinolyl (e.g., 1-

30 isoquinolyl, 3-isoquinolyl, etc.), tetrahydroquinolyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, etc.), 1,2,3,4-tetrahydroisoquinolyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolyl, etc.), quinoxalinyl, β -carboline, 2-benzofurancarboxyl, 1-, 2-, 4-5-benzimidazolyl, and the

35 like. The term "cycloalkylalkoxycarbonyl" means an acyl group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O-COOH wherein cycloalkylalkyl has the significance given above. The


term "aryloxyalkanoyl" means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term "heterocyclyloxycarbonyl" means an acyl group derived from heterocyclyl-O-COOH wherein heterocyclyl is as defined above. The term "heterocyclylalkanoyl" is an acyl radical derived from a heterocyclyl-substituted alkane carboxylic acid wherein heterocyclyl has the significance given above. The term "heterocyclylalkoxycarbonyl" means an acyl radical derived from a heterocyclyl-substituted alkane-O-COOH wherein heterocyclyl has the significance given above. The term "heteroaryloxycarbonyl" means an acyl radical derived from a carboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl has the significance given above. The term "aminoalkanoyl" means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term "halogen" means fluorine, chlorine, bromine or iodine. The term "leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine or an alcohol nucleophile. Such leaving groups are well known and include carboxylates, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates -OR and -SR and the like. Preferred leaving groups are indicated herein where appropriate.

Procedures for preparing the compounds of Formula I are set forth below. It should be noted that the general procedure is shown as it relates to preparation of compounds having the specified stereochemistry, for example, wherein the stereochemistry about the hydroxyl group is designated as (R). However, such procedures are generally applicable, as illustrated in Example 45, to those compounds of opposite configuration, e.g.,

where the stereochemistry about the hydroxyl group is (S).

Preparation of Compounds of Formula II


The compounds of the present invention represented by Formula II above can be prepared utilizing the following general procedure. An N-protected chloroketone derivative of an amino acid having the formula:



wherein P represents an amino protecting group, and R² is as defined above, is reduced to the corresponding alcohol utilizing an appropriate reducing agent. Suitable amino protecting groups are well known in the art and include carbobenzoxy, butyryl, t-butoxycarbonyl, acetyl, benzoyl and the like. A preferred amino protecting group is carbobenzoxy. A preferred N-protected chloroketone is N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone. A preferred reducing agent is sodium borohydride. The reduction reaction is conducted at a temperature of from -10°C to about 25°C, preferably at about 0°C, in a suitable solvent system such as, for example, tetrahydrofuran, and the like. The N-protected chloroketones are commercially available from Bachem, Inc., Torrance, California. Alternatively, the chloroketones can be prepared by the procedure set forth in S. J. Fittkau, J. Prakt. Chem., 315, 1037 (1973), and subsequently N-protected utilizing procedures which are well known in the art.

The resulting alcohol is then reacted, preferably at room temperature, with a suitable base in a suitable solvent system to produce an N-protected amino epoxide of the formula:

14



10

wherein P and R² are as defined above. Suitable solvent systems for preparing the amino epoxide include ethanol, methanol, isopropanol, tetrahydrofuran, dioxane, and the like including mixtures thereof. Suitable bases for producing the epoxide from the reduced chloroketone include potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBU and the like. A preferred base is potassium hydroxide.

The amino epoxide is then reacted, in a suitable solvent system, with an excess of a desired amine of the formula:




wherein R³ is hydrogen or is as defined above. The reaction can be conducted over a wide range of temperatures, e.g., from about 10°C to about 100°C, but is preferably, but not necessarily, conducted at a temperature at which the solvent begins to reflux. Suitable solvent systems include those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, and toluene, N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A preferred solvent is isopropanol. Exemplary amines corresponding to the formula R³NH₂ include benzyl amine, isobutylamine, n-butyl amine, isopentyl amine, isoamylamine, cyclohexanemethyl amine, naphthylene methyl amine and the like. The resulting product is a 3-(N-protected amino)-3-(R²)-1-(NHR³)-propan-2-ol derivative (hereinafter referred to as an amino alcohol)

15

is a novel intermediate and can be represented by the formula:

5




10

wherein P, R² and R³ are as described above.

A salt of the resulting amino alcohol described above is then reacted, in a suitable solvent system, with carbonyldiimidazole and an amine salt to produce a urea derivative of the amino alcohol. This reaction can be represented as follows:

20




25

30

wherein R⁴ is as described above and L represents a leaving group such as a halide, e.g., chloride, imidazole radical, the radical p-NO₂-(C₆H₄)-O-, and the like is prepared by reacting a carbonyldiimidazole with an amine salt, e.g., the hydrochloride salt of a compound represented by the formula:

40




45

in a suitable solvent such as, for example, chloroform. The resulting product is then reacted with the salt,

such as, for example, the hydrochloride salt, of the amino alcohol described above. The corresponding sulfur analogs can be utilized where Y of Formula II is S.

Alternatively, one can react the amino alcohol
5 with an isocyanate of the formula:



15 either in the presence or absence of a suitable base, such as triethylamine, diisopropylethylamine, and the like in a suitable solvent such as toluene, methylene chloride, chloroform or tetrahydrofuran. The isocyanate
20 can be readily prepared and isolated, if desired, by standard methods such as the reaction of an amine of the formula:



30


with phosgene or a phosgene equivalent, such as triphosgene, in the presence or absence of a suitable
35 base, such as triethylamine, diisopropylamine and the like in a suitable solvent such as toluene, methylene chloride, chloroform or tetrahydrofuran. Alternatively, one can generate the isocyanate in situ by the Curtius rearrangement of a carboxylic acid of the formula:

40

45

17

5




10

by an appropriate method. One such method is by the reaction of the carboxylic acid with diphenylphosphoryl azide in the presence of a suitable base, such as triethylamine, N-methylmorpholine or diisopropylethylamine, in a suitable solvent such as toluene, methylene chloride, chloroform and tetrahydrofuran and the like.

The carboxylic acids are either commercially available or can be prepared in a number of ways, which are known to those skilled in the art. For example, one can form the dianion of a carboxylic acid (or the monoanion of the corresponding ester) of the formula:


25

30



by deprotonation with a strong base, such as lithium diisopropyl amide or lithium hexamethyldisilazide, in a suitable solvent such as tetrahydrofuran and react the anion or dianion with an electrophilic reagent of the formula:

40



45


where X is an appropriate leaving group such as chloride, bromide, iodide, methanesulfonyl, p-

toluenesulfonyl or trifluoromethanesulfonyl and the like.

Alternatively, one can alkylate a diester of malonic acid of the formula:

5

10



15

20 where P' is a suitable acid protecting groups such as methyl, ethyl, isopropyl, benzyl, tertiary-butyl, trimethylsilyl, t-butyldimethylsilyl, and the like, with appropriate electrophiles;




25 where R⁷, R^{7'} and X are as defined above, in the presence of a suitable base such as sodium hydride, potassium hydride, sodium alkoxide or potassium alkoxide.


Suitable alkoxides being methoxide, ethoxide, isopropoxide and tertiary-butoxide and the like. The reaction is carried out in a suitable solvent such as tetrahydrofuran, N,N-dimethylformamide or an alcohol solvent, such as methanol, ethanol, isopropanol or tertiary-butanol. The reaction with R⁷ and R^{7'} can be done sequentially if R⁷ and R^{7'} are different, or
30 simultaneously if R⁷ and R^{7'} are identical or form a cyclic ring during the alkylation step. The resulting product is a mono- or di-substituted malonate diester of the formula:

40

45




In order to generate the carboxylic acid required for the Curtius rearrangement, the acid protecting group P' is selectively removed. Suitable methods for removal are (1) hydrolysis with lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, (2) acidolysis with an acid such as hydrochloric acid, hydrobromic acid, trifluoroacetic acid and the like, and (3) hydrogenolysis with hydrogen in the presence of a suitable catalyst such as palladium-on-carbon. The resulting carboxylic acid has the formula:



30


In the case where R^8 is an amino group $NR^{16}R^{17}$, the amino group can be introduced either by displacement of an appropriate leaving group or reductive amination with an appropriate aldehyde. The displacement of the leaving group from an ester of the formula:




45

where P' and X are as defined above, can be readily accomplished by one skilled in the art. The protecting

group P' is then removed by the methods discussed above to provide the required carboxylic acid of the formula:



The reductive amination procedure is readily accomplished by the reaction of an aldehyde of the formula:



30

with the amine $\text{HNR}^{16}\text{R}^{17}$ in the presence of sodium cyanoborohydride or hydrogen and a suitable catalyst, such as palladium-on-carbon, and the acid protecting group P' is removed by the methods discussed above. The required aldehydes can be prepared by a number of methods well-known to those in the art. Such methods include reduction of an ester, oxidation of an alcohol or ozonolysis of an olefin.

In the case where R^8 is a keto-group and t is 0, one can mono- or dialkylate an ester of acetoacetic acid of the formula:


45

21




10

as described above for the malonate diesters to provide a compound of the formula:




25

The acid protecting group can be removed to provide the desired carboxylic acid for the Curtius rearrangement, or the ketone can be converted to a ketal, such as the dimethyl ketal, diethyl ketal or ethylene glycol ketal, by reaction with the appropriate alcohol in the presence of a suitable acid, such as p-toluenesulfonic acid or the like, and a dehydrating agent such as trimethyl- or triethylorthoformate to provide, for example, a compound of the following formula:



50 The protecting group P' can then be removed to provide a compound of the formula:




15

which is suitable for the Curtius rearrangement. If desired, the ketal group can be converted at any time during the subsequent synthesis to the corresponding ketone by hydrolysis in the presence of an acid such as aqueous hydrochloric acid.

The urea derivative of the amino alcohol, and the corresponding sulfur analog, are novel intermediates and can be represented by the formula:

25




30

35

Following preparation of the urea derivative, or corresponding analogs wherein Y is S, the amino protecting group P is removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of the protecting group, e.g., removal of a carbobenzoxy group, by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or

mixtures thereof. Where the protecting gr up is a t-butoxycarbonyl group, it can be removed utilizing an inorganic or organic acid, e.g., HCl or trifluoroacetic acid, in a suitable solvent system, e.g., dioxane or methylene chloride. The resulting product is the amine salt derivative. Following neutralization of the salt, the amine is then reacted with an amino acid or corresponding derivative thereof represented by the formula $(PN[CR^1R^2]CH(R^3)COOH)$ wherein t, R^1 , R^2 , and R^3 are as defined above, to produce the antiviral compounds of the present invention having the formula:




20

wherein t, B, P, R^1 , R^2 , R^3 , R^4 , and Y are as defined above. Preferred protecting groups in this instance are a benzyloxycarbonyl group or a t-butoxycarbonyl group. Where the amine is reacted with a derivative of an amino acid, e.g., when t=1 and R^1 and R^2 are both H, so that the amino acid is a β -amino acid, such β -amino acids can be prepared according to the procedure set forth in a copending application, U. S. Serial No. 07/345,808. Where t is 1, one of R^1 and R^2 is H and R^3 is hydrogen so that the amino acid is a homo- β -amino acid, such homo- β -amino acids can be prepared by the same procedure. Where t is 0 and R^1 is alkyl, cycloalkyl, $-CH_2SO_2NH_2$ or an amino acid side chain, such materials are well known and many are commercially available from Sigma-Aldrich.


The N-protecting group can be subsequently removed, if desired, utilizing the procedures described above, and then reacted with a carboxylate represented by the formula:

5




- 10 wherein R is as defined above and L is an appropriate
leaving group such as a halide. Preferably, when R¹ is a
side chain of a naturally occurring α -amino acid, R is a
2-quinoline carbonyl group derived from N-
hydroxysuccinimide-2-quinoline carboxylate, i.e., L is
15 hydroxy succinimide or R is a 2-benzofuroyl (2-
benzofurancarbonyl) derived from benzofuran-2-carboxylic
acid. A solution of the free amine (or amine acetate
salt) and about 1.0 equivalent of the carboxylate are
mixed in an appropriate solvent system and optionally
20 treated with up to five equivalents of a base such as,
for example, N-methylmorpholine, at about room
temperature. Appropriate solvent systems include
tetrahydrofuran, methylene chloride or N,N-
dimethylformamide, and the like, including mixtures
25 thereof.

Alternatively, the protected amino alcohol from the epoxide opening can be further protected at the newly introduced amino group with a protecting group P' which is not removed when the first protecting P is removed. One skilled in the art can choose appropriate combinations of P and P'. One suitable choice is when P is Cbz and P' is Boc. The resulting compound represented by the formula:



can be carried through the remainder of the synthesis to provide a compound of the formula:




and the new protecting group P' is selectively removed, and following deprotection, the resulting amine reacted to form the urea derivative as described above. This selective deprotection and conversion to the urea can be accomplished at either the end of the synthesis or at any appropriate intermediate step if desired. This alternate procedure is also suitable for producing compounds at formulas III-VI.

Preparation of Compounds of Formula III


A mercaptan of the formula R'SH is reacted with a substituted methacrylate of the formula:

26



10

by way of a Michael Addition. The Michael Addition is conducted in a suitable solvent and in the presence of a suitable base, to produce the corresponding thiol derivative represented by the formula:



20

25


wherein R and R¹ represent radicals defined above; R²⁰ and R²¹ represent hydrogen and radicals as defined for R¹; and R²² represents radicals as defined by R³.

Suitable solvents in which the Michael Addition can be conducted include alcohols such as, for example, methanol, ethanol, butanol and the like, as well as ethers, e.g., THF, and acetonitrile, DMF, DMSO, and the like, including mixtures thereof. Suitable bases include Group I metal alkoxides such as, for example sodium methoxide, sodium ethoxide, sodium butoxide and the like as well as Group I metal hydrides, such as sodium hydride, including mixtures thereof.

The thiol derivative is converted into the corresponding sulfone of the formula:

45


5



10 by oxidizing the thiol derivative with a suitable
 oxidation agent in a suitable solvent. Suitable
 oxidation agents include peracids such as, for example,
 sodium meta-perborate, oxone (potassium peroxy
 monosulfate), meta-chloroperoxybenzoic acid, and the
 15 like, including mixtures thereof. Suitable solvents
 include acetic acid (for sodium meta-perborate) and, for
 other peracids, ethers such as THF and dioxane, and
 acetonitrile, DMF, DMSO, and the like, including
 mixtures thereof.

20 The sulfone is then converted to the
 corresponding free acid of the formula:

25




30 utilizing a suitable base, e.g., lithium hydroxide,
 sodium hydroxide, and the like, including mixtures
 thereof, in a suitable solvent, such as, for example,
 THF, acetonitrile, DMF, DMSO, methylene chloride and the
 35 like, including mixtures thereof.

The free acid is then coupled, utilizing, as
 described above, procedures well known in the art, to
 the urea derivative, or analog thereof, of an amino
 alcohol which is described above for the preparation of
 40 compounds of Formula II. The resulting product is a
 compound represented by Formula III.

Alternatively, one can couple the urea
 isostere to the commercially available acid,


5



10 remove the thioacetyl group with a suitable base, such as hydroxide, or an amine, such as ammonia, and then react the resulting thiol with an alkylating agent, such as an alkyl halide, tosylate or mesylate to afford compounds of the following structure:

15

20




25

The sulfur can then be oxidized to the corresponding sulfone using suitable oxidizing agents, as described above, to afford the desired compounds of the following structure:

30


35



40

Alternatively, to prepare compounds of Formula III, a substituted methacrylate of the formula:

45



50

wherein


L represents a leaving group as previously defined,
 R^{35} and R^{36} represent hydrogen and radicals as defined for
 R^1 ; and

- 5 R^{37} represents alkyl, aralkyl, cycloalkyl and
 cycloalkylalkyl radicals, is reacted with a suitable
 sulfonating agent, such as, for example, a sulfinic
 acid represented by the formula RSO_2M ,

wherein

- 10 R' represents radicals as defined above and M
 represents a metal adapted to form a salt of the
 acid, e.g., sodium, to produce the corresponding
 sulfone represented by the formula:


15



20

- wherein R' , R^{35} , R^{36} and R^{37} are as defined above. The
 25 sulfone is then hydrolyzed in the presence of a suitable
 base, such as lithium hydroxide, sodium hydride and the
 like, to the compound represented by the formula:


30



35

- wherein R , R^{35} and R^{36} represent radicals as defined
 above. The resulting compound is then asymmetrically
 hydrogenated utilizing an asymmetric hydrogenation
 40 catalyst such as, for example, a ruthenium-BINAP
 complex, to produce the reduced product, substantially
 enriched in the more active isomer, represented by the
 formula:

45




15

wherein R' , R^{35} and R^{36} represent radicals as defined above. Where the more active isomer has the R-stereochemistry, a Ru(R-BINAP) asymmetric hydrogenation catalyst can be utilized. Conversely, where the more active isomer has the S-stereochemistry, a Ru(S-BINAP) catalyst can be utilized. Where both isomers are active, or where it is desired to have a mixture of the two diastereomers, a hydrogenation catalyst such as platinum, or palladium, on carbon can be utilized to reduce the above compound. The reduced compound is then coupled to the urea isostere, as described above, to produce compounds of Formula III.

Preparation of Compounds of Formula IV

To produce compounds of Formula IV, starting with a lactate of the formula:




40

wherein P'' represents alkyl radicals, such as, for example, methyl, ethyl, and the like. The hydroxyl group of the lactate is protected as its ketal by reaction in a suitable solvent system with methyl isopropenyl ether (1,2-methoxypropene) in the presence of a suitable acid. Suitable solvent systems include

methylene chloride, DMF, and the like, including mixtures thereof. Suitable acids include POCl_3 , HCl , and the like. It should be noted that well-known groups other than methyl isopropenyl ether can be utilized to form the ketal. The ketal is then reduced with diisobutylaluminum hydride (DIBAL) at -78°C to produce the corresponding aldehyde which is then treated with ethylidene triphenylphosphorane (Wittig reaction) to produce a compound represented by the formula:

10

15




20

The ketal protecting group is then removed utilizing procedures well-known in the art such as by mild acid hydrolysis. The resulting compound is then esterified with isobutyryl chloride to produce a compound of the formula:

30

35



40

This compound is then treated with lithium diisopropyl amide at -78°C followed by warming of the reaction mixture to room temperature to effect a Claisen rearrangement ([3,3]) to produce the corresponding acid represented by the formula:

45



15 Treatment of the acid with benzyl bromide in the presence of a tertiary amine base, e.g., DBU, produces the corresponding ester which is then cleaved oxidatively to give a trisubstituted succinic acid:



30 The trisubstituted succinic acid is then coupled to the urea isostere as described above. To produce the free acid, the benzyl ester is removed by hydrogenolysis to produce the corresponding acid. The acid can then be converted to the primary amide by


35 methods well-known in the art.

 An alternative method for preparing trisubstituted succinic acids involves reacting an ester of acetoacetic acid represented by the formula:




wherein R is a suitable protecting group, such as methyl, ethyl, benzyl or t-butyl, with sodium hydride and a hydrocarbyl halide ($R^{31}X$ or $R^{32}X$) in a suitable solvent, e.g., THF, to produce the corresponding

5 disubstituted derivative represented by the formula:



15 This disubstituted acetoacetic acid derivative is then treated with lithium diisopropyl amide at about -10°C and in the presence of $\text{PhN}(\text{triflate})_2$ to produce a vinyl triflate of the formula:




30 The vinyl triflate is then carbonylated utilizing a palladium catalyst, e.g., $\text{Pd}_2(\text{OAc})_2(\text{Ph}_3\text{P})$, in the presence of an alcohol ($R''\text{OH}$) or water ($R''=\text{H}$) and a base, e.g., triethylamine, in a suitable solvent such as

35 DMF, to produce the olefinic ester or acid of the formula:




The olefin can then be subsequently asymmetrically
 hydrogenated, as described above, to produce a
 trisubstituted succinic acid derivative of the formula:



15

If R'' is not H, R'' can be removed by hydrolysis,
 acidolysis or hydrogenolysis, to afford the
 corresponding acid which is then coupled to the urea
 isostere as described above and then, optionally, the R
 group is removed to produce the corresponding acid, and,
 optionally, converted to the amide.


Alternatively, one can react the urea isostere
 with either a suitably monoprotected succinic acid or
 glutaric acid of the following structure;



35

where P is a suitable protecting group, such as benzyl
 or t-butyl or the like, and remove the protecting group
 and convert the resulting acid to an amide. One can
 also react an anhydride of the following structure;

45



5
10 with the urea isostere and separate any isomers or convert the resulting acid to an amide and separate any isomers.

It is contemplated that for preparing
15 compounds of the Formulas having R^6 , the compounds can be prepared following the procedure set forth above and, prior to coupling the urea derivative or analog thereof to the amino acid $\text{PNH}(\text{CH}_2)_t\text{CH}(\text{R}^1)\text{COOH}$, carried through a procedure referred to in the art as reductive amination.
20 Thus, a sodium cyanoborohydride and an appropriate aldehyde $\text{R}^6\text{C}(\text{O})\text{H}$ or ketone $\text{R}^6\text{C}(\text{O})\text{R}^6$ can be reacted with the urea derivative compound or appropriate analog at room temperature in order to reductively aminate any of the compounds of Formulas I-VI. It is also contemplated
25 that where R^3 of the amino alcohol intermediate is hydrogen, the inhibitor compounds can be prepared through reductive amination of the final product of the reaction between the amino alcohol and the amine or at any other stage of the synthesis for preparing the
30 inhibitor compounds.

Contemplated equivalents of the general
formulas set forth above for the antiviral compounds and derivatives as well as the intermediates are compounds
otherwise corresponding thereto and having the same
35 general properties wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than that indicated. In addition, where a substituent is designated as, or can be, a hydrogen, the exact
40 chemical nature of a substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical

or a halogen, hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.

The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.


Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

All reagents were used as received without purification. All proton and carbon NMR spectra were obtained on either a Varian VXR-300 or VXR-400 nuclear magnetic resonance spectrometer.

Example 1

This example illustrates preparation of compounds wherein B represents:


5



10

15 **Methyl aminoisobutyrate hydrochloride.**

20



25

A 500 mL round bottomed flask equipped with nitrogen inlet, thermometer adapter, solids addition funnel, and magnetic stirrer was placed in an ice salt bath and charged with 100 mL of methanol. To this solution was added thionyl chloride (18.0 mL, 0.25 mol) via syringe at such a rate that the internal temperature was maintained at less than 0 °C. This solution was then treated with aminoisobutyric acid (19.6g, 0.19 mol) portion wise from the addition funnel at such a rate that the temperature did not rise above 5 °C. The ice bath was removed and replaced with an oil bath and the solution warmed to 50 °C for 1h and then concentrated in vacuo. The salt was thoroughly dried under vacuum to give the desired product as a white solid 28g, 96%, mp 185 °C. ¹H nmr (CDCl₃) 300 MHz 8.87 (brs, 3H), 3.74 (s, 3H), 1.65 (s, 6H).


40

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-methyl ester, [3S- (3R*, 6R*, 7S*)]-

45

5

10



15

A 100 mL round bottomed flask equipped with a reflux condenser, nitrogen inlet, and magnetic stir bar was charged with methyl aminoisobutyrate hydrochloride (298 mg, 1.95 mmol) and 30 mL of chloroform. The slurry was warmed to reflux whereupon the salt dissolved and then the solution was treated with carbonyldiimidazole (317 mg, 1.95 mmol) and maintained at this temperature for 40 m. In a separate 50 mL round bottomed flask was placed the hydrochloride of (2R,3S)-3-amino-1-(3-methylbutyl)-1-[(1,1-dimethylethyl)amino] carbonyl)-4-phenyl-2-butan-1-ol (910 mg, 1.68 mmol), 20 mL of chloroform and triethylamine (648 mg, 6.40 mmol). This mixture was stirred at room temperature for 30 m and then added to the 100 mL round bottomed flask. The entire mixture was heated to 50 °C for 16 h and then poured into a separatory funnel. The mixture was diluted with 5% aq. citric acid and the phases separated. The organic phase was washed with an additional portion of citric acid, sat. aq. NaHCO₃, brine, dried over anhyd. MgSO₄, filtered and concentrated in vacuo to give a white solid, 820 mg, 75%, that was further purified by flash chromatography over SiO₂ eluting with methanol/CH₂Cl₂. The pure product was isolated by concentration of the appropriate fraction, 410 mg, 38% yield along with 150 mg of 95% pure product.

Example 2A. General Procedure for Curtius Rearrangement and Reaction with Amino Alcohol Derivative.

To a solution of 1 mmol of carboxylic acid in 12 mL of
5 toluene and 3 mmol of triethylamine at 90°C under a
nitrogen atmosphere, was added 1 mmol of
diphenylphosphoryl azide. After 1 hour, a solution of 1
mmol of amino alcohol derivative in 3.5 mL of either
N,N-dimethylformamide or toluene was added. After 1
10 hour, the solvent was removed under reduced pressure,
ethyl acetate and water added and the layers separated.
The organic layer was washed with 5% citric acid, sat d
sodium bicarbonate, brine, dried, filtered and
concentrated to afford the crude product. This was then
15 recrystallized or chromatographed on silica gel to
afford the purified final compound.

B. Preparation of Intermediate.B1. Preparation of mono-tertiary-butyl 2,2-dimethylmalonate.

20 To a solution of mono-methyl mono-t-butyl malonate
(20.5g, 117.7 mmol) in THF (275 ml) was added NaH
(2.95g, 117.7 mmol) in portions at 0°C over 15 min then
stirred at r.t. for 30 min. The mixture was then cooled
to 0°C and to this was added MeI (7.5 ml, 118 mmol)
25 slowly and stirred at r.t. for 1 h. After it was cooled
to 0°C, to this cold solution was added NaH (2.95g, 118
mmol) then MeI (7.5 ml, 118 mmol) by following the
procedure described above. A usual workup (10 ml sat.
NH₄Cl, 100 ml Et₂O-pet ether, 5% HCl, 5% NaHCO₃, finally
30 sat. NaCl) gave 16.2g (68%) of desired product as a pale
yellow oil. The oil (10.1g, 50.0 mmol) was dissolved in
MeOH (150 ml) and to this was added 1.25N NaOH (20 ml of
2.5N NaOH with 20 ml of H₂O, 50.0 mmol) over a period of
2 h and stirred at 0°C for 3 h and r.t. for 16 h.
35 Removal of solvents in vacuo (<40°C) gave an oil. The
oil was dissolved in water (125 ml) and extracted with
Et₂O (25 ml). The aqueous layer was collected and
acidified with 6N HCl (a white precipitate was formed

immediately) to pH ~ 1 and extracted with Et₂O (75 ml x 3). The combined extracts were washed with sat. NaCl (50 ml), dried (Na₂SO₄) and concentrated to afford 7.1g (75%) of mono-tertiary-butyl 2,2-dimethylmalonate as a white solid.

B2. Preparation of 2,2-Dimethylmalonate, mono-ethyl ester.

- 10 To a suspension of NaH (2.5g, 95%, 100 mmol) in dry THF (200 ml) was added diethylmalonate (8.0g, 50 mmol) slowly at 0°C and stirred at r.t. for 1 h. The solution was cooled to 0°C and to this was added a solution of MeI (14.9g, 105 mmol) in THF (20 ml) slowly. The mixture was stirred at 0°C for 1 h, r.t. for 2 h and diluted with Et₂O-Pet ether (5:1, 150 ml) then washed with H₂O (80 ml) and sat. NaCl solution (50 ml). The organic phase was separated, dried (Na₂SO₄) and concentrated to afford 8.2g (87%) of desired product as an oil. This oil was dissolved in EtOH (50 ml) and cooled to 0°C. To this cold solution was added 10% NaOH (20 ml, 50 mmol) dropwise at 0°C and stirred at 0°C for 2 h, at r.t. for 16 h. Removal of solvents gave an oil. The oil was dissolved in H₂O (40 ml) and Et₂O (20 ml). The aqueous layer was separated and acidified with 6N HCl to pH ~ 1 then extracted with ether (50 ml x 2). The combined extracts were washed with sat. NaCl (20 ml), dried (Na₂SO₄) and concentrated to afford 6.5g (81%) of desired acid as an oil.

30

B3. Preparation of 2-Ethyl-2-methylmalonate, mono-ethyl ester.

- To a suspension of NaH (1.25g, 95%, 50 mmol) in dry THF (200 ml) was added diethylmalonate (8.0g, 50 mmol) slowly at 0°C. The reaction mixture was allowed to warm up to r.t. and stirred for 1 h then cooled to 0°C. To this cold solution was added MeI (7.1g, 50 mmol) dropwise. After the resulting mixture was stirred at

- r.t. for 2 h, it was cooled to 0°C. To the cold solution was added EtBr (5.6g, 5.1 mmol) and stirred at r.t. for 2 h. The mixture was diluted with ether-Pet ether (5:1, 150 ml) and washed with H₂O (50 ml), sat. NaCl solution, dried (Na₂SO₄) and concentrated to afford 10g (99%) of desired product as an oil. This oil was dissolved in EtOH (50 ml) and cooled to 0°C. To this cold solution was added 10% NaOH (20 ml, 50 mmol) dropwise via an additional funnel and stirred at 0°C for 2 h, at r.t. for 16 h. Removal of solvents gave an oil. The oil was dissolved in H₂O (40 ml) and Et₂O (20 ml). The aqueous layer was separated and acidified with 6N HCl to pH ~ 1 then extracted with ether (50 ml x 2). The combined ether solutions were washed with sat. NaCl (20 ml), dried (Na₂SO₄), and concentrated to afford 7.2g (83%) of desired acid as an oil.

B4. Preparation of 2,2-Dimethyl-3-(4-morpholinyl)propionic Acid.

- 20 Dissolve 2.62 ml (30 mmoles, 1.2eq.) oxalyl chloride in anhydrous CH₂Cl₂. Cool to -78 degrees C under N₂. Slowly add 2.66 ml (37.5 mmoles, 1.5eq.) DMSO. Stir 15 minutes. To this solution add 3.19 ml (25 mmoles, 1.0 eq.) methyl 2,2 dimethyl-3-hydroxypropionate. Stir an additional 25 hour at -78 degrees. Quench reaction with 13.94 ml (100 mmoles, 4.0 eq.) triethylamine. Warm to room temperature. Wash organic layer 1x0.1N HCl, 1x saturated sodium bicarbonate, 1x saturated NaCl. Dry with MgSO₄ and rotovap. Yield=69% M+H=131
- 30 Dissolve 1.00ml (11.53 mmoles, 3eq.) morpholine in 43ml 1% AcOH/MeOH. Add 500mg (3.83 mmoles, 1eq.) aldehyde from above. Cool to 0 degrees C under N₂. Slowly add 362.0mg (5.76 mmoles, 1.5eq) NaCNBH₃. Stir 2-3 days.
- 35 Strip off MeOH. Dissolve in minimum H₂O. Add Conc HCl to pH=2. Wash 2xEt₂O. Add 6N NaOH to aqueous layer to pH>9. Extract 3xEtOAc. Dry with MgSO₄ and rotovap.

Purify by silica flash chromatography (60:1 CH₂Cl₂:CH₃OH)

Yield=18% M+H=202

- 5 Dissolve 337mg (1.7mmoles, 1eq) methyl ester from above in 18ml AcOH. Add 4.5ml HCl. Heat to 60 degrees C. under N₂. Stir overnight. Rotovap off solvent. Azeotrope with toluene. Rotovap 1x 4N HCl/ dioxane. Dessiccate over P₂O₅ overnight. Yield=94% M+H=188

10

B5. Preparation of 2,2-dimethyl-4-(1-methylpiperazinyl)butanoic acid.

- A mixture of 2,2-dimethylpentenoic acid (5.66g, 42 mmol) BnBr (6.84g, 40 mmol) K₂CO₃ (5.8g, 42 mmol) and NaI (3g, 15 20 mmol) in acetone (65 ml) was heated to reflux (oil bath 80°C) for 16 h. The acetone was stripped off and the residue was dissolved in H₂O (20 ml) and ether (60 ml). The ether layer was separated, dried (Na₂SO₄) and concentrated to afford 8.8g (100%) of desired ester as 20 an oil.

- To a solution of ester from above (8.8g, 40.0 mmol) in CH₂Cl₂ (150 ml) was bulbed through a stream of ozone at - 78°C until the blue color persisted. Excess ozone was 25 removed by a stream of N₂, dimethylsulfide (10 ml) was added, and the reaction mixture was allowed to warm to room temperature and stirred for 56 h. After the removal of solvents, the residue was dissolved in Et₂O (50 ml) and washed with H₂O (15 ml) then sat. NaCl 30 solution (10 ml). The organic layer was dried (Na₂SO₄) concentrated to afford 8.2 g (93%) of aldehyde as an oil.

- To a solution of aldehyde from above (4.2g, 19.1 mmol) 35 in MeOH (80 ml) was added NaCNBH₃ (2.4g, 38.2 mmol) and acetic acid (2 ml) at 0°C. To this cold solution was add d N-methylpiperizine (2.5g, 25 mmol) slowly at 0°C. The r action mixture was stirred at 0°C for 2 h and room

temperature for 16 h. The removal of solvents gave a solid. To the solid was added H₂O (25 ml) and ether (50 ml). The organic layer was separated and to this was added 5% HCl (25 ml). The aqueous layer was collected
5 and to this was added 2.5N NaOH until pH - 14, and extracted with ether (25 ml x 3). The combined organic extracts were washed with brine (15 ml), dried (Na₂SO₄) and concentrated to afford 5.5g (95%) of desired amine as an oil. This oil was hydrogenated (1.5g of 10% Pd/C,
10 50 psi H₂) in MeOH (50 ml) at room temperature for 2 h. the reaction mixture was filtered and the filtrate was concentrated to afford 4.0g (98%) of the desired amino acid as a white solid.

15 B6. Preparation of 2,2-dimethyl-6-(4-morpholinyl)-4-oxahexanoic acid.

To a suspension of NaH (1.5g, 60.0 mmol) in THF (155 ml) was added a solution of methyl 2,2-dimethyl-3-hydroxypropionate (6.6g, 50.0 mmol) slowly at 0°C.
20 After the addition was completed, the reaction mixture was stirred at room temperature for 1 1/2 h. It was cooled to 0°C. To this cold solution was added allyl bromide (7.3g, 60.0 mmol) slowly and NaI (150 mg) in one portion. The resulting reaction mixture was stirred at
25 room temperature for 36 h. Diluted with 5:1 ether:petane (100 ml) and washed with H₂O (50 ml), brine (50 ml). The combined organic phases were dried (Na₂SO₄), concentrated to give 8.4g (74%) of olefin.

30 To a solution of olefin (3.45g, 20 mmol) in CH₂Cl₂ (75 ml) was bubbled through a stream of ozone at -78°C until the blue color persisted. Excess ozone was removed by a stream of N₂, dimethyl sulfide (5 ml) was added, and the reaction mixture was allowed to warm to room temperature
35 and stirred for 36 h. After removal of all solvents, the residue was dissolved in Et₂O (35 ml) and washed with H₂O (10 ml) and sat. NaCl solution (10 ml). The organic extracts were dried (Na₂SO₄), concentrated to afford 3.2g

(92%) of aldehyde. To a solution of this aldehyd
(3.2g, 18.4 mmol) in MeOH (80 ml) was added Na CNBH₃
(2.3g, 36.8 mmol) and acetic acid (2 ml) at 0°C. To
this cold solution was added morpholine (2g, 23 mmol)
5 slowly at 0°C and stirred for 2 h at 0°C, 16 h at room
temperature. The removal of solvents gave a solid, to
this solid was added H₂O (20 ml) and Et₂O (50 ml). The
organic layer was separated and to this was added 5% HCl
(20 ml). The aqueous layer was collected and to this
10 was added 2.5N NaOH solution until pH ~ 14, and
extracted with Et₂O (25 ml x 3). The combined organic
extracts were washed with brine (15 ml), dried (Na₂SO₄)
and concentrated to afford 1.6g (35%) the desired amine.
The amine (1.58g, 6.4 mmol) was subjected to a mixture
15 of 10% NaOH (13 ml, 32 mmol) and MeOH (10 ml) and
stirred for 16 h. Acetic acid (2.5 ml, 41.6 mmol) was
added and the solvents were removed in vacuo to give a
solid. The solid was washed with CH₂Cl₂ (25 ml x 4).
The combined CH₂Cl₂ solutions were dried (Na₂SO₄) and
20 concentrated to give an oil. The purification of the
oil by plug filtration (silica gel, 20% MeOH/CH₂Cl₂ the
MeOH) gave 350 mg (24%) pure amine acid as an oil.


Following generally the general procedure set
forth below and the procedures set forth in Examples
25 1-5, the compounds listed in Tables A and B were
prepared.

TABLE A

5

10

15



20

25

30

35

R^3	R^{16}	Method of Preparation
$-\text{CH}_2\text{CH}(\text{CH}_3)$	$-\text{H}$	Ex. 1
"	$-\text{CH}_3$	"
"	$-\text{CH}_2\text{CH}_3$	"
"	$-\text{CH}(\text{CH}_3)_2$	"
"	$-\text{C}(\text{CH}_3)_3$	Ex. 2
"	$-\text{CH}_2\text{Ph}$	Ex. 1
$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	$-\text{H}$	Ex. 2
"	$-\text{CH}_3$	Ex. 1
"	$-\text{C}(\text{CH}_3)_3$	Ex. 2
$-\text{CH}_2-\text{C}_6\text{H}_4-\text{R}$	$-\text{OH}$	"
	$-\text{CH}_2\text{CH}_3$	"
	$-\text{C}(\text{CH}_3)_3$	"

40

TABLE B







5				
10				
15	n	R ³	R ⁸	Method of Preparation
	0	-CH ₂ CH(CH ₃) ₂	-CN	Ex. 1
	0	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
20	1	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂	-C(O)N(CH ₃) ₂	Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂	-CO ₂ CH ₃	Ex. 2
	2	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
	1			Ex. 2

TABLE B (Cont'd)









5	n	R ³	R ⁸	Method of Preparation
	1			Ex. 2
10	0	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	$\begin{array}{c} \text{O} \\ \\ -\text{C}-\text{CH}_3 \end{array}$	Ex. 2
	0		$\begin{array}{c} \text{O} \\ \\ -\text{C}-\text{CH}_3 \end{array}$	Ex. 2
15	1			Ex. 2
20	1	$-\text{CH}_2\text{CH}(\text{CH}_3)_2$	OH	Ex. 2
	1		OH	Ex. 2
	2			Ex. 2

TABLE B (Cont'd)







5	n	R ³	R ⁸	Method of Preparation
	2			Ex. 2
	1		-SCH ₃	Ex. 2
	1		-SO ₂ CH ₃	Ex. 2
10	1		-SO ₂ CH ₃	Ex. 2
	1	-CH ₂ CH(CH ₃) ₂	-CO ₂ CH ₃	Ex. 1
	1		-CO ₂ H	Ex. 2

TABLE B (Cont'd)











5	n	R ³	R ⁸	Method of Preparation
	1			Ex. 2
	1		-SO ₂ Ph	Ex. 2
	1		-SO ₂ Ph	Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
10	2	-CH ₂ CH ₂ CH(CH ₃) ₂	-N(CH ₃) ₂	Ex. 2
	2	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2

TABLE B (Cont'd)

	n	R ³	R ⁸	M thod of Pr paration
5	1	-CH ₂ CH ₂ CH(CH ₃) ₂	-N(CH ₃) ₂	Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂		Ex. 2
	1	-CH ₂ CH ₂ CH(CH ₃) ₂	-N(CH ₃)Ph	Ex. 2
10	1	-CH ₂ CH ₂ CH(CH ₃) ₂	-O-CH ₂ CH ₂ - 	Ex. 2

Example 3

Following generally the procedure of Examples
 15 1-5, the compounds shown in Table 3 were prepared.

TABLE C

5

10


15

20

25

30

35



t	R ₁	R ₂	R	Method of Preparation
0	CH ₃	-CH ₂ CH ₃	-C(O)OC(CH ₃) ₃	Ex. 1
0	CH ₃	CH ₂ Ph	-C(O)OCH ₂ CH ₃	Ex. 1
0	H	H	CF ₃	Ex. 1
1	R ¹ +R ² =cyclopentyl		4-pyridyl	Ex. 2
1	R ¹ +R=cyclobutyl		4-pyridyl	Ex. 2

Example 4

40


Following generally the procedure of Example 1, the compounds shown in Table 4 were prepared.

TABLE 4

5

10

15



20

25

30

n	R ³	R ¹⁶
0	isoamyl	CH ₂ CH ₃
1	isoamyl	CH ₂ CH ₃
2	isoamyl	CH ₂ CH ₃
3	isoamyl	CH ₂ CH ₃

Example 5

This example illustrates an alternate procedure for preparing compounds of Formula II.

A. Intermediates35 Preparation of 2,2-Dimethyl-3-phenylpropionic Acid

To a mixture of 1.23g (41.0 mmol) of 80% sodium hydride and 50 mL of anhydrous tetrahydrofuran under a nitrogen atmosphere, was added 3.88g (38.3 mmol) of diisopropylamine and then 3.3g (37.5 mmol) of isobutyric acid. After heating at reflux for 15 minutes and cooling to 0°C, 15 mL (37.5 mmol) of 2.5M n-butyllithium in hexane was added. The mixture was warmed to 35°C for 30 min, cooled to 0°C and 5.40g (37.5 mmol) of benzyl bromide added. The mixture was stirred for 30 minutes at 0°C, then warmed to 35°C for one hour and recooled to 0°C. Water was added and the aqueous layer extracted with diethyl ether, acidified with 6N aqueous HCl and

extracted with diethyl ether. The organic layer was dried and concentrated to provide 4.0g of crude product. Chr matography on silica gel using 10% methanol/methylene chloride afforded 1.0g of pure 2,2-dimethyl-3-phenylpropionic acid, m/e 185 (M + Li).

Preparation of 2,2-Dimethyl-3-(4-pyridyl)propionic Acid

Under a nitrogen atmosphere, 1.23g (41 mmol) of 80% sodium hydride was added to 50 mL of anhydrous tetrahydrofuran, followed by 3.88g (38.3 mmol) of diisopropylamine. To the resulting mixture was added 3.3g (37.5 mmol) of isobutyric acid and the resulting mixture heated to reflux for 15 minutes. Upon cooling to 0°C, 15 mL (37.5 mmol) of 2.5M n-butyllithium in hexane was added and the mixture then warmed to 35°C for 30 minutes. After cooling to 0°C, 4.8g (37.5 mmol) of 4-chloromethylpyridine (freshly prepared by neutralization of the hydrochloride salt with aqueous sodium bicarbonate, extraction with hexane, dried and concentrated) was added. After 30 minutes at 0°C, the mixture was warmed to 30°C for one hour, cooled to 0°C and 50 mL of water carefully added. The aqueous layer was separated and washed twice with diethyl ether, acidified with 6N aqueous hydrochloric acid, rewashed twice with diethyl ether and then neutralized with aqueous sodium bicarbonate. After the addition of citric acid, the aqueous layer was extracted 3 xs with ethyl acetate to afford 283 mg of a white powder which was identified as 2,2-dimethyl-3-(4-pyridyl)propionic acid, m/e 180 (M + H⁺).

Preparation of 1-(4-Pyridylmethyl)cyclopentanecarboxylic Acid

To a suspension of 3.69g (123 mmol) of 80% sodium hydride in 150 mL of anhydrous tetrahydro-furan and 11.6g (115 mmol) of diisopropylamine, at 0°C was added 12.82g (112 mmol) of cyclo-pentanecarboxylic acid. This was then heated at reflux for 15 minutes, cooled to 0°C

and 45 mL of 2.5M n-butyllithium in hexane added. After 15 minutes at 0°C and 30 minutes at 35°C, the mixture was recooled to 0°C and a solution of 14.4g (112 mmol) of 4-chloromethylpyridine (freshly prepared from 4-chloromethylpyridine hydrochloride by neutralization with aqueous sodium bicarbonate, extraction with hexane, drying and concentrating) was added. After 30 minutes at 0°C and 60 minutes at 35°C, the mixture was cooled to 0°C, water carefully added and extracted twice with diethyl ether. The aqueous layer was acidified to pH3 with 6N hydrochloric acid whereupon a precipitate formed. The pH was adjusted to 5.9 with 10% sodium hydroxide and the solids collected. Recrystallization from hot ethanol and hexane afforded 5.7g of desired product, m/e 206 (M + H).

Preparation of 2,2-Dimethyl-3-(methylsulfonyl)propionic Acid.

To a suspension of 1.23g (41 mmol) of 80% sodium hydride in 50 mL of anhydrous tetrahydrofuran and 3.88g (38 mmol) of diisopropylamine, was added 3.3g (37 mmol) of isobutyric acid and the mixture refluxed for 30 minutes. Upon cooling to 0°C, 15 mL (37 mmol) of 2.5M n-butyllithium in hexane was added, stirred for 15 minutes at 0°C and then warmed to 35°C for 45 minutes. After cooling to 0°C, 3.62g (37 mmol) of chloromethyl methyl sulfide was added and stirred for 30 minutes at 0°C and then 60 minutes at 35°C. After cooling to 0°C, water was added, washed with diethyl ether, acidified with 6N hydrochloric acid and extracted with diethyl ether, dried and concentrated to afford 4g of crude material. This was distilled (Bp 85°C, 0.25 mm Hg) to afford 1.2g of 2,2-dimethyl-3-(thiomethyl)propionic acid, m/e 155 (M + Li). To a solution of 525 mg (3.5 mmol) of 2,2-dimethyl-3-(thiomethyl)propionic acid in 8 mL of acetic acid was added 1.2 mL of 30% aqueous hydrogen peroxide and the mixture refluxed for 2 hours. The solution was cooled, 15 mL of 10% sodium sulfite added and

concentrated under reduced pressure. The residue was acidified with 12N hydrochloric acid, extracted with ethyl acetate, washed with brine, dried and concentrated to afford 341 mg of 2,2-dimethyl-3-(methylsulfonyl)-
5 propionic acid.

Preparation of 2,2-Dimethyl-3-(phenylsulfonyl)propionic Acid.

10 To a mixture of 1.23g (41 mmol) of 80% sodium hydride in 50 mL of dry tetrahydrofuran was added 3.88g (38.3 mmol) of diisopropylamine and then 3.3g (37.5 mmol) of isobutyric acid. After heating at reflux for 15 min, and cooling to 0°C, 15 mL (37.5 mmol) of a 2.5M n-
15 butyllithium in hexane solution was added over 10 min. After 15 min, the solution was heated to 35°C for 30 min, cooled to 0°C and 5.94g (37.5 mmol) of chloromethylphenyl sulfide was added. After 30 min at 0°C and 35°C for 1 hour, the solution was recooled to
20 0°C, water added and then diethyl ether. The water layer was separated, acidified and extracted with diethyl ether, dried and concentrated to afford 4.23g of crude product. Recrystallization from methylene chloride/hexane afforded 1.49g of 2,2-dimethyl-3-
25 (thiophenyl)propionic acid, m/e 211 (M + H). To a mixture of 1.1g (5.2 mmol) of 2,2-dimethyl-3-(thiophenyl)propionic acid in 12 mL of acetic acid was added 1.8 mL (17.8 mmol) of 30% aqueous hydrogen peroxide. After 10 minutes at room temperature, all the
30 solids dissolved and the solution was heated to reflux for two hours. After cooling in an ice bath, 23 mL of 10% aqueous sodium sulfite was added and the volatiles removed under vacuum. The residue was acidified with 12N aqueous HCl, extracted with ethyl acetate, dried and
35 concentrated to afford 1.23g of 2,2-dimethyl-3-(phenylsulfonyl)propionic acid, m/e 260 (M + NH₄⁺).

B. Compounds of the InventionI. Preparation of Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-phenylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-

5 quinolinylcarbonyl)amino]-,
[1S-[1R*(R*), 2S*]]-

To a solution of 72 mg (0.40 mmol) of 2,2-dimethyl-3-phenylpropionic acid in 5 mL of toluene and 0.12g (1.2
 10 mmol) of triethylamine at 90°C, was added 0.11g (0.40 mmol) of diphenylphosphoryl azide. After one hour, a solution of 208 mg (0.40 mmol) of N-3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginy]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl) in 1.5 mL of N,N-
 15 dimethylformamide was added. After one hour, the solvent was removed under reduced pressure, ethyl acetate added, washed with water, sat d sodium bicarbonate, sat d sodium chloride, dried, filtered and concentrated to afford 200 mg of crude product. This
 20 was recrystallized from ethyl acetate and hexane to afford 42 mg of the desired product, m/e 701 (M + Li).

II. Preparation of Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)amino]carbonyl](3-(4-
 25 fluorophenyl)methyl)amino]-2-hydroxy-1-
(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-,
[1S-[1R*(R*), 2S*]]-

To a solution of 96 mg (0.54 mmol) of 2,2-dimethyl-3-(4-pyridyl)propionic acid in 5 mL of toluene and 0.16g
 30 (1.62 mmol) of triethylamine at 95°C, was added 149 mg (0.54 mmol) of diphenylphosphoryl azide. After one hour, a solution of 300 mg (0.54 mmol) of N-3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginy]amino-2(R)-hydroxy-4-phenylbutylamine, N-(4-fluorophenyl)-methyl in 2 mL of
 35 N,N-dimethylformamide was added.. After one hour, the solvents w r removed under reduced pressure, ethyl acetate added, washed with water, sat d sodium

bicarbonate, brin , dried, filtered and concentrated to afford 320 mg of crude product. Chromatography on silica gel using 5-30% isopropanol/methylene chloride afforded 60 mg of the desired product, m/e 734 (M + H).

5

III. Preparation of Butanediamide, N -[3-[[[(1,1-dimethy-2-hydroxyethyl)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-

10 [1S-[1R*(R*), 2S*]]-

To a solution of mono-tertiary-butyl 2,2-dimethylmalonate (188 mg, 1.0 mmol), Et₃N (303 mg, 3.0 mmol) in toluene (2 ml) was added DPPA (283 mg, 1.0 mmol) in toluene (0.5 ml) dropwise over 5 min at 95° (oil bath). After stirring at 95°C (oil bath) for another 45 min, the mixture was cooled to r.t. and to this was added a solution of amino alcohol derivative (588 mg, 1.0 mmol) in DMF (5 ml) and stirred at r.t. for 45 min. The mixture diluted with EtOAc (25 ml) and washed with 5% NaHCO₃ (10 ml x 2), 5% citric acid (5 ml) and H₂O (10 ml) then sat. NaCl (10 ml). The organic phase was dried (Na₂SO₄) and concentrated to afford 840 mg crude product. Purification of crude product by flash chromatography (silica gel, 3% then 5% MeOH/CH₂Cl₂) afforded 568 mg (76%) of pure desired product as a white solid, m/e 749 (M + Li). This white solid (520 mg, 0.699 mmol) was dissolved in CH₂Cl₂ (3 ml) and to this was added TFA (1.5 ml). After the mixture was stirred at r.t. for 16 h, the solvents were removed in vacuo to afford 475 mg (98%) of acid as a white solid. This white solid (450 mg, 0.65 mmol) was dissolved in THF (3 ml) and cooled to 0°C. To this cold solution was added BH₃·Me₂S (0.3 ml of 10 M solution, 3 mmol) dropwise via a syringe. After the mixture was stirred at 0°C for another 1 h and at r.t. for 16 h, it was quenched with MeOH (1 ml). The solvents were removed in vacuo and MeOH (2 ml) was added and stripped off again. This procedure was repeated for 3 more times. A white solid

was obtained. Purification of the crude product by flash chromatography (silica gel, 10% MeOH/.CH₂Cl₂) gave 108 mg (25%) of pure alcohol as a white solid, m/e 679 (M + Li).

5

IV. Preparation of Butanediamide, N -[3-[[[3-(3,3-dimethylpropionic acid, dimethyl amide)amino]-carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*), 2S*]]-

10

Part A. Preparation of 2,2-Dimethylsuccinic acid, 4-(mono-para-methoxybenzyl ester).

A 250 ml RB flask equipped with magnetic stir bar, reflux condensor and N₂ inlet was charged with 5.0g (39 mmol) of 2,2-dimethyl succinic anhydride, 5.39g (39 mmol) of p-methoxy benzyl alcohol (MOS-OH) in 65 ml toluene. After overnight reflux the reaction mixture was concentrated in vacuo and triturated with hexane to yield 9.1g crude solid: 6:1 mixture of regioisomers. After washing with hexane the crude solid was recrystallized from 85 ml boiling hexane to yield 5.9g (57%) of white solid. Regioisomeric purity was >25:1 by 400 MHz ¹H-NMR.

25

Part B. Preparation of Butanediamide, N -[3-[[[3-(3,3-dimethyl propionic acid, 4-methoxy-phenylmethyl ester)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-[1S-[1R*(R*), 2S*]]-

30

A 100 ml RB flask equipped with magnetic stir bar, reflux condensor and N₂ inlet was charged with 120 mg (.45 mmol) of product from Part A, 189 µl (1.35 mmol) NEt₃ in 5 ml dry toluene. The reaction was stirred at 95°C while 125 ml (.45 mmol) DPPA was slowly added. After 1 hour the amino alcohol derivative: 250 mg (.45 mmol), pre-dissolved in 4 ml DMF, was added. After 1 hour the reaction was concentrated in vacuo and

35

partitioned between EA and 5% aq citric acid. Organics washed with H₂O, sat bicarb, brine and dried over Na₂SO₄. Concentration in vacuo yielded 440 mg crude foam. Flash chromatography (100% EA) yielded 270 mg (73%) solid. Pure by ¹H-NMR and FAB mass spec (M + H = 822).

Part C. Preparation of Butanediarnide, N -[3-[[[3-(3,3-dimethylpropionic acid)amino]carbonyl]-(4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)-amino]-, [1S-[1R*(R*), 2S*]]-.

A 100 mL RB flask equipped with magnetic stir bar and N₂ inlet was charged with 260 mg (.32 mmol) of product from Part B in 20 ml 4N HCl/dioxane. The homogeneous solution was stirred at RT 30 min then to 50°C for 30 min. The reaction mixture was concentrated in vacuo to yield an oily solid that was titrated from excess Et₂O, filtered and dried to yield 150 mg (68%) of white powder suitable for use without further purification. FAB mass spec gave M + H = 702, M + Li = 708.

Part D. Preparation of Butanediarnide, N -[3-[[[3-(3,3-dimethylpropionic acid, dimethyl amide)amino]-carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*), 2S*]]-.

A 25 ml RB flask equipped with magnetic stir bar and N₂ inlet was charged with 50 mg (.07 mmol) acid from Part C in 1 ml DMF. The reaction was cooled to 0°C when 15 mg HOBt (.11 mmol) was added followed by 15 mg (.08 mmol) EDCI. After stirring 20 minutes 50 ml 40% aq. dimethyl amine was added. The reaction was stirred 2 hours @ 0°C and allowed to stir at room temperature overnight. The reaction was taken up in EA and washed with 2x20 ml sat. bicarb, 2x20 ml 5% aq citric acid, 1x30 ml brine, and over MgSO₄. Concentration in vacuo yield 21 mg crude

solid TLC (5% MeOH-CH₂Cl₂). Showed 50% conversion to product with other impurities. Flash chromatography (MeOH-CH₂Cl₂) yield 6.5 mg product (13%). Mass spec M + H = 728.

5

Preparation of Butanediamide, N -[3-[[[(1,1-dimethyl-2-oxo-propyl)amino]carbonyl](2-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-,

10 [1S-[1R*(R*), 2S*]]-

Part A. Preparation of Methyl 2,2-Dimethyl-3-oxobutyric Acid.

A 250 ml RB flask equipped with magnetic stir bar, addition funnel and N₂ inlet was charged with 8.9g of 95% NaH (372 mmol, 2.2 eq) and 125 ml dry THF. The slurry was cooled to -30°C when 20g (170 mmol) of methyl acetoacetate was slowly added. After 5 min 51g (359 mmol, 2.1 eq) of methyl iodide was added and the reaction was stirred 1 hour at -25°C and allowed to sit at room temperature overnight. Upon workup the reaction was diluted with 125 ml EA and the precipitated sodium iodide was filtered and the filtrate was washed with 100 ml sat. bicarb, 100 ml 5% aq Na₂S₂O₅ and 100 ml brine. The organics were dried and concentrated in vacuo to yield 19g of a yellow oil suitable for use without further purification.

Part B. Synthesis of 2,2-Dimethyl-3-oxobutyric acid, ethylene glycol Kemi Dicyclohexyl-ammonium Salt.

A 100 ml RB flask equipped with magnetic stir bar and N₂ inlet was charged with 5g (34.7 mmol) 2,2-dimethyl methylacetoacetate in 25 ml anhydrous ethylene glycol, 20 ml trimethylorthoformate with a catalytic amount of p-toluenesulfonic acid. The reaction mixture was stirred @ 55°C overnight then worked up by pouring into 200 ml 20% aq KOH and heating to 95°C for 4 hours. The cooled reaction mixture was extracted with ether and the aqueous phase was acidified to pH 3 with 35 ml conc

HCl/ice. The product was extracted with 2x100 ml EA. The organics were dried over Na_2SO_4 and concentrated in vacuo to ~ 5g crude free acid.

- 5 The acid was taken up in 50 ml ether and 5.3g dicyclohexyl amine salt was added and the product was filtered and dried to yield 6.5g (~ 53%) white solid. Mp 124-127°C.

- 10 **Part C. Preparation of N^3 -3(S)-(Benzyloxycarbonyl)amino-2-(R)-hydroxy-4-pentylbutyl amine, N-(3-methyl)butyl, N-[[[(1,1-dimethyl-2-oxo-propyl)amino]carbonyl, ethylene glycol ketal].**

- A 250 ml RBF equipped with magnetic stir bar and N_2 inlet
15 was charged with 2.0g (11.5 mmol) free acid: (free acid liberated from DCHA salt by partitioning between Et_2O and 5% aq KHSO_4), 6.11 ml (43.7 mmol - 3.8 eq) NEt_3 in 75 ml dry toluene. The solution was heated to 95°C and 3.16g (11.7 mmol) DPPA was added. The reaction was stirred at
20 95°C for 1 hour when 4g (11.7 mmol) of amino alcohol derivative in 50 ml toluene was added. The reaction was stirred at 90°C for 1 hour then at room temperature overnight. The reaction was concentrated in vacuo and partitioned between EA and 5% aq citric acid. The
25 organic phase was washed with sat. bicarb, brine, dried, and concentrated to 6g of crude foam. The product was purified by flash chromatography on silica gel to yield 4.3g (73%) white foam, pure by TLC and high field NMR. FAB mass spec, $\text{M} + \text{Li} = 562 \text{ z/m}$.

30

- Part D. Preparation of butanediamide, N-[3-[[[(1,1-dimethyl-2-oxo-propyl)amino]carbonyl](2-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*), 2S*]]-.**
35 A Fisher Porter tube equipped with magnetic stir bar was charged with 1.5g of product from Part C, 45 mL of methanol and a catalytic amount of 10% Pd-C. The mixture was hydrogenated at 45 psi for 20 hours. The

reaction was filtered through celite and concentrated in vacuo to yield 1.1g (>95%) of free amine, which was used without further purification.

A 100 ml RBF equipped with magnetic stir bar and N₂ inlet
5 was charged with 824 mg (3.14 mmol, 1.15 eq) 2-asparagine in 100 ml DMF. The solution was cooled to 0°C and 550 mg (4.07 mmol, 1.5 eq) HOBt was added followed by 60 mg (3.13 mmol, 1.15 eq) EDCI. The reaction was stirred 10 minutes when 1.13g (2.7 mmol)
10 crude free amine was added. The reaction was stirred 1 hour at 0°C then overnight at room temperature. The reaction was poured into 100 ml sat. bicarb and extracted with 100 ml EA. The organics were washed with 5% citric acid, brine, dried over Na₂SO₄, and
15 concentrated in vacuo to yield 1.37g (75%) white solid which was identified as the CBZ-asparagine adduct. FAB mass spec gave M + Li 676 z/m.

A Fisher Porter tube equipped with magnetic stir bar was
20 charged with 1.37g of CBZ-asparagine adduct, 50 mL MeOH and a catalytic amount of 10% Pd-C. The reaction mixture was hydrogenated at 50 psi for 16 hours. The reaction was filtered through celite and concentrated in vacuo to yield 1.05g (97%) of free asparagine amine as a
25 foam that was used without further purification. FAB mass spec gave M + Li = 542.

A 100 ml RBF equipped with magnetic stir bar and N₂ inlet was charged with 356 mg (2.06 mmol, 1 eq) 2-quinaldic
30 acid in 10 ml dry DMF. The solution was cooled to 0°C and 415 mg (3.07 mmol, 1.5 eq) HOBt was added followed by 415 mg EDCI (2.16 mmol, 1.05 eq). The reaction was stirred 2 hours at 0°C when 1.1g (2.06 mmol, 1 eq) of free asparagine amine in 10 ml dry DMF was added. The
35 reaction was stirred at 0°C for 2 hours then room temperature overnight. The reaction was poured into sat. bicarb and extracted with 2x65 mL ethyl acetate. The combined organics were washed with 5% aq. citric

acid, brine, dried and concentrated to 1.4g crude foam. Purification by flash chromatography on silica gel (100% EA) yielded 850 mg (61%) of quinoline adduct.

- 5 A 100 ml RBF equipped with magnetic stir bar was charged with 117 mg quinoline Ketal, 30 ml of THF and 15 ml 30% aq HCl. The reaction was stirred 2 hours at room temperature then diluted with 50 ml EA. The organic phase was washed with sat. bicarb, brine, dried and concentrated in vacuo to 105 mg pure ketone. FAB mass spec gave M + Li at 653 z/mol.

- Preparation of butanediamide, N-[3-[[[1,1-dimethyl-2-(4-morpholinyl)ethyl]amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*), 2S*]-.
- 15 Dissolve 90.40 mg (0.4 mmoles, 1.05 eq.) 2,2-dimethyl-3-(4-morpholinyl)propionic acid in toluene. Heat to 95 degrees C. under N₂. Add 225 μ l (1.61mmoles, 4.2 eq.) triethylamine.
- 20 Slowly add 87.1 μ l (0.4 mmoles, 1.05eq.) diphenylphosphoryl azide. Stir 1 hour. To this solution add 200 mg (0.38 mmoles, 1 eq.) 3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginy]amino-2(R)-hydroxy-4-phenylbutyl amine, N-(3-methylbutyl) dissolved in DMF.
- 25 Stir 1 hour. Cool to room temperature. Strip off toluene. Dissolve in EtOAc. Wash 1xH₂O, 1x saturated NaHCO₃, 1x saturated NaCl. Dry with MgSO₄ and rotovap. Purify by silica flash chromatography (30:1 CH₂Cl₂:CH₃OH)
- 30 Yield=50% M+H=704

- Preparation of butanediamide, N-[3-[[[1,1-dimethyl-3-(4-(1-methylpiperazinyl))propyl]amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*), 2S*]-.
- 35 Dissolve 122.2 mg (0.57 mmoles, 1.5 eq.) amino acid of 2,2-dimethyl-4-(1-(4-methylpiperazinyl))butanoic acid in toluene. Heat to 95 degrees C. under N₂. Add 238 μ l

(1.71 mmol, 4.5 eq.) triethylamine. Slowly add 122.8 μ l (0.57 mmol, 1.5 eq.) diphenylphosphoryl azide. Stir 1 hour. To this solution add 200 mg (0.38 mmol, 1 eq.) 3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutyl amine, N-(3-methylbutyl) dissolved in DMF. Stir 1 hour. Cool to room temperature. Strip off toluene. Dissolve in EtOAc. Wash 1x H₂O, 1x saturated NaHCO₃, 1x saturated NaCl. Dry with MgSO₄ and rotovap. Purify by recrystallizing in EtOAc/pet. ether. Yield=66%

10 M+Li=737

Preparation of butanediamide, N-[3-[[[(1,1-dimethyl-5-(4-morpholinyl)-3-oxapentyl]-amino]carbonyl]](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinyl-carbonyl)amino]-, [1S-[1R*(R*), 2S*]-.

15 To a mixture of acid 2,2-dimethyl-6-(4-morpholinyl)-4-oxahexanoic acid (231 mg, 1.0 mmol) EtN₃ (303 mg, 3.0 mmol) in toluene (2 ml) was added DPPA (283 mg, 1.0 mmol) in toluene (0.5 ml) dropwise over 5 min at 95°C (oil bath). After stirring at 95°C (oil bath) for another 45 min, the mixture was cooled to room temperature and to this was added a solution of 3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutyl amine, N-(3-methylbutyl) (519.6 mg, 1.0 mmol) in DMF (5 ml) and stirred at room temperature for 45 min. The mixture was diluted with EtOAc (25 ml) and washed with 5% NaHCO₃ (10 ml x 2), 5% citric acid (5 ml) and H₂O (10 ml) then sat. NaCl solution (10 ml). The combined extracts were dried (Na₂SO₄) and concentrated to give a solid. The purification of the crude product by flash chromatography (silica gel, 3% MeOH/CH₂Cl₂) gave 262 mg (35%) pure product.

20
25
30


The above procedures could be utilized to prepare compounds of the present invention wherein the group B as defined above is incorporated into the compound shown below in Examples 6-36. It is contemplated that the resulting compounds would inhibit retroviral proteases with activities similar to the

35

activities of the compounds of Examples 1-5. Thus, a compound of the formula



10 can be utilized in place of the isocyanate of Step D of Example 1. Alternatively, the compounds represented by the formula:



25

30 can be prepared, carried through the synthesis, P' selectively removed and the resulting amine can be reacted with the above compound as in Examples 1-5. Example 31 demonstrates the preparation of the desired amine.

35

Example 6

Example 6A

Preparation of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-guininylcarbonyl)amino]-butanediamide

40 Part A:

To a solution of 75.0g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of 807 mL of methanol and 807 mL of

45 tetrahydrofuran at -2°C, was added 13.17g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one

hundred minutes. The solvents were removed under reduced pressure at 40°C and the residue dissolved in ethyl acetate (approx. 1L). The solution was washed sequentially with 1M potassium hydrogen sulfate, 5 saturated sodium bicarbonate and then saturated sodium chloride solutions. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced pressure. To the resulting oil was added hexane (approx. 1L) and the mixture warmed to 10 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3g (43% yield) of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)- 15 butanol, mp 150-151°C and $M+Li^+ = 340$.

Part B:

To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at room temperature, was added 32.3g (0.097 mol) of N-CBZ- 20 3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes, the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate, filtering and stripping, one 25 obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and $MH^+ 298$.

Part C:

30 A solution of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00g, 3.36 mmol) and isobutylamine (4.90g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was heated to reflux for 1.5 hours. The solution was cooled to room temperature, 35 concentrated in vacuo and then poured into 100 mL of stirring hexane where upon the product crystallized from solution. The product was isolated by filtration and air dried to give 1.18g, 95% of N=[3(S)-

phenylmethylcarbamoyl)amino-2(R)-hydroxy-4-phenylbutyl]N-[(2-methylpropyl)amine mp 108.0-109.5°C, MH^+ m/z = 371.

Part D:

5 A solution of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[(2-methylpropyl)amine in 10 ml of tetrahydrofuran was treated with tert-butylisocyanate (267 mg, 2.70 mmol) at room temperature for 5 minutes. The solvent was removed
10 in vacuo and replaced with ethyl acetate. The ethyl acetate solution was washed with 5% citric acid, water, and brine, dried over anhydrous $MgSO_4$, filtered and concentrated in vacuo to give 1.19g, 97% of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)amino-2-(1,1-dimethyl)amino]carbonyl]butane, MH^+ m/z - 470.

Part E:

A solution of (1.00g, 2.21 mmol) [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-
20 1-[(2-methylpropyl)amino-1-(1,1-dimethylethyl)amino]carbonyl]butane in 20 mL of methanol was hydrogenated over 10% palladium-on-carbon for 4 hours to give [2(R), 3(S)]-N-[[3-amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)amino-1-(1,1-dimethylethyl)amino]carbonyl]butane 720 mg, 97%.

Part F:

A solution of N-Cbz-L-asparagine (602mg, 2.26 mmol) and N-hydroxybenzotriazole (493 mg, 3.22 mmol) in 2mL of dimethylformamide was cooled to 0°C and treated
30 with EDC (473 mg, 2.47 mmol). The solution was allowed to stir at 0°C for 20 minutes and then treated with [2(R), 3(S)]-N-[[3-amino]-2-hydroxy-4-phenyl]-1-[(2-methylpropyl)amino-1-(1,1-dimethylethyl)amino]carbonyl]butane (720 mg, 2.15 mmol)
35 in 1mL of dimethylformamide. The solution was allowed to warm to room temperature and held at this temperature for 7 hours. The reaction mixture was then poured into 100 mL of 60% saturated aqueous sodium bicarbonate

whereupon a white precipitate formed that was isolated by filtration. The filter cake was washed with water, 5% aqueous citric acid, water and then dried in vacuo to give 1.04g, 83% of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino], mp. 164.0-166.5°C, MH⁺ m/z = 584.

Part G.

A solution of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbonyl)amino]-butanediamide (1.00g, 1.72 mmol) in 10 mL of methanol was hydrogenated over 10% palladium-on-carbon for 4 hours to give [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-amino]-butanediamide, 784mg, 99%.

Part H:

A mixture of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-amino]-butanediamide, (784 mg, 1.70 mmol), 2-quinoline carboxylic acid N-hydroxysuccinimide ester (459 mg, 1.70 mmol), N-methylmorpholine (343 mg, 3.40 mmol) in 5 mL of dichloromethane was stirred at room temperature for 15 minutes. The solvent was removed in vacuo and replaced with ethyl acetate and the solution washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate, brine, dried over anhydrous MgSO₄, filtered and concentrated in vacuo. The crude product was recrystallized from acetone/hexane to give 790 mg, 77% of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide, mp 107.0-109.8°C, MH⁺ = 605.

Example 6B

The procedure described in Example 6A, part C-H, was used to prepare [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-

5 hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide.

- a) From the reaction of 1.06g (3.56mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 6.25g (71.7mmol) of isoamylamine, one obtains 1.27g (92%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)]amine, mp 130-132°C and MH⁺ 385. This amine (400mg, 1.04mmol) was then reacted with tert-butylisocyanate (110mg, 1.11mmol) to afford 500mg (100%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(3-methylbutyl)]amino-1-(1,1-dimethylethyl)amino]carbonyl]butane; as an oil, MH⁺ 484.
- 20 b) The CBZ protected compound (530mg, 1.10mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (377mg, 1.42mmol) in the presence of N-hydroxybenzotriazole (290mg, 2.15mmol) and EDC (300mg, 1.56mmol) to yield 430mg (53%) of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide, mp 148-151°C (dec) and MH⁺ 598. This compound (370mg, 0.619mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with 2-quinolinecarboxylic acid N-hydroxy-succinimide ester (193mg, 0.714mmol), in the presence of N-methylmorpholine, to afford 310mg (70%) of pure [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-

quinolinylcarbonyl)amino]-butan diamide; mp 93.5-95.56°C and MH⁺ 619.

Example 6C

- The procedure described in Example 6A, part C-H, was used to prepare [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl]2-naphthylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amio]-butanediamide.
- a) From the reaction of 1.80g (6.05mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 1.15g (7.31mmol) of 2-(aminomethyl)naphthalene, one obtains 2.11g (77%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[(2-naphthylmethyl)]amine, MH⁺ 455. This amine (366.8mg, 0.807mmol) was then reacted with tert-butylisocyanate (66.4mg, 0.67mmol) to afford 350.0mg (94%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(2-naphthylmethyl)]amino-1-(1,1-dimethylethyl)amino]carbonyl]butane; as an oil, MH⁺ 554.
- b) The CBZ protected compound (330mg, 0.596mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (165.1mg, 0.62mmol) in the presence of N-hydroxybenzotriazole (142.3mg, 0.93mmol) and EDC (130.7mg, 0.68mmol) to yield 161.7mg (41%) of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-naphthylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide; mp 151-152 C (dec) and MH⁺ 668. This compound (91.0mg, 0.136mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with 2-quinolinecarboxylic acid N-hydroxysuccinimide ester (36.8mg, 0.136mmol), in the presenc of N-methylmorpholine, to afford 65.8mg

(70%) f pure [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-naphthylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide; mp 119-120°C and MH⁺ 689.

Example 6D

The procedure described in Example 6A, part C-H, was used to prepare [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-phenylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide.

- a) From the reaction of 1.00g (3.36mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 8.19g (67.0mmol) of 2-phenethylamine, one obtains 1.10g (79%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbonyl)amino]-2-hydroxy-4-phenylbutyl]N-[(2-phenylethyl)amine], mp 137-138°C and MH⁺ 419. This amine (750mg, 1.79mmol) was then reacted with tert-butylisocyanate (178mg, 1.79mmol) to afford 897mg (97%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbonyl)amino]-2-hydroxy-4-phenyl]-1-[(2-phenylethyl)amino]-1-(1,1-dimethylethyl)amino]carbonyl]butane; as an oil, MH⁺ 518.
- b) The CBZ protected compound (897mg, 1.73mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (620.7mg, 2.33mmol) in the presence of N-hydroxybenzotriazole (509.5mg, 3.33mmol) and EDC (488.0mg, 2.55mmol) to yield 1.00g (92%) of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-phenylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbonyl)amino]-butanediamide; mp 145°C (dec) and MH⁺ 632. This compound (860mg, 1.36mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine

coupled with 2-quinolinecarboxylic acid N-hydroxysuccinimide ester (338mg, 1.25mmol), in the presence of N-methylmorpholine, to afford 450.4mg (55%) of pure [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-phenylethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide; mp 139-140°C and MH⁺ 653.

Example 6E

- 10 The procedure described in Example 6A, part C-H, was used to prepare [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2,2-dimethylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide.
- 15 a) From the reaction of 1.00g (3.36mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 7.9mL (approx. 67mmol) of neopentylamine, one obtains 0.69g (49%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[(2,2-dimethylpropyl)amine], MH⁺ 385. This amine (686mg, 1.78mmol) was then reacted with tert-butylisocyanate (180mg, 1.78mmol) to afford 860mg (100%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(2,2-dimethylpropyl)amino]-1-(1,1-dimethylethyl)amino]carbonyl]butane; MH⁺ 484.
- 20 25 b) The CBZ protected compound (860mg, 1.78mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (471mg, 1.77mmol) in the presence of N-hydroxybenzotriazole (406mg, 2.66mmol) and EDC (374mg, 1.95mmol) to yield 326mg (34%) of [1S-[R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2,2-dimethylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide; mp 177-178°C and MH⁺ 598. This compound (245mg,

0.41mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with 2-quinolinecarboxylic acid N-hydroxy-succinimide ester (111mg, 0.41mmol), in the presence of N-methylmorpholine, to afford 150mg (59%) of pure [1S-[R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](2,2-dimethylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide; mp 115-117°C and MH⁺ 619.

The procedure described in Example 6A, part C-H, was used to prepare [1S-[R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](4-methoxyphenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;

20 Example 6F

- a) From the reaction of 1.00g (3.36mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 9.2g (67mmol) of 4-methoxybenzyl amine, one obtains 1.12g (76%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbonyl)amino]-2-hydroxy-4-phenylbutyl]N-[(4-methoxyphenylmethyl)]amine, MH⁺ 435. This amine (1.12g, 2.58mmol) was then reacted with tert-butylisocyanate (260mg, 2.58mmol) to afford 1.35g (98%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbonyl)amino]-2-hydroxy-4-phenyl]-1-[(4-methoxyphenylmethyl)]amino-1-(1,1-dimethylethyl)amino]carbonyl]butane; MH⁺ 534.
- b) The CBZ protected compound (1.35g, 2.53mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (684mg, 2.57mmol) in the presence of N-hydroxybenzotriazole (590mg, 3.35mmol) and EDC (543mg, 2.83mmol) to yield 442mg

- (29%) of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](4-methoxyphenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[phenylmethylcarbamoyl)amino]-butanediamide; mp 175°C (dec) and MH⁺ 648. This compound (345mg, 0.53mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with 2-quinolinecarboxylic acid N-hydroxy-succinimide ester (118mg, 0.44mmol), in the presence of N-methylmorpholine, to afford 108mg (31%) of pure [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](4-methoxyphenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide; mp 220C (dec) and MLi⁺ 675.

Example 7

- The procedure described in Example 6A, part C-H, was used to prepare [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](n-butyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide.

- a) From the reaction of 1.48g (5.0mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 7.314g (100.0mmol) of n-butyl amine, one obtains 1.50g (80%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[n-butyl]amine. This amine (1.48g, 4.0mmol) was then reacted with tert-butylisocyanate (396mg, 4.0mmol) to afford 1.87g (100%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(n-butyl)amino]-1-(1,1-dimethylethyl)amino]carbonyl] butane as an oil.
- b) The CBZ protected compound (1.87g, 4.0mmol) was then d protected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (1.05g, 3.96mmol) in the presence

of N-hydroxybenzotriazole (535mg, 7.9mmol) and EDC (759mg, 3.96mmol) to yield 1.75g (76%) of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](n-butyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide; mp 166-167°C and MH⁺ 584.

A solution of [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](n-butyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide (1.03g, 1.77 mmol) in 40 mL of abs. ethanol was then deprotected by hydrogenolysis in the presence of 10% palladium on carbon catalyst to give, after filtration and concentration, the free amine (428mg) which was coupled with N-hydroxysuccinimide ester of 2-quinoline carboxylate (270mg, 1.0 mmol) in dichloromethane for 16 h to give 380 mg, 63% of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](n-butyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide, mp 102.1-103°C.

Example 8

The procedure described in Example 6A, part C-H, was used to prepare [1S-[1R*(R*), 2S*]]- N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide.

a) From the reaction of 1.48g (5.0mmol) of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane and 10.68g (100.0mmol) of benzyl amine, one obtains 1.88g (95%) of [2(R), 3(S)]-N-[[3-(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenylbutyl]N-[(phenylmethyl)amine]. This amine (1.88g, 4.65mmol) was then reacted with tert-butylisocyanat (460.0mg, 4.6mmol) to afford 2.24g (96%) of [2(R), 3(S)]-N-[[3-

(phenylmethylcarbamoyl)amino]-2-hydroxy-4-phenyl]-1-[(phenylmethyl)amino]-1-(1,1-dimethylethyl)amino]carbonyl] butane.

- b) The CBZ protected compound (2.22g, 4.4mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with N-CBZ-L-asparagine (1.17g, 4.4mmol) in the presence of N-hydroxybenzotriazole (1.19g, 8.8mmol) and EDC (843mg, 4.4mmol) to yield 2.11g (78%) of [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(phenylmethylcarbamoyl)amino]-butanediamide; mp 156-158°C and MH⁺ 618. This compound (1.0g, 1.62mmol) was then deprotected by hydrogenation over 10% palladium-on-carbon and the resulting free amine coupled with 2-quinolinecarboxylic acid N-hydroxysuccinimide ester (437mg, 1.62mmol), in the presence of N-methylmorpholine, to afford 640mg (62%) of pure [1S-[1R*(R*), 2S*]]-N¹[3-[[[(1,1-dimethylethyl)amino]carbonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide; mp 110.5-112.5°C and MH⁺ 639.

25


EXAMPLE 9

Additional exemplary compounds of the present invention are listed in Table 1. These compounds were prepared according to the following general procedures.

30

General Procedure for the Synthesis of 1,3-Diamino 4-phenyl Butan-2-ol Derivatives.

- A mixture of the amine R³NH₂ (20 equiv.) in dry isopropyl alcohol (20mL/mmol of epoxide to be converted) was heated to reflux and then treated with an N-Cbz amino poxide of the formula:



10 from a solids addition funnel over a 10-15 minute period. After the addition is complete the solution was maintained at reflux for an additional 15 minutes and the progress of the reaction monitored by TLC. The reaction mixture was then concentrated in vacuo to give
15 an oil that was treated with n-hexane with rapid stirring whereupon the ring opened material precipitated from solution. Precipitation was generally complete within 1 hr and the product was then isolated by filtration on a Büchner funnel and then air dried. The
20 product was further dried in vacuo. This method affords amino alcohols of sufficient purity for most purposes.
General procedure for the Reaction of Amino Alcohols with Isocyanates: Preparation of Ureas

A solution from the amino alcohol in
25 tetrahydrofuran (THF) was treated at room temperature with the appropriate isocyanate of formula R'NCO via syringe under nitrogen. After the reaction has stirred for ~5m the progress of the reaction was monitored by TLC. The solvent was removed in vacuo and the product
30 obtained was of sufficient purity for most purposes. The product may be further purified by dissolution in ethyl acetate and washing with 5% aqueous citric acid, water, and brine. The solvent is dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to
35 give the pure urea.

General Procedure for the Removal of the Protecting Groups by Hydrogenolysis with Palladium on Carbon

A. Alcohol Solvent

The Cbz-protected peptide derivative was dissolved in methanol (ca. 20 mL/mmol) and 10% palladium on carbon catalyst is added under a nitrogen atmosphere. The reaction vessel is sealed and flushed 5 times with nitrogen and then 5 times with hydrogen. The pressure is maintained at 50 psig for 1-16 hours and then the hydrogen replaced with nitrogen and the solution filtered through a pad of celite to remove the catalyst. The solvent is removed in vacuo to give the free amino derivative of suitable purity to be taken directly on to the next step.

B. Acetic Acid Solvent

The Cbz-protected peptide derivative was dissolved in glacial acetic acid (20 mL/mmol) and 10% palladium on carbon catalyst is added under a nitrogen atmosphere. The reaction vessel is flushed 5 times with nitrogen and 5 times with hydrogen and then maintained at 40 psig for about 2h. The hydrogen was then replaced with nitrogen and the reaction mixture filtered through a pad of celite to remove the catalyst. The filtrate was concentrated and the resulting product taken up in anhydrous ether and evaporated to dryness 3 times. The final product, the acetate salt, was dried in vacuo and is of suitable purity for subsequent conversion.

General Procedure for Removal of Boc-protecting Group with 4N Hydrochloric Acid in Dioxane

The Boc-protected amino acid or peptide is treated with a solution of 4N HCl in dioxane with stirring at room temperature. Generally the deprotection reaction is complete within 15 minutes, the progress of the reaction is monitored by thin layer chromatography (TLC). Upon completion, the excess dioxane and HCl are removed by evaporation in vacuo. The last traces of dioxane and HCl are best removed by evaporation again from anhydrous ether or acetone. The

hydrochloride salt thus obtained is thoroughly dried in vacuo and is suitable for further reaction.

EDC/HOBt Coupling of Cbz-Asparagine (General Procedure)

N-CBZ-(L-asparagine (1.10eq) and N-
5 hydroxybenzotriazole (HOBt) (1.5eq) are dissolved in dry dimethylformamide (DMF) (2-5mL/mmol) and cooled in an ice bath. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (1.10eq) is added to the stirring solution and maintained at 0°C for 10
10 minutes. A solution of the amino component (free amine), 1.0eq in DMF (1-2mL/mmol), is added. [In the case of the amine hydrochloride or acetate salt, an equivalent of N-methylmorpholine is also added.] The reaction mixture is stirred at 0°C for 1 hour and then
15 at room temperature for ~5-6 hours. The reaction mixture is then poured into a rapidly stirring solution of 60% saturated aqueous sodium bicarbonate (ca-50mL/mmol). An immediate white precipitate forms which is collected on a Büchner funnel and the solid washed
20 thoroughly with saturated aqueous sodium bicarbonate, water, 5% aqueous citric acid solution and water. The product is thoroughly dried in vacuo and redissolved in DMF, filtered and reprecipitated by the addition to water. The precipitated product is isolated by
25 filtration, washed again with water and dried in vacuo.

General Procedure for Acylation with 2-Quinoline Carboxylic Acid N-Hydroxysuccinimide Ester

A solution of the free amine (or amine acetate salt) and 1.0 equivalent of N-hydroxysuccinimide 2-
30 quinoline carboxylate in anhydrous dichloromethane was treated with 1.5 equivalents of N-methylmorpholine (NMM) at room temperature. The progress of the reaction was monitored by TLC and when the reaction was complete, the reaction mixture was diluted with additional
35 dichloromethane and the solution washed with saturated aqueous sodium bicarbonate, 5% aqueous citric acid, water and brine. The solution was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo.

The product thus obtained was recrystallized from a mixture of acetone and hexane.


81

TABLE 1

5

10

15



Entry No.	R	R ³	R ⁴
1	Cbz ^a	CH ₃	n-Butyl
2	Cbz	i-Butyl	CH ₃
3	Cbz	i-Butyl	n-Butyl
25 4	Q ^b	i-Butyl	n-Butyl
5	Cbz	i-Propyl	n-Butyl
6	Q	i-Propyl	n-Butyl
7	Cbz	C ₆ H ₅	n-Butyl
8	Cbz	-CH ₂ -	n-Butyl
30 9	Cbz	-CH ₂ -	n-Butyl
10	Q	-CH ₂ -	n-Butyl
11	Cbz	-	n-Butyl
12	Cbz	i-Butyl	n-Propyl
13	Cbz	i-Butyl	-CH ₂ CH(CH ₃) ₂
35 14	Cbz	(R) -CH(CH ₃) -	n-Butyl
15	Cbz	-CH ₂ -	i-Propyl
16	Cbz	-CH ₂ -	-CH ₂ CH ₂ CH(CH ₃) ₂
17	Cbz	i-Butyl	-CH ₂ CH ₃
18	Cbz	i-Butyl	-CH(CH ₃) ₂

40

TABLE 1 (Cont'd)










Entry No.	R	R ³	R ⁴
5			
19	Cbz	i-Butyl	
20	Q	i-Butyl	
21	Cbz	-CH ₂ 	-(CH ₂) ₂ CH(CH ₃) ₂
22	Cbz	(CH ₂) ₂ CH(CH ₃) ₂	-CH(CH ₃) ₂
10 23	Q	i-Butyl	-CH(CH ₃) ₂
24	Cbz	i-Butyl	-C(CH ₃) ₃
25	Q	i-Butyl	-C(CH ₃) ₃
26	Cbz	-CH ₂ 	-C(CH ₃) ₃
27	Q	-CH ₂ 	-C(CH ₃) ₃
15 28	Cbz	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃
29	Q	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃
30	Cbz	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃
31	Q	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃
32	Cbz	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃
20 33	Cbz	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃
34	Cbz	n-Butyl	-C(CH ₃) ₃
35	Cbz	n-Pentyl	-C(CH ₃) ₃
36	Cbz	n-Hexyl	-C(CH ₃) ₃
37	Cbz	-CH ₂ 	-C(CH ₃) ₃
25 38	Cbz	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃
39	Q	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃
40	Cbz	-CH ₂ CH ₂ - 	-C(CH ₃) ₃
41	Cbz	-CH ₂ C ₆ H ₅ OCH ₃ (para)	-C(CH ₃) ₃
42	Cbz	-CH ₂ 	-C(CH ₃) ₃
30 43	Cbz	-CH ₂ - 	-C(CH ₃) ₃
44	Cbz	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃
45	Q	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃

TABLE 1 (Cont'd)









Entry No.		R	R ³	R ⁴
5	46	Cbz	$-(\text{CH}_2)_4\text{OH}$	$-\text{C}(\text{CH}_3)_3$
	47.	Q	$-(\text{CH}_2)_4\text{OH}$	$-\text{C}(\text{CH}_3)_3$
	48.	Q	$-\text{CH}_2-$  $-\text{F}$	$-\text{C}(\text{CH}_3)_3$
	49.	Q	$-\text{CH}_2-$ 	$-\text{C}(\text{CH}_3)_3$
	50.		$-(\text{CH}_2\text{CH}(\text{CH}_3)_2$	$-\text{C}(\text{CH}_3)_3$
10	51.		"	"
	52.		"	"
	53.		"	"
	54.		"	"
	55.		"	"

TABLE 1 (Cont'd)







5	Entry No.	R	R ³
	R ⁴		
	56.		"
	57.		"
10	58.		"
	59.		"
	60.		"
	61.		"

TABLE 1 (Cont'd)









Entry No.	R	R ³
5 62.		" "
63.		" "
64.		" "
10 65.		" "
66.		" "
67.		" "

TABLE 1 (Cont'd)

Entry No.	R	R ³
5		
68.		" "
69.		" "
10		
^a benzyloxycarbonyl		
^b 2-quinolinylcarbonyl		


EXAMPLE 10

Following the generalized procedures set forth in Example 9, the compounds set forth in Table 2 were prepared.

TABLE 2

10

15



20

Entry	A	R ³	R ⁴
1.	Cbz-Val	<u>i</u> -amyl	t-Bu
2.	Cbz-Leu	<u>i</u> -amyl	<u>t</u> -Bu
3.	Cbz-Ile	<u>i</u> -amyl	<u>t</u> -Bu
25 4.	Ac-D- <u>homo</u> -Phe	<u>i</u> -Bu	<u>n</u> -Bu
5.	Qui-Orn(γ -Cbz)	-CH ₂ -	<u>t</u> -Bu
6.	Cbz-Asn	-CH ₂ CH=CH ₂	<u>t</u> -Bu
7.	Acetyl-t-BuGly	<u>i</u> -amyl	<u>t</u> -Bu
8.	Acetyl-Phe	<u>i</u> -amyl	<u>t</u> -Bu
30 9.	Acetyl-Ile	<u>i</u> -amyl	<u>t</u> -Bu
10.	Acetyl-Leu	<u>i</u> -amyl	<u>t</u> -Bu
11.	Acetyl-His	<u>i</u> -amyl	<u>t</u> -Bu
12.	Acetyl-Thr	<u>i</u> -amyl	<u>t</u> -Bu
35 13.	Acetyl-NHCH(C(CH ₃) ₂ (SCH ₃))C(O)-	<u>i</u> -amyl	<u>t</u> -Bu
14.	Cbz-Asn	<u>i</u> -amyl	<u>t</u> -Bu
15.	Cbz-Ala	<u>i</u> -amyl	<u>t</u> -Bu
16.	Cbz-Ala	<u>i</u> -amyl	<u>t</u> -Bu
17.	Cbz-beta-cyanoAla	<u>i</u> -amyl	<u>t</u> -Bu
40 18.	Cbz-t-BuGly	<u>i</u> -amyl	<u>t</u> -Bu

TABLE 2 (Cont'd)

Entry	A	R ³	R ⁴
5	19. Q-t-BuGly	<u>i</u> -amyl	<u>t</u> -Bu
	20. Q-SCH ₃ Cys	<u>i</u> -amyl	<u>t</u> -Bu
	21. Cbz-SCH ₃ Cys	<u>i</u> -amyl	<u>t</u> -Bu
	22. Q-Asp	<u>i</u> -amyl	<u>t</u> -Bu
	23. Cbz-(NHCH(C(CH ₃) ₂ (SCH ₃))C(O)-	<u>i</u> -amyl	<u>t</u> -Bu
10	24. Cbz-EtGly	<u>i</u> -amyl	<u>t</u> -Bu
	25. Cbz-PrGly	<u>i</u> -amyl	<u>t</u> -Bu
	26. Cbz-Thr	<u>i</u> -amyl	<u>t</u> -Bu
	27. Q-Phe	<u>i</u> -amyl	<u>t</u> -Bu
	28. Cbz-Phe	<u>i</u> -amyl	<u>t</u> -Bu


EXAMPLE 11

Following the generalized procedure of Example 9, the compounds listed in Table 3 were prepared.

TABLE 3

5

10



15

Entry

R¹

1

CH₂SO₂CH₃

2

(R) -CH(OH)CH₃

3

CH(CH₃)₂

20

4

(R, S) CH₂SOCH₃

5

CH₂SO₂NH₂

6

CH₂SCH₃

7

CH₂CH(CH₃)₂

8

CH₂CH₂C(O)NH₂

25

9

(S) -CH(OH)CH₃

EXAMPLE 12


Following the generalized procedures of Example 6, Part D and Example 9, the compounds set forth in Table 4 were prepared.

5

TABLE 4

10

15



20

	Entry	R ²	A
	1.	n-Bu	Cbz-Asn
	2.	cyclohexylmethyl	Cbz-Asn
	3.	n-Bu	Boc
25	4.	n-Bu	Cbz
	5.	C ₆ H ₅ CH ₂	Boc
	6.	C ₆ H ₅ CH ₂	Cbz
	7.	C ₆ H ₅ CH ₂	benzoyl
	8.	cyclohexylmethyl	Cbz
30	9.	n-Bu	Q-Asn
	10.	cyclohexylmethyl	Q-Asn
	11.	C ₆ H ₅ CH ₂	Cbz-Ile
	12.	C ₆ H ₅ CH ₂	Q-Ile
	13.	C ₆ H ₅ CH ₂	Cbz-t-BuGly
35	14.	C ₆ H ₅ CH ₂	Q-t-BuGly
	15.	C ₆ H ₅ CH ₂	Cbz-Val
	16.	C ₆ H ₅ CH ₂	Q-Val
	17.	2-naphthylmethyl	Cbz-Asn
	18.	2-naphthylmethyl	Q-Asn
40	19.	2-naphthylmethyl	Cbz
	20.	n-Bu	Cbz-Val

TABLE 4 (Cont'd)

Entry	R ²	A
5	21. n-Bu	Q-Val
	22. n-Bu	Q-Ile
	23. n-Bu	Cbz-t-BuGly
	24. n-Bu	Q-t-BuGly
	25. p-F(C ₆ H ₄)CH ₂	Q-Asn
10	26. p-F(C ₆ H ₄)CH ₂	Cbz
	27. p-F(C ₆ H ₄)CH ₂	Cbz-Asn

EXAMPLE 13


15 The compounds listed in Table 5 were prepared according to the generalized procedures of Example 9.

TABLE 5

20

25

30




35

Entry	XR ⁴	A
1.	-NH ^t Bu	Cbz-Asn
40	2. -NEt ₂	Cbz
	3. -NHC(CH ₃) ₂ CH ₂ CH ₃	Cbz

EXAMPLE 14

The compounds of Table 6 were prepared according to the generalized procedures set forth in Example 9 except that instead of an isocyanate, an isothiocyanate equivalent was utilized.

Table 6



Entry	XHR ⁴
1.	NHEt
2.	NH ^t Bu

The Cbz group of the compounds shown in Examples 13 and 14 can be removed as described in Example 9 and the resulting compound can be coupled to a desired α - or β -amino acid or the like to produce compounds of the present invention.

Example 15

The compounds shown in Table 7 were prepared according to the following general procedure. This general procedure represents a Curtius Rearrangement and reaction with the amino alcohol derivative as prepared following the general procedure in Example 9.

To a solution of 1 mmol of carboxylic acid in 12 mL of toluene and 3 mmol of triethylamine at 90°C under a nitrogen atmosphere, was added 1 mmol of diphenylphosphoryl azide. After 1 hour, a solution of 1

mmol of amino alcohol derivative in 3.5 mL of either N,N-dimethylformamide or toluene was added. After 1 hour, the solvent was removed under reduced pressure, ethyl acetate and water added and the layers separated.

- 5 The organic layer was washed with 5% citric acid, sodium bicarbonate, brine, dried, filtered and concentrated to afford the crude product. This was then recrystallized or chromatographed on silica gel to afford the purified final compound.

TABLE 7

5

Chemical structure of a peptide derivative. The structure shows a naphthalene-1-carboxamide group attached to a backbone. The backbone includes a chiral center with a benzyl group (wedge bond), a hydroxyl group (dash bond), and a side chain containing a secondary amide with an R^4 group. A dashed line indicates a continuation of the polymer chain.

R^3

R^4

$-\text{CH}_2\text{CH}(\text{CH}_3)_2$

$-\text{C}(\text{CH}_3)_2$


20

$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$


$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$

$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$

$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$

Example 16A. Preparation of 4(4-methoxybenzyl)itaconate

A 5 L three-necked round bottomed flask equipped with constant pressure addition funnel, reflux condenser, nitrogen inlet, and mechanical stirrer was charged with itaconic anhydride (660.8g, 5.88 mol) and toluene (2300 mL). The solution was warmed to reflux and treated with 4-methoxybenzyl alcohol (812.4g, 5.88 mol) dropwise over a 2.6h period. The solution was maintained at reflux for an additional 1.5h and then the contents were poured into three 2 L erlenmeyer flasks to crystallize. The solution was allowed to cool to room temperature whereupon the desired mono-ester crystallized. The product was isolated by filtration on a Buchner funnel and air dried to give 850.2g, 58% of material with mp 83-85°C, a second crop, 17% was isolated after cooling of the filtrate in an ice bath. ¹H NMR (CDCl₃) 300 MHz 7.32(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 6.49(s, 1H), 5.85(s, 1H), 5.12(s, 2H), 3.83(s, 3H), 3.40(s, 2H).

B. Preparation of Methyl 4(4-methoxybenzyl) itaconate


A 5 L three-necked round bottomed flask equipped with reflux condenser, nitrogen inlet, constant pressure addition funnel and mechanical stirrer was charged with 4(4-methoxybenzyl) itaconate (453.4g, 1.81 mol) and treated with 1,5-diazabicyclo[4.3.0]non-5-ene (275.6g,

1.81 mol), (DBU), dropwise so that the temperature did not rise above 15°C. To this stirring mixture was added a solution of methyl iodide (256.9g, 1.81 mol) in 250 mL of toluene from the dropping funnel over a 45m period.

- 5 The solution was allowed to warm to room temperature and stirred for an additional 3.25h.

The precipitated DBU hydroiodide was removed by filtration, washed with toluene and the filtrate poured into a separatory funnel. The solution was
10 washed with sat. aq. NaHCO₃ (2 X 500 mL), 0.2N HCl (1 X 500 mL), and brine (2 X 500 mL), dried over anhyd. MgSO₄, filtered, and the solvent removed in vacuo. This gave a clear colorless oil, 450.2g, 94% whose NMR was consistent with the assigned structure. ¹H NMR (CDCl₃)
15 300 MHz 7.30(d, J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 2H), 6.34(s, 1H), 5.71(s, 1H), 5.09(s, 2H), 3.82(s, 3H), 3.73(s, 3H), 3.38(s, 2H). ¹³C NMR (CDCl₃) 170.46, 166.47, 159.51, 133.55, 129.97, 128.45, 127.72, 113.77, 66.36, 55.12, 51.94, 37.64.

20 C. Preparation of Methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate



A 500 mL Fisher-Porter bottle was charged with methyl 4(4-methoxybenzyl) itaconate (71.1g, 0.269 mol), rhodium (R,R) DiPAMP catalyst (204mg, 0.269 mmol, 0.1 mol%) and
35 degassed methanol (215 mL). The bottle was flushed 5 times with nitrogen and 5 times with hydrogen to a final pressure of 40 psig. The hydrogenation commenced immediately and after ca. 1h the uptake began to taper off, after 3h the hydrogen uptake ceased and the bottle
40 was flushed with nitrogen, opened and the contents concentrated on a rotary evaporator to give a brown oil


that was taken up in boiling iso-octane (ca. 200 mL, this was repeated twice), filtered through a pad of celite and the filtrate concentrated *in vacuo* to give 66.6g, 93% of a clear colorless oil, ^1H NMR (CDCl_3 , 300 MHz) 7.30(d, $J=8.7$ Hz, 2H), 6.91(d, $J=8.7$ Hz, 2H), 5.08(s, 2H), 3.82(s, 3H), 3.67(s, 3H), 2.95(ddq, $J=5.7$, 7.5, 8.7 Hz, 1H), 2.79(dd, $J=8.1$, 16.5 Hz, 1H), 2.45(dd, $J=5.7$, 16.5 Hz, 1H), 1.23(d, $J=7.5$ Hz, 3H).

10 D. Preparation of Methyl 2(R)-methylsuccinate

A 3 L three-necked round-bottomed flask equipped with a nitrogen inlet, mechanical stirrer, reflux condenser and constant pressure addition funnel was charged with methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate (432.6g, 1.65 mol) and toluene (1200 mL). The stirrer was started and the solution treated with trifluoroacetic acid (600 mL) from the dropping funnel over 0.25h. The solution turned a deep purple color and the internal temperature rose to 45°C. After stirring for 2.25h the temperature was 27°C and the solution had acquired a pink color. The solution was concentrated on a rotary evaporator. The residue was diluted with water (2200 mL) and sat. aq. NaHCO_3 (1000 mL). Additional NaHCO_3 was added until the acid had been neutralized. The aqueous phase was extracted with ethyl acetate (2 X 1000 mL) to remove the by-products and the aqueous layer was acidified to pH=1.8 with conc. HCl. This solution was extracted with ethyl acetate (4 X 1000 mL), washed with brine, dried over anhyd. MgSO_4 , filtered and concentrated on a rotary evaporator to give a colorless liquid 251g, >100% that was vacuum distilled through a short path apparatus cut 1: bath temperature 120°C @ >1mm, bp 25-29°C; cut 2: bath temperature 140°C @ 0.5mm, bp 95-103°C, 151g, $[\alpha]_D^{25} = +1.38^\circ\text{C}$ ($c=15.475$, MeOH), $[\alpha]_D^{25} = +8.48^\circ\text{C}$ (neat); cut 3: bath temperature 140°C, bp 108°C, 36g, $[\alpha]_D^{25} = +1.49^\circ\text{C}$ ($c=15.00$, MeOH), $[\alpha]_D^{25} = +8.98^\circ\text{C}$ (neat). Cuts 2 and 3 were combined to give 189g, 78% of product, ^1H NMR (CDCl_3 , 300 MHz) 11.6(brs,


1H), 3.72(s, 3H), 2.92(ddq, J=5.7, 6.9, 8.0 Hz, 1H), 2.81(dd, J=8.0, 16.8 Hz, 1H), 2.47(dd, J=5.7, 16.8 Hz, 1H), 1.26(d, J=6.9 Hz, 3H).

E. Preparation of Methyl Itaconate



A 50 mL round bottomed flask equipped with reflux condenser, nitrogen inlet and magnetic stir bar was charged with methyl 4(4-methoxybenzyl) itaconate (4.00g, 16 mmol). The solution was kept at room temperature for 18 hours and then the volatiles were removed *in vacuo*. The residue was taken up in ethyl acetate and extracted three times with saturated aqueous sodium bicarbonate solution. The combined aqueous extract was acidified to pH=1 with aqueous potassium bisulfate and then extracted three times with ethyl acetate. The combined ethyl acetate solution was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated *in vacuo*. The residue was then vacuum distilled to give 1.23g, 75% of pure product, bp 85-87 @ 0.1 mm. ¹H NMR (CDCl₃) 300 MHz 6.34(s, 1H), 5.73(s, 2H), 3.76(s, 3H), 3.38(s, 2H). ¹³C NMR (CDCl₃) 177.03, 166.65, 129.220, 132.99, 52.27, 37.46.

F. Curtius Rearrangement of Methyl 2(R)-methylsuccinate: Preparation of Methyl N-Moz-α-methyl β-alanine.



A 5L four necked round bottomed flask equipped with a nitrogen inlet, reflux condenser, mechanical stirrer,


constant pressure addition funnel, and thermometer adapter was charged with methyl 2(R)-methylsuccinate (184.1g, 1.26 mol), triethylamine (165.6g, 218 mL, 1.64 mol, 1.3 equivalents), and toluene (1063 mL). The solution was warmed to 85°C and then treated dropwise with a solution of diphenylphosphoryl azide (346.8g, 1.26 mol) over a period of 1.2h. The solution was maintained at that temperature for an additional 1.0h and then the mixture was treated with 4-methoxybenzyl alcohol (174.1g, 1.26 mol) over a 0.33h period from the dropping funnel. The solution was stirred at 88°C for an additional 2.25h and then cooled to room temperature. The contents of the flask were poured into a separatory funnel and washed with sat. aq. NaHCO₃ (2 X 500 mL), 0.2N HCl (2 X 500 mL), brine (1 X 500 mL), dried over anhyd. MgSO₄, filtered, and concentrated in vacuo to give 302.3g, 85% of the desired product as a slightly brown oil. ¹H NMR (CDCl₃) 300 MHz 7.32(d, J=8.4 Hz, 2H), 6.91(d, J=8.4 Hz, 2H), 5.2(brm, 1H), 5.05(s, 2H), 3.83(s, 3H), 3.70(s, 3H), 3.35(m, 2H), 2.70(m, 2H), 1.20(d, J=7.2 Hz, 3H).

G. Hydrolysis of Methyl N-Moz-α-methyl β-alanine:

Preparation of α-methyl β-alanine Hydrochloride

25


30



A 5 L three-necked round bottomed flask equipped with a reflux condenser, nitrogen inlet and mechanical stirrer was charged with methyl N-Moz-α-methyl β-alanine (218.6g, 0.78 mol), glacial acetic acid (975 mL) and 12N hydrochloric acid (1960 mL). The solution was then heated to reflux for 3h. After the solution had cooled to room temperature (ca. 1h) the aqueous phase was decanted from organic residue

(polymer) and the aqueous phase concentrated on a rotary evaporator. Upon addition of acetone to the concentrated residue a slightly yellow solid formed that was slurried with acetone and the white solid was isolated by filtration on a Buchner funnel. The last traces of acetone were removed by evacuation to give 97.7g, 90% of pure product, mp 128.5-130.5°C [α]_D 25°C=9.0°C (c=2.535, Methanol). ¹H NMR (D₂O) 300 MHz 3.29(dd, J=8.6, 13.0 Hz, 1H), 3.16(dd, J=5.0, 13.0m Hz, 1H), 2.94(ddq, J=7.2, 5.0, 8.6 Hz, 1H), 1.30(d, J=7.2 Hz, 3H); ¹³C NMR (D₂O) 180.84, 44.56, 40.27, 17.49.

H. Preparation of N-Boc α -Methyl β -Alanine



A solution of α -methyl β -alanine hydrochloride (97.7g, 0.70 mol) in water (1050 mL) and dioxane (1050 mL) the pH was adjusted to 8.9 with 2.9N NaOH solution. This stirring solution was then treated with di-tert-butyl pyrocarbonate (183.3g, 0.84 mol, 1.2 equivalents) all at once. The pH of the solution was maintained between 8.7 and 9.0 by the periodic addition of 2.5N NaOH solution. After 2.5h the pH had stabilized and the reaction was judged to be complete. The solution was concentrated on a rotary evaporator (the temperature was maintained at <40°C). The excess di-tert-butyl pyrocarbonate was removed by extraction with dichloromethane and then the aqueous solution was acidified with cold 1N HCl and immediately extracted with ethyl acetate (4 X 1000 mL). The combined ethyl acetate extract was washed with brine, dried over anhyd. MgSO₄, filtered and concentrated on a rotary evaporator to give a thick oil 127.3g, 90% crude yield that was stirred with n-hexane whereupon crystals of pure product formed, 95.65g, 67%, mp 76-78°C, [α]_D 25°C=-11.8°C (c=2.4, EtOH). A second crop was obtained by

concentration of the filtrate and dilution with hexane, 15.4g, for a combined yield of 111.05g, 78%. ¹H NMR (acetone D₆) 300 MHz 11.7 (brs, 1H), 6.05 (brs 1H), 3.35 (m, 1H), 3.22 (m, 1H), 2.50 (m, 1H), 1.45(s, 9H), 1.19 (d, J=7.3 Hz, 3H); ¹³C NMR (acetone D₆) 177.01, 79.28, 44.44, 40.92, 29.08, 15.50. Elemental analysis calc'd. for C₉H₁₇NO₄: C, 53.19, H, 8.42; N, 6.89. Found: C, 53.36; H, 8.46; N, 6.99.

10 I. Preparation of N-4-Methoxybenzyloxycarbonyl α-Methyl β-Alanine

A solution of N-4-methoxybenzyloxycarbonyl α-methyl β-alanine methyl ester (2.81g, 10.0 mmol) in 30 mL of 25% aqueous methanol was treated with lithium hydroxide (1.3 equivalents) at room temperature for a period of 2h. The solution was concentrated in vacuo and the residue taken up in a mixture of water and ether and the phases separated and the organic phase discarded. The aqueous phase was acidified with aqueous potassium hydrogen sulfate to pH=1.5 and then extracted three times with ether. The combined ethereal phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to give 2.60 g, 97% of N-4-Methoxybenzyloxycarbonyl α-methyl β-alanine (N-Moz-AMBA) which was purified by recrystallization from a mixture of ethyl acetate and hexane to give 2.44g, 91% of pure product, mp 96-97°C, MH⁺=268. ¹H NMR (D₆-acetone/300 MHz) 1.16 (3H, d, J=7.2Hz), 2.70 (1H, m), 3.31 (2H, m), 3.31 (3H, s), 4.99 (2H, s), 6.92 (2H, 4, J=8.7 Hz), 7.13 (2H, d, J=8.7 Hz).

35 J. Preparation of Propanamide, 3-(4-methoxybenzyloxycarbonyl)-N-[3-[[[(1,1-dimethylethyl)amine]carbonyl](3-methylbutyl)aminol-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-[1S-[IR*(S*)], 2S*]]-

N-Moz-AMBA (468mg, 1.75mmol) was dissolved in 5mL of DMF, HOBT (355mg, 2.6mmol) was added and the solution was cooled to 0°C. The solution was treated

- with (336mg, 1.75mmol) EDC for 15 minutes. To this was added (612mg, 1.75mmol) of [2R,3S 3-amino-1-isoamyl-1-(t-butylcarbonyl)amino 4-phenyl-2-butanol in 10mL of DMF and the reaction stirred for 16 hours at room
- 5 temperature. The DMF was concentrated to 5mL and the product was precipitated by addition to 60% saturated aqueous NaHCO_3 . The solid was taken up in ethyl acetate and washed with KHSO_4 , NaHCO_3 , NaCl (saturated), dried over MgSO_4 and concentrated to yield 680mg of crude
- 10 product which was crystallized from CH_2Cl_2 , Et_2O , hexane, to yield 300mg of pure product.

Example 17

The compounds of Table 8 were prepared according to the procedure listed below and that utilized in Example 16.

5 Propaneamide, 3-[(1,1-
dimethylethyl)butoxycarbonyl]amino-N-[3-[[[(1,1--
dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
hydroxy-1-(phenylmethyl)propyl]-2-methyl-, [1S-
[1R*(S*), 2S*]]- (Table 8, Entry 11)

10 Part A.

A solution of N-t-butyloxycarbonyl-2-(R)-methyl-3-aminopropionic acid (372 mg, 1.83 mmol) and N-hydroxybenzotriazole (371 mg, 2.75 mmol) in 5 mL of dimethylformamide was cooled to 0°C. To this was added
15 EDC (351 mg, 1.83 mmol) and the solution was stirred for 15 minutes. To this chilled solution was added a solution of 3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2(R)-hydroxy-
1(S)(phenylmethyl)propylamine in 5 mL of
20 dimethylformamide and stirred for 15 hours. The dimethylformamide was removed and replaced with 50 mL of ethyl acetate, and the organic phase was extracted with 5% potassium hydrogen sulfate, saturated sodium bicarbonate and brine. The ethyl acetate layer was
25 dried over magnesium sulfate, filtered and concentrated to yield 613 mg of product after recrystallization from ethyl acetate, hexanes. (63 % yield). M+Li 541

Part B.

Preparation of Propaneamide, 3-amino-N-[3-
30 [[[(1,1-dimethylethyl)amino] carbonyl]- (3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, [1S-[1R*(S*), 2S*]]-hydrochloride

The product from part A. (577 mg, 1.08 mmol)
35 was dissolved in 40 mL of 4N HCl in dioxane and the solution stirred for 2 hours, and concentrated to yield the hydrochloride salt in quantitative yield.

Part C.


Preparation of Propanamide, 3-(2-methylpropanoylamino)-N-[3-[[[(1,1-dimethylethyl)-amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, [1S-[1R*(S*),2S*]-

The product from part B. (236 mg, 0.5 mmol) was dissolved in anhydrous tetrahydrofuran and to this was added N-methylmorpholine (160 mg, 1.5 mmol) upon which time a precipitate formed. To this suspension was added isobutyryl chloride (53.5 mg, 0.5 mmol) and the suspension stirred for 15 hours. The suspension was diluted with ethyl acetate and washed with 5% potassium hydrogen sulfate, saturated sodium bicarbonate and brine. the organic layer was dried over magnesium sulfate, filtered and concentrated to yield 195 mg of crude product which was chromatographed on silica gel with 5% methanol methylene chloride to yield 121.5 mg (50 % yield) of pure product. M+Li 511

TABLE 8

20

25



30

35

R

R₁

1.






-CH₃

TABLE 8 (Cont'd)

5	<hr/>	
	R	R ₁
10	<hr/>	
2.		-CH ₃
3.		-CH(CH ₃) ₂
4.		-CH(CH ₃) ₂
5.		-C(CH ₃) ₃

-106-

then methylene chloride/hexane ne obtains 1.1g (28%) of trans-monoethyl 1,2-cyclopropanedicarboxylate, $m/e = 159$ ($M + H$).

Part B:

5 To a solution of 297 mg (1.87 mmol) of trans-monoethyl 1,2-cyclopropanedicarboxylate and 429 mg (2.8 mmol) N-hydroxybenzotriazole (HOBT) in 3 mL of anhydrous N,N-dimethylformamide (DMF) at 0°C was added 394 mg (2.0 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). After 30 min. a solution of 591 mg (1.7 mmol) of product from Part A in 2 mL DMF and 171 mg (1.69 mmol) of N-methylmorpholine (NMM) was added. After 2 hours at 0°C, the reaction was stirred at RT overnight, poured into water, extracted with ethyl acetate, washed with water, 5% aq. citric acid, sat'd NaHCO₃, brine, dried over anhydride MgSO₄ and stripped to afford 771 mg of crude product. This was chromatographed on silica gel using 5-20% methanol/methylene chloride to afford 670 mg (80%) of cyclopropane carboxylic acid, 2-[[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-, ethyl ester; $m/e = 490$ ($M + H$).

Part C:

25 To a solution of 658 mg (1.32 mmol) of product from Part B in 5 mL of 50:50 THF/water was added 66 mg (1.58 mmol) of lithium hydroxide. After 19 hours, the THF was removed in vacuo, the water washed with ethyl acetate, acidified and reextracted with ethyl acetate. 30 The organic layer was dried and stripped to afford 328 mg (54%) of the corresponding acid, $m/e = 462$ ($M + H$).

Part D:

To a solution of 304 mg (0.66 mmol) of product from Part C, 151 mg (0.99 mmol) HOBT in 2.2 mL DMF at 35 0°C was added 139 mg (0.73 mmol) EDC. After 30 min. at 0°C, 1.1 mL of conc. aqueous ammonia was added. After stirring at 0°C for 2 hours and RT for 20 hours, the reaction was poured into brine and extracted with ethyl

-107-

acetate. After washing with sat'd NaHCO_3 , brine, drying and stripping, ne obtains 141 mg of crude product. This was chromatographed on silica gel with 1-5% methanol/methylene chloride to afford 40 mg (13%) of the desired final product, $m/e = 561$ ($M + H$).

Example 37

Preparation of trans-but-2-enediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*, 2S*]].

10 Part A:

To a solution of 137 mg (0.95 mmol) fumaric acid monoethyl ester in 1 mL of DMF at 0°C was added 183 mg (0.95 mmol) EDCI. After 15 minutes, a solution of 333 mg (0.95 mmol) of the compound of Example 34 Part E in 1 mL DMF was added and the reaction stirred for 14 hours at RT. Ethyl acetate was added and extracted with sat'd brine, 0.2 N HCl, sat'd NaHCO_3 , dried and stripped to afford 0.32g of crude product. Chromatography on silica gel using 0-50% ethyl acetate/hexane afforded 0.26g (58%) of but-2-enoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-4-oxo-, [1S-[1R*, 2S*]]-, ethyl ester, $m/e = 476$ ($M + H$).

Part B:

25 To a solution of 26.6 mg (0.56 mmol) of product from Part A in 3 mL of 50:50 THF/water was added 34 mg (0.82 mmol) of lithium hydroxide and the reaction stirred at RT for 1 hour. The THF was removed in vacuo, the aqueous layer acidified with 1N HCl and extracted with ethyl acetate. The organic layer was washed with brine, dried and stripped to afford 233 mg (93%) of trans-but-2-enoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-4-oxo-, [1S-[1R*, 2S*]]-, $m/e = 448$ ($M + H$).

Part C:

To a solution of 225 mg (0.50 mmol) of the product from Part B in 1 mL of DMF was added 95 mg (0.50

-108-

mmol) EDC. After 15 minutes at RT, 0.50 mL of conc. aqueous ammonia was added and the reaction stirred for 15 hours. Ethyl acetate was added and washed with 0.2N HCl, brine, dried and stripped to afford 170 mg of crude product. After chromatography on silica gel using 0-40% methanol/methylene chloride, one obtains 50 mg (22%) of trans-but-3-enediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*, 2S*]-, m/e = 447 (M + H).

Example 38

Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, [1S-[1R*(2S*), 2S*]-.

Part A:

To a suspension of 24.7g (0.22 mol) of itaconic anhydride in 100 mL of anhydrous toluene at reflux under a nitrogen atmosphere was added dropwise over 30 minutes 23.9g (0.22 mol) of benzyl alcohol. The insoluble material dissolved to provide a homogeneous solution which was refluxed for 1.5 hours. The solution was cooled to RT, then in an ice bath and the resulting white precipitate collected by filtration to afford 24.8g (51%) of 4-benzyl itaconate.

Part B:

To a solution of 2.13g (9.5 mmol) of the product from Part A in 12 mL of methylene chloride at 0°C was added 4.02g (29.1 mmol) of para-methoxybenzyl alcohol, 605 mg (4.95 mmol) of N,N-dimethyl 4-aminopyridine, 128 mg of N,N-dimethyl 4-aminopyridine hydrochloride salt and then 2.02g (4.7 mmol) dicyclohexylcarbodiimide (DCC). After stirring at 0°C for 1 hour and then RT for 2 hours, the precipitate was collected and discarded. The filtrate was washed with 0.5 N HCl, sat'd NaHCO₃, dried and stripped to afford 4.76g of crude product. This was chromatographed on

-109-

silica gel using 0-50% ethyl acetate/hexan to afford
1.24g of pure 4'-methoxybenzyl-4-benzylsuccinate
, MH^+ m/z = .

Part C:

5 A solution of 1.24g (3.65 mmol) of product
from Part B and 20 mg of [(R,R)-
Dipamp)cyclooctadienylrhodium] tetrafluoroborate in 30
mL of methanol was thoroughly degassed, flushed with
nitrogen and then hydrogen and then stirred under 50
10 psig of hydrogen for 15 hours. The solution was
filtered and stripped, dissolved in methylene chloride
and washed with sat'd $NaHCO_3$, dried and stripped to
afford 0.99g of a brown oil. This was then dissolved in
40 mL of methylene chloride, 3 mL of trifluoroacetic
15 acid added and the solution stirred at RT for 3.5 hours.
Water was added and separated and the organic layer
extracted with sat'd $NaHCO_3$. The aqueous layer was
acidified and reextracted with ethyl acetate, separated
and the organic layer washed with brine, dried and
20 stripped to afford 320 mg (50%) of 2(R)-methyl-4-
benzylsuccinic acid.

Part D:

To a solution of 320 mg (1.44 mmol) of product
from Part C and 314 mg (2.05 mmol) HOBT in DMF at 0°C
25 was added 303 mg (1.58 mmol) of EDC. After stirring for
30 minutes, a solution of 467 mg (1.34 mmol) of the
product from Example 34, Part E in 4 mL of DMF was
added. After stirring for 1 hour at 0°C and 14 hours at
RT, ethyl acetate was added and washed with sat'd $NaHCO_3$,
30 5% aqueous citric acid, dried and stripped to afford
0.97g of crude product. This was chromatographed on
silica gel using 0-10% ethyl acetate/hexane to afford
420 mg of pure butanoic acid, 4-[[[3-[[[(1,1-
dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
35 hydr xy-1-(phenylmethyl)propyl]amino]-3-methyl-4-oxo-,
[1S-[1R*(3S*), 2S*]-, benzyl ester.

-110-

Part E:

A solution of 150 mg (0.27 mmol) of product from Part D in 15 mL of methanol was hydrogenated over 10% palladium on carbon under 50 psig hydrogen for 17 hours. The reaction was filtered and stripped to afford 125 mg (100%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3S*), 2S*]-.

10 Part F:

To a solution of 125 mg (0.27 mmol) of product from Part E and 65 mg (0.42 mmol) of HOBT in 5 mL of DMF at 0°C was added 59 mg (0.31 mmol) of EDC. After 30 min. at 0°C, 1 mL of conc. aqueous ammonia was added. After stirring at 0°C for 2 hours and RT for 15 hours, ethyl acetate was added and washed with sat'd NaHCO₃, 5% aqueous citric acid, dried and stripped to afford 90 mg of crude product. This was recrystallized from ethyl acetate/hexane to afford 40 mg (32%) of pure butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl, [1S-[1R*(2S*), 2S*]-.

Example 39

25 Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl, [1S-[1R*(2R*), 2S*]-.

Part A:

30 A solution of 1.41g (4.1 mmol) of 4'-methoxybenzyl 4-benzylitaconate and 25 mg of [(S,S-Dipamp)cyclooctadienylrhodium]tetrafluoroborate in 20 mL of methanol was thoroughly degassed, flushed with nitrogen and then hydrogen and then stirred under 40 psig hydrogen for 72 hours. The solution was filtered and concentrated to provide 1.34g of a brown oil. This was dissolved in 40 mL of methylene chloride and 3 mL of trifluoroacetic acid was added. After stirring for 4

-111-

hours, water was added, separated and the organic layer extracted with sat'd NaHCO_3 . The aqueous layer was separated, reacidified, extracted with ethyl acetate which was separated, washed with brine, dried and
5 stripped to afford 440 mg of 2(S)-methyl-4-benzylsuccinic acid.

Part B:

To a solution of 440 mg (1.98 mmol) of the product from Part A and 437 mg (2.86 mmol) of HOBt in 9
10 mL of DMF at 0°C was added 427 mg (2.23 mmol) of EDCI. After 30 minutes at 0°C, a solution of 653 mg (1.87 mmol) of the product from Example 34, Part E in 3 mL DMF was added. After 1 hour at 0°C and 15 hours at RT, ethyl acetate was added, extracted with sat'd NaHCO_3 , 5%
15 aqueous citric acid, dried and concentrated to afford 0.98g of crude product. Chromatography on silica gel using 0-10% ethyl acetate afforded 610 mg (59%) of pure butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)-amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-
20 (phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3R*), 2S*], benzyl ester.

Part C:

A solution of 310 mg (0.56 mmol) of the product from Part B in 20 mL of methanol was
25 hydrogenated over 20 mg of 10% palladium on carbon under 50 psig hydrogen for 19 hours. The solution was filtered and concentrated to afford 220 mg (85%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)-amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-
30 (phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3R*), 2S*].

Part D: To a solution of 190 mg (0.41 mmol) of the product from Part C and 90 mg (0.58 mmol) HOBt in 5 mL
35 of DMF at 0°C, was added 88 mg (0.46 mmol) of EDCI. After 30 minutes at 0°C, 2 mL of conc. aqueous ammonia was added. After 1 hour at 0°C and 15 hours at RT, ethyl acetate was added, washed with sat'd NaHCO_3 , 5%

-112-

aqueous citric acid, dried and concentrated to afford crude product. Recrystallization from ethyl acetate/hexane afforded 20 mg (11%) of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl, [1S-[1R*(2R*), 2S*]-].

Example 40

Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, [1S-[1R*(3S*), 2S*]-].

Part A: In a similar manner to the procedure used above, p-methoxybenzyl alcohol was reacted with itaconic anhydride in refluxing toluene to provide 4-(p-methoxybenzyl)itaconate.

Part B: To a solution of 3.30g (13.2 mmol) of the product from Part A in 17 mL of toluene, was added 2.08g (13.7 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene and then 2.35g (13.7 mmol) of benzyl bromide. After 2 hours, the solution was filtered and the filtrate washed with sat'd NaHCO₃, 3N HCl, brine, dried and concentrated to afford 3.12g of an oil. After chromatography on silica gel using 0-5% ethyl acetate/hexane one obtains 2.19g (49%) of benzyl 4-(4-methoxybenzyl)itaconate.

Part C:

A solution of 1.22g (3.6 mmol) of product from Part B and 150 mg of [(R,R-Dipamp) cyclooctadienylrhodium] tetrafluoroborate in 15 mL of methanol was thoroughly degassed, flushed with nitrogen and then hydrogen and hydrogenated under 50 psig for 16 hours. The solution was filtered and concentrated to afford 1.2g of a brown oil. This was dissolved in 5 mL of methylene chloride and 5 mL of toluene and 3 mL of trifluoroacetic acid was added. After 4 hours, the solvents were removed in vacuo, the residue dissolved in methylene chloride, which was then extracted with sat'd

-113-

NaHCO₃. After separation, the aqueous layer was acidified, reextracted with methylene chloride which was then dried and concentrated to afford 470 mg (60%) of 3(R)-methyl-4-benzylsuccinic acid.

5 Part D:

To a solution of 470 mg (2.11 mmol) of product from Part C and 463 mg (3.03 mmol) of HOBT in 5 mL of DMF at 0°C was added 451 mg (2.35 mmol) of EDC. After 30 min. at 0°C, a solution of 728 mg (2.08 mmol) of the product from Example 34, Part E in 3 mL of DMF was added. After stirring at 0°C for 1 hour and 15 hours at RT, ethyl acetate was added and extracted with sat'd NaHCO₃, 5% aqueous citric acid, brine, dried and concentrated to give 930 mg of crude product chromatography on silica gel using 0-10% ethyl acetate/hexane one obtains 570 mg (50%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-4-oxo-, [1S-[1R*(2S*), 2S*]-, benzyl ester.

Part E:

The product was hydrogenated in methanol using 10% palladium on carbon under 40 psig of hydrogen to afford butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-4-oxo-, [1S-[1R*(2S*), 2S*]-.

Part F:

To a solution of 427 mg (0.92 mmol) of product from Part E and 210 mg (1.37 mmol) in 3 mL of DMF at 0°C was added 196 mg (1.02 mmol) of EDC. After 30 min. at 0°C, 2 mL of conc. aqueous ammonia was added. After 1 hour at 0°C and 15 hours at RT, ethyl acetate was added and then extracted with sat'd NaHCO₃, brine, dried and concentrated to afford crude product. Recrystallization from ethyl acetate/hexane afforded 50 mg (12%) of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-

TABLE 11 (Cont'd)








5	R_3	$X-R_4$ $ $ R^5
10		
	"	$N(CH_3)(t-Bu)$
15	"	
	"	
	"	
	"	

TABLE 11 (Cont'd)

5	R_3	$\begin{array}{c} X-R_4 \\ \\ R^5 \end{array}$
10		
15		

Example 23

3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino-2(R)-hydroxy-1(S)-(phenylmethyl)propyl amine

This example illustrates preparation of compounds of Formula II wherein R^1 is an alkyl group other than an alkyl group of a naturally occurring amino acid side chain. In particular, R^1 is a t-butyl group.

Part A:

3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino-2(R)-hydroxy-1(S)-[N-(benzyloxycarbonyl)(phenylmethyl)propyl amine] (4.7 gm, 9.7 mmol) was combined with 10% Pd on carbon (200 mg) and conc. HCl (3 mL) in ethanol (35 mL) and hydrogenated at 50 psi of hydrogen for 2.5 h. The reaction mixture was filtered through diatomaceous earth and concentrated on a rotary evaporator to a yellow hygroscopic solid; 3.7 gm, 100%.

Part B:

Butaneamide, 2-[(phenylmethyloxycarbonyl)amino]-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl-3,3-dimethyl-1S-[1R*(R*),2S*]]-

N-Cbz-L-tert-leucine (172 mg, 0.65 mmol) and N-hydroxybenzotriazole (100 mg, 0.65 mmol) in DMF (3 mL) was cooled to 0°C and EDC (115 mg, 0.60 mmol) added. After 45 min the amine from Part A (193 mg, 0.50 mmol) and N-methylmorpholine (60 uL, 0.55 mmol)

and poured into a solution of 50% saturated NaHCO_3 (25 mL). The solid was collected by suction filtration, washed with water and dried in-vacuo.

The solid was chromatographed on SiO_2 using 2% MeOH in CH_2Cl_2 .

The appropriate fractions were pooled and concentrated to afford a white

5 solid; 220 mg, MH^+ 597, TLC (SiO_2 2%MeOH/ CH_2Cl_2) $R_f = .2$.

CHN requires: C, 68.42, H, 8.78, N, 9.39; found: C, 68.03, H, 8.83, N, 9.33.

Part C:

Butaneamide, 2-amino-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-
methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,3-dimethyl-, [1S-
 10 [1R*(R*), 2S*]-

The product from Part B (570 mg, 0.95 mmol) and 4% Pd on carbon (150 mg) in ethanol (30 mL) was hydrogenated at 5 psi for 2.75 h.

The reaction mixture was filtered through diatomaceous earth and concentrated on a rotary evaporator to an oil; 438 mg, 100%.

15 Part D:

Butaneamide, 2-(acetyl-amino)-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-
methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,3-dimethyl-, [1S-
[1R*(R*), 2S*]-

The product from Part C (206 mg, 0.41 mmol) and N-
 20 methylmorpholine (45 μL , 0.41 mmol) were dissolved in CH_2Cl_2 (2.5 mL) and cooled to 0 C. Acetic anhydride (39 μL , 0.41 mmol) was then added and the reaction stirred 30 min at 0 C, then allowed to warm to ambient temperature and stir for 30 min. The solvent was removed on a rotary evaporator and the residue dissolved in ethanol (2 mL). The ethanolic
 25 solution was slowly poured into 50 % saturated NaHCO_3 (20 mL) and stirred vigorously. The solid was collected by suction filtration and washed with water, 5% citric acid, and again with water; 157 mg, 75%. CHN / 1.5 H_2O requires: C 63.24, H, 9.67, N, 10.54; found:
 C, 63.40, H, 9.41, N, 10.39.

30

Butaneamide, 2-amino-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3,3-dimethyl-, [1S-[1R*(R*), 2S*]- was also capped with the acyl groups shown in Table 12.

TABLE 12

Acyl Group (R)	
5	benzyloxycarbonyl
	tert -butoxycarbonyl
	acetyl
10	2-quinoylcarbonyl
	phenoxyacetyl
15	benzoyl
	methyloxaloyl
	pivaloyl
20	trifluoracetyl
	bromoacetyl
25	hydroxyacetyl
	morpholinylacetyl
	N,N-dimethylaminoacetyl
30	N-benzylaminoacetyl
	N-phenylaminoacetyl
35	N-benzyl-N-methylaminoacetyl
	N-methyl-N-(2-hydroxyethyl)aminoacetyl
	N-methylcarbamoyl
40	3-methylbutyryl
	N-isobutylcarbamoyl
45	succinoyl (3-carboxypropionyl)
	carbamoyl

-118-

Example 24A

The procedure described below illustrates preparation of compounds of Formula III.

Propanamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(2-phenylethylsulfonyl)-, [1S-[1R*(R*),2S*]] and its diastereomer.

Part A

10 A solution of methyl methacrylate (7.25 g, 72.5 mmol) and phenethyl mercaptan (10.0 g, 72.5 mmol) in 100 mL of methanol was cooled in an ice bath and treated with sodium methoxide (100 mg, 1.85 mmol). The solution was stirred under nitrogen for 3 h and then
15 concentrated in vacuo to give an oil that was taken up in ether and washed with 1 N aqueous potassium hydrogen sulfate, saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered and concentrated to give 16.83 g, 97.5% of methyl 2-(R,S)-methyl-4-thia-
20 6-phenyl hexanoate as an oil. TLC on SiO₂ eluting with 20:1 hexane:ethyl acetate (v:v) R_f=0.41.

Part B

A solution of methyl 2-(R,S)-methyl-4-thia-6-phenyl hexanoate (4.00 g, 16.8 mmol) in 100 mL of
25 dichloromethane was stirred at room temperature and treated portion wise with meta-chloroperoxybenzoic acid (7.38 g, 39.2 mmol) over approximately 40 m. The solution was stirred at room temperature for 16 h and then filtered and the filtrate washed with saturated
30 aqueous sodium bicarbonate, 1N sodium hydroxide, saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated to give 4.50 g, 99% of desired sulfone. The unpurified sulfone was dissolved in 100 mL of tetrahydrofuran and treated
35 with a solution of lithium hydroxide (1.04 g, 24.5 mmol) in 40 mL of water. The solution was stirred at room temperature for 2 m and then concentrated in vacuo. The residue was then acidified with 1N aqueous potassium

-119-

hydr gen sulfate to pH=1 and then extracted thre times with ethyl acetate. The combined ethyl acetate solution was washed with saturated aqueous sodium chlorid , dried over anhydrous magnesium sulfate, filtered and
5 concentrated to give a white solid. The solid was taken up in boiling ethyl acetate/hexane and allowed to stand undisturbed whereupon white needles formed that were isolated by filtration and air dried to give 3.38 g, 79% of 2-(R,S)-methyl-3(β -phenethylsulfonyl)-propionic acid,
10 mp 91-93°C.

Part C

A solution of 2-(R,S)-methyl-3(β -phenethylsulfonyl)-propionic acid (166.1 mg, 0.65 mmol), N-hydroxybenzotriazole (HOBT) (146.9 mg, 0.97 mmol), and
15 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (145.8 mg, 0.75 mmol) in 4 mL of anhydrous dimethylformamide (DMF) cooled to 0°C and stirred under nitrogen for 0.5 h. This solution was then treated with 3-[[[(dimethylethyl)amino]carbonyl](3-methylbutyl)amino-2(R)-hydroxy-1(S)-(phenylmethyl)propyl
20 amine (201.9 mg, 0.59 mmol) and stirred at room temperature for 16 h. The solution was poured into 30 mL of 60% saturated aqueous sodium bicarbonate solution. The aqueous solution was then decanted from the organic
25 residue. The organic residue was taken up in dichloromethane and washed with 10% aqueous citric acid, brine, dried over anhydrous magnesium sulfate, filtered and concentrated to give 110.0 mg, 32% of (2R,3S)-3-[N-2-(R)-methyl-3-(β -phenethylsulfonyl)propionyl]amido-1-isoamyl-1-(tert-butylcarbamoyl)amino-4-phenyl-2-butanol
30 and (2R,3S)-3-[N-2-(S)-methyl-3-(β -phenethylsulfonyl)propionyl]amido-1-isoamyl-1-(tert-butylcarbamoyl)amino-4-phenyl-2-butanol, FAB mass spectrum (MH+) =588. Flash chromatography of the
35 mixture on silica gel eluting with 1:1 hexane:ethyl acetat afforded the separated diastereomers.

-120-

Example 24B

- Pr panamide, N-[3-[[[(1,1-dimethylethyl)amino]carb nyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)- [1S-[1R*(R*), 2S*]], and its diastereomer.

Part A

- A solution of methyl 2-(bromomethyl)-acrylate (26.4 g, 0.148 mol) in 100 mL of methanol was treated with sodium methanesulfinate (15.1 g, 0.148 mol) portion wise over 10 m at room temperature. The solution was then stirred at room temperature for a period of 1.25 h and the solution concentrated in vacuo. The residue was then taken up in water and extracted four times with ethyl acetate. The combined ethyl acetate solution was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered and concentrated to give a white solid, 20.7 g which was taken up in boiling acetone/methyl tert-butyl ether and allowed to stand whereupon crystals of pure methyl 2-(methylsulfonylmethyl) acrylate 18.0 g, 68% formed, mp 65-68 °C.

Part B

- A solution of methyl 2-(methylsulfonylmethyl) acrylate (970 mg, 5.44 mmol) in 15 mL of tetrahydrofuran was treated with a solution of lithium hydroxide (270 mg, 6.4 mmol) in 7 mL of water. The solution was stirred at room temperature for 5 m and then acidified to pH=1 with 1 N aqueous potassium hydrogen sulfate and the solution extracted three times with ethyl acetate. The combined ethyl acetate solution was dried over anhydrous magnesium sulfate, filtered, and concentrated to give 793 mg, 89% of 2-(methylsulfonylmethyl) acrylic acid, mp 147-149 °C.

Part C

- A solution of 2-(methylsulfonylmethyl) acrylic acid (700 mg, 4.26 mmol) in 20 mL of methanol was charged into a Fisher-Porter bottle along with 10%

-121-

palladium on carbon catalyst under a nitrogen atmosphere. The reaction vessel was sealed and flushed five times with nitrogen and then five times with hydrogen. The pressure was maintained at 50 psig for 16 h and then the hydrogen was replaced with nitrogen and the solution filtered through a pad of celite to remove the catalyst and the filtrate concentrated in vacuo to give 682 mg 96% of 2-(R,S)-methyl-3-methylsulfonyl propionic acid.

10 Part D

A solution of 2-(R,S)-methyl-3(methylsulfonyl) propionic acid (263.5 mg, 1.585 mmol), N-hydroxybenzotriazole (HOBT) (322.2 mg, 2.13 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (339.1 mg, 1.74 mmol) in 4 mL of anhydrous dimethylformamide (DMF) cooled to 0°C and stirred under nitrogen for 0.5 h. This solution was then treated with 3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl amine (543.5 mg, 1.58 mmol) and stirred at room temperature for 16 h. The solution was poured into 60 mL of 60% saturated aqueous sodium bicarbonate solution. The aqueous solution was then decanted from the organic residue. The organic residue was taken up in dichloromethane and washed with 10% aqueous citric acid, brine, dried over anhydrous magnesium sulfate, filtered and concentrated to give 471.8 mg, 60% of Propanamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, [1S-[1R*(R*), 2S*]]- and its diastereomer.

Example 25

Preparation of Sulfone Inhibitors From L-(+)-S-acetyl-

35 β -mercaptoisobutyric Acid

Part A:

Propanamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-

-122-

hydr xy-1-(phenylmethyl)propyl]-2-methyl-3-S-acetyl)-
[1S-[1R*),2S*]]-.

- A round-bottomed flask was charged with
(2R,3R)-3-amino-1-isoamyl-1-(tert-butylcarbamoyl)amino-
5 4-phenyl-2-butanol (901.5 mg, 2.575 mmol), L-(+)-S-
acetyl-b-mercaptoisobutyric acid (164.5 mg, 2.575 mmol),
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC) (339.1 mg, 1.74 mmol), and 10 mL of
CH₂Cl₂ and allowed to stir at room temperature for 16 h.
10 The solution was concentrated in vacuo and the residue
taken up in ethyl acetate, washed with 1N KHSO₄ sat. aq.
NaHCO₃, brine, dried over anhydrous MgSO₄, filtered and
concentrated to give an oil that was purified by radial
chromatography on SiO₂ eluting with ethyl acetate to give
15 the pure product, 800 mg, 63%.

Part B:

- Propanamide, N-[3-[[[1,1-
dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-mercapto)-,
20 [1S-[1R*(R*),2S*]]-.

- A solution of [1S-[1R*(R*),2S*]]- N-[3-
[[[(1,1-dimethylethyl)amino]carbonyl](3-
methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-
methyl-3-S-acetyl)-propanamide (420 mg, 0.85 mmol) in 10
25 mL of methanol was treated with anhydrous ammonia for
ca. 1 m at 0°C. The solution was stirred at that
temperature for 16 h and then concentrated in vacuo to
give 380 mg, 99%, of the desired product that was used
directly in the next step without further purification.

30 Part C:

Propanamide, N-[3-[[[(1,1-
dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-S-methyl-,
[1S-[1R*(R*),2S*]]-.

- 35 A solution of [1S-[1R*(R*),2S*]]- N-[3-
[[[(1,1-dimethylethyl)amino]carbonyl](3-
methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-
methyl-3-mercapto)-propanamide (380 mg, 0.841 mmol) in

-123-

10 mL of dry toluene under nitrogen was treated in rapid succession with 1,8-diazabicyclo[5.4.0]undec-7-en , (DBU), (128.1 mg, 0.841 mmol) and iodomethane (119.0 mg, 0.841 mmol). After 0.5 h at room temperature the
5 reaction was found to be complete and the solution was diluted with ethyl acetate washed with 1N KHSO₄, sat. aq. NaHCO₃, brine. After the solution was dried over anhydrous MgSO₄, filtered and concentrated in vacuo the desired product was obtained as white foam was obtained,
10 370 mg, 94.5%, that was used directed in the next step.

Part D:

Propanamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, [1S-[1R*(R*),2S*]]-.

A solution of [1S-[1R*(R*),2S*]]-N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-S-methyl)-propanamide (340 mg, 0.73 mmol) and sodium perborate
20 (500 mg, 3.25 mmol) in 30 mL of glacial acetic acid was warmed to 55°C for 16 h. The solution was concentrated in vacuo and then the residue taken up in ethyl acetate, washed with water, sat. aq. NaHCO₃, brine, dried over anhydrous MgSO₄, filtered and concentrated to give the
25 desired product as a white solid, 350 mg, 96%.

Example 26


The compounds shown in Tables 12 and 13 were prepared generally according to the procedure set forth in Examples 24 and 25.

-124-

TABLE 12A

5

10



15

R

20

 CH_3- CH_3CH_2- $\text{CH}_3\text{CH}_2\text{CH}_2-$

25

 $\text{PhCH}_2\text{CH}_2-$ PhCH_2- $\text{Ph}-$

30

 $(\text{CH}_3)_2\text{CH}-$ $\text{HOCH}_2\text{CH}_2-$

35

$$\text{C}_6\text{H}_5\text{CH}_2\text{O}-\overset{\text{O}}{\parallel}\text{CCH}_2$$

40

$$\text{H}_2\text{NC}-\overset{\text{O}}{\parallel}\text{CH}_2-$$



45

 $\text{CH}_2=\text{CH}-\text{CH}_2-$

50

-125-

TABLE 13

5		
10		
15		
20	<u>R'</u>	<u>R₁</u>
	CH ₃	-CH(CH ₃) ₂

25

Example 27Preparation of 2(S)-methyl-3-(methylsulfonyl)propionic Acid.

To a solution of 10g of D-(-)-S-benzoyl-b-
 30 mercaptioisobutyric acid t-butyl ester in 20 mL of
 methanol was bubbled in gaseous ammonia at 0°C. The
 reaction was allowed to then warm to room temperature,
 stirred overnight and concentrated under reduced
 pressure. The resulting mixture of a solid (benzamide)
 35 and liquid was filtered to provide 5.21g of a pale oil
 which then solidified. This was identified as 2(S)-
 methyl-3-mercaptopropionic acid t-butyl ester.

To a solution of 5.21g of 2(S)-methyl-3-
 40 mercaptopropionic acid t-butyl ester in 75 mL of toluene
 at 0°C was added 4.50g of 1,8-diazabicyclo[5.4.0]undec-
 7-ene and 1.94 mL of methyl iodide. After stirring at
 room temperature for 2.5 hours, the volatiles were
 removed, ethyl acetate added, washed with dilute
 45 hydrochloric acid, water, brine, dried and concentrated

-126-

to afford 2.82g of a pale oil, identified as 2(S)-methyl-3-(thiomethyl)propionic acid t-butyl ester.


To a solution of 2.82g of 2(S)-methyl-3-(thiomethyl)propionic acid t-butyl ester in 50 mL of acetic acid was added 5.58g of sodium perborate and the mixture heated to 55°C for 17 hours. The reaction was poured into water, extracted with methylene chloride, washed with aqueous sodium bicarbonate, dried and concentrated to afford 2.68g of 2(S)-methyl-3-(methylsulfonyl)propionic acid t-butyl ester as a white solid.

To 2.68g of 2(S)-methyl-3-(methylsulfonyl)propionic acid t-butyl ester was added 20 mL of 4N hydrochloric acid/dioxane and the mixture stirred at room temperature for 19 hours. The solvent was removed under reduced pressure to afford 2.18g of crude product, which was recrystallized from ethyl acetate/hexane to yield 1.44g of 2(S)-methyl-3-(methylsulfonyl)propionic acid as white crystals.

Example 28

This example illustrates preparation of compounds of Formula IV wherein t is 1.

4-N-benzyl itaconamide.




A 500 mL three necked round bottomed flask equipped with a dropping funnel, mechanical stirrer, nitrogen inlet and reflux condenser was charged with itaconic anhydride (33.6g, 0.3 mol) and 150 mL of toluene. This solution was added a solution of benzylamine (32.1g, 0.3 mol) in 50 mL of toluene dropwise over 30 m at room temperature.

-127-


The solution was stirred at this temperature an additional 3h and then the solid product isolated by filtration on a Büchner funnel. The crude product, 64.6g 98%, was recrystallized from 300 mL of isopropyl alcohol to give after two crops 52.1g, 79% of pure product, mp 149-150 °C

2(R)-Methyl 4-N-benzyl succinamide.



A large Fisher-Porter bottle was charged with the acid from the above reaction (10.95g, 0.05 mol), rhodium (R,R)-DiPAMP (220mg, 0.291 mmol) and 125 mL of degassed methanol. The solution was then hydrogenated at 40 psig for 16h at room temperature. After the hydrogen uptake ceased, the vessel was opened and the solution concentrated *in vacuo* to give a yellow solid, 11.05g, 100%. The product was then taken up in absolute ethanol and allowed to stand whereupon crystals of the desired product formed, 7.98g, 72%, mp 127-129 °C $[\alpha]_D^{25}$ $^{\circ}$ C=+14.9° (c=1.332, EtOH), ^1H nmr (CDCl_3) 300MHz 7.30(m, 5H), 6.80(brs, 1H), 4.41(d, J=5.8Hz, 2H), 2.94(m, 1H), 2.62(dd, J=8.1, 14.9Hz, 1H), 2.33(dd, J=5.5, 14.9Hz, 1H), 1.23(d, J=7.2Hz, 3H).

4-N(4-methoxybenzyl)itaconamide.




-128-

A 500 mL three necked round bottomed flask quipped with a dropping funnel, mechanical stirrer, nitrogen inlet and reflux condenser was charged with itaconic anhydride (44.8g, 0.4 mol) and 150 mL of toluene. This solution
5 was added a solution of 4-methoxybenzylamine (54.8g, 0.4 mol) in 50 mL of toluene dropwise over 30 m at room temperature. The solution was stirred at this temperature an additional 2h and then the solid product isolated by filtration on a Büchner funnel. The crude
10 product was recrystallized from ethyl acetate/ethanol to give after two crops 64.8g, 65% of pure product, mp 132-134 °C, ¹H nmr (CDCl₃) 300MHz 7.09(d, J=9.1Hz, 2H), 6.90(brt, J=5.9Hz, 1H), 6.74(d, J=9.1Hz, 2H), 6.22(s, 1H), 5.69(s, 1H), 4.24(d, J=5.9Hz, 2H), 3.69(s, 3H),
15 3.15(s, 2H). ¹³C nmr (CDCl₃) 170.52, 169.29, 159.24, 135.61, 131.08, 129.37, 128.97, 114.36, 55.72, 43.37, 40.58.

20 **2(R)-Methyl 4-N(4-methoxybenzyl)succinamide.**

25



A large Fisher-Porter bottle was charged with the acid
30 from the above reaction (5.00 g, 0.02 mol), rhodium (R,R)-DiPAMP (110 mg, 0.146 mmol) and 50 mL of degassed methanol. The starting acid was not completely soluble initially, but as the reaction progressed the solution became homogeneous. The solution was then hydrogenated
35 at 40 psig for 16h at room temperature. After the hydrogen uptake ceased, the vessel was opened and the solution concentrated in vacuo to give a yellow solid. The crude product was then taken up in ethyl acetate and washed three times with sat. aq. NaHCO₃ solution. The
40 combined aqueous extracts were acidified to pH=1 with 3 N HCl and then extracted three times with ethyl acetate.


-129-

The combined ethyl acetate extracts were washed with brine, dried over anhyd. MgSO_4 , filtered and concentrated to give the expected product as a white solid, 4.81g, 95%. This material was recrystallized from a mixture of methyl ethyl ketone/hexane to give 3.80g, 75% of pure product, $[\alpha]_D^{25} = +11.6^\circ$ ($c=1.572$, MeOH). ^1H nmr (CDCl_3) 300MHz 11.9(brs, 1H), 7.18(d, $J=9.2\text{Hz}$, 2H), 6.82(d, $J=9.2\text{Hz}$, 2H), 6.68(brt, $J=5.6\text{Hz}$, 1H), 4.33(d, $J=5.6\text{Hz}$, 2H), 3.77(s, 3H), 2.92(ddq, $J=7.9$, 5.4, 7.3Hz, 1H), 2.60(dd, $J=5.4$, 15.0Hz, 1H), 2.30(dd, $J=7.9$, 15.0Hz, 1H), 1.22(d, $J=7.3\text{Hz}$, 3H).

Butanediamide, N'-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N-4-methoxyphenylmethyl-2-methyl, [1S-[1R*(2R*),2S*]]-

20

25




30

A 50 mL round bottomed flask was charged with 2(R)-methyl 4-N(4-methoxybenzyl)succinamide (588 mg, 2.35 mmol), N-hydroxybenzotriazole (511 mg, 3.34 mmol) and 6 mL of DMF. The solution was cooled to 0°C and treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (502 mg, 2.62 mmol) for 20 min. A solution of (2R,3S)-3-amino-1-(3-methylbutyl)-1-[(1,1-dimethylethyl)amino]carbonyl)-4-phenyl-2-butanol (782 mg, 2.24 mmol) in 2 mL of DMF was added and the solution stirred at room temperature for a period of 24 h. The solution was concentrated in vacuo and poured into 50 mL

-130-

of 50% sat. aq. NaHCO_3 , the aqueous phase was extracted with CH_2Cl_2 . The organic phase was washed with 5% citric acid, NaHCO_3 , brine, dried over anhyd. MgSO_4 , filtered and concentrated to give an oil that was purified by radial chromatography on SiO_2 eluting with hexane/ethyl acetate to give 790 mg, 59% of pure product as a white foam.

Butanediamide, N'-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-N-phenylmethyl-2-methyl, [1S-[1R*(2R*),2S*]]-



A 50 mL round bottomed flask was charged with 2(R)-methyl 4-N-(benzyl) succinamide (243 mg, 1.1 mmol), N-hydroxybenzotriazole (213 mg, 1.39 mmol) and 3 mL of DMF. The solution was cooled to 0° C and treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (228 mg, 1.17 mmol) for 20 m. A solution of (2R,3S)-3-amino-1-(3-methylbutyl)-1-[(1,1-dimethylethyl)amino]carbonyl)-4-phenyl-2-butanol (327 mg, 0.95 mmol) in 2 mL of DMF was added and the solution stirred at room temperature for a period of 24 h. The solution was concentrated in vacuo and poured into 50 mL of 50% sat. aq. NaHCO_3 , the aqueous phase was extracted with CH_2Cl_2 . The organic phase was washed with 5% citric acid, NaHCO_3 , brine, dried over anhyd. MgSO_4 , filtered and concentrated to give an oil that was purified by

-131-

flash chromatography on SiO₂ eluting with hexane/ethyl acetate to give 370 mg, 70% of pure product as a white foam.

Example 29

5 Following the procedure generally as set forth in Example 28, as well as in Examples 31-45, the compounds shown in Table 14 were prepared.


TABLE 14

10

15

20

25



30

35

40

45

	R ¹	R ³⁰	R ³¹	R ³²	X'	R ³³	R ³⁴
	H	H	H	H	N	H	H
	H	H	H	H	O	H	-
	H	H	H	H	O	CH ₃	-
	CH ₃	H	H	H	N	H	H
	CH ₃	H	H	H	O	H	-
	H	H	CH ₃	H	N	H	H
	H	H	CH ₃	H	O	H	-
	CH ₃	CH ₃	H	H	N	H	H
	CH ₃	CH ₃	H	H	O	H	-
	CH ₃	CH ₃	H	H	O	CH ₂ C ₆ H ₄ OCH ₃	-
	H	H	CH ₃	CH ₃	N	H	H
	H	H	CH ₃	CH ₃	O	H	-
	H	H	CH ₃	CH ₃	O	CH ₂ C ₆ H ₄ OCH ₃	-

50

TABLE 14 (Cont'd)

	R ¹	R ³⁰	R ³¹	R ³²	X'	R ³³	R ³⁴
5	CH ₃	H	CH ₃	H	N	H	H
	CH ₃	H	CH ₃	H	N	H	CH ₃
	CH ₃	H	CH ₃	H	N	CH ₃	CH ₃
	CH ₃	H	CH ₃	H	O	H	-
10	CH ₃	H	CH ₃	H	N	H	-CH ₂ C ₆ H ₅ OCH ₃
	OH	H	H	H	N	H	H
	OH	H	H	H	O	H	-
	H	H	OH	H	N	H	H
	H	H	OH	H	O	H	-
15	CH ₃	H	H	H	N	H	H
	CH ₂ C(O)NH ₂ H	H	H	H	N	H	H
20	CH ₂ C(O)NH ₂ H	H	H	H	O	H	-
	CH ₂ C(O)NH ₂ H	H	H	H	O	CH ₃	-
25	CH ₂ Ph	H	H	H	N	H	H
30							

-133-

Example 30


Following the procedure generally as set forth in Example 28, as well as in Examples 31-45, the compounds shown in Table 15 were prepared.

5

TABLE 15

10


15



20

25


30



35

40

45



50


-134-

TABLE 15 (Cont'd)

5

10

15

Example 31

Preparation of 3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl).

Part A:

Preparation of N-3(S)-(Benzyloxycarbonyl)-amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl). A solution of 20g (67 mmol) of N-benzyloxycarbonyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane in 140 mL of isopropyl alcohol was treated with 83g (952 mmol) of isoamylamine and refluxed for one hour. The solution was cooled, concentrated, hexane added and the resulting solid filtered to afford 22.4g of the desired product.

Part B:

Preparation of N-3(S)-(Benzyloxycarbonyl)-amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl)-N-(t-butyloxycarbonyl). To a solution of 22.4g (58.3 mmol) of product from Part A above, 6.48g (64.1 mmol) of triethylamine and 150 mg of N,N-dimethyl-4-aminopyridine in 200 mL of tetrahydrofuran at 0°C was added 12.7g (58.3 mmol) of di-t-butylpyrocarbonate in 10 mL of THF. After 3.5 hours at room temperature, the volatiles were removed, ethyl acetate added and washed with 5% citric acid, sat'd NaHCO₃, dried and concentrated

-135-

to afford 30g of crude product. Chromatography on silica gel using 20% ethyl acetate/hexane afforded 22.5g (79%) of the desired product.

Part C:

5 Preparation of N-3(S)-[N-benzyloxycarbonyl-L-asparaginy]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl)-N-(t-butyloxycarbonyl). A solution of 22.5g of product from Part B above in 200 mL of ethanol was hydrogenated over 5.9g of 10% palladium-on-carbon
10 under 50 psig hydrogen for one hour. The catalyst was filtered and the solvent removed under reduced pressure to afford 15.7g of free amine. This was dissolved in 130 mL of DMF and 4.54g (44.9 mmol) of N-methylmorpholine an added to a mixture of 13.3g (49.9
15 mmol) N-benzyloxy-carbonyl-L-asparagine, 11.5g (74.9 mmol) of N-hydroxybenzotriazole and 10.5g (54.9 mmol) of EDCI in 120 mL of DMF at 0°C, which had been preactivated for one hour prior to the addition. The mixture was stirred for 2 hours at 0°C and then for 12
20 hours at room temperature. The reaction was poured into 1L of sat d aqueous sodium bicarbonate, the solid collected, dissolved in ethyl acetate, washed with water, sat d sodium bicarbonate, 5% citric acid and brine, dried and concentrated to afford 16.7g of the
25 desired product.

Part D:

Preparation of N-3(S)-[N-(2-quinolinylcarbonyl)-L-asparaginy]amino-2(R)-hydroxy-4-
30 phenylbutylamine, N-(3-methylbutyl)-N-(t-butyloxycarbonyl). A solution of 16.7g (28.0 mmol) of product from Part C in 250 mL of methanol was hydrogenated over 6.0g of 10% palladium-on-carbon and under 50 psig hydrogen for one hour. The catalyst was
35 filtered and the solution concentrated to afford 10.0g of free amine. This was dissolved in 100 mL of methylene chloride, 4.35g (43 mmol) of N-methylmorpholine was added follow d by 5.53g (20.5

-136-

mmol) of quinoline-2-carboxylic acid, N-hydroxysuccinimide ester. This was stirred at room temperature overnight, the solvent removed, ethyl acetate added and washed with 5% citric acid, saturated sodium bicarbonate, brine, dried and concentrated to afford 14g of crude product. Recrystallization from ethyl acetate and hexane afforded 10.5g (83%) of desired product.

10 Part E:

Preparation of N-3(S)-[N-(2-quinolinyl-carbonyl)-L-asparaginyl]amino-2(R)-hydroxy-4-phenylbutylamine, N-(3-methylbutyl). To 80 mL of 4N hydrochloric acid in dioxane was added 9.17g (14.8 mmol) of product from Part D above. After one hour, the product becomes gummy. The solvents were removed, diethyl ether added and removed and the residue dissolved in 20 mL of methanol. This solution was added to 400 mL of saturated aqueous sodium bicarbonate, the solids collected, washed with acetone and hexane and dried in vacuo over P_2O_5 to afford 4.75g of the desired product.

Example 32A

Preparation of Benzyl 2,2,3(R)-trimethylsuccinate

25 Part A:

Preparation of Methyl (S)-lactate, 2-methoxy-2-propyl ether. To a mixture of methyl(s)-(-)-lactate (13.2g, 100 mmol) and, 2-methoxypropene (21.6g, 300 mmol) in CH_2Cl_2 (150 ml) was added $POCl_3$ (7 drops) at r.t. and the resulting mixture was stirred at this temperature for 16 hours. After the addition of Et_3N (10 drops), the solvents were removed in vacuo to give 20.0g of (98%) desired product.

35 Part B:

Preparation of 2(S)-hydroxypropanal, 2-methoxy-2-propyl ether. To a solution of compound from Part A (20.0g) in CH_2Cl_2 (100 ml) was added DIBAL (65 ml

-137-

of 1.5M solution in toluene, 97.5 mmol) dropwise at -78°C for 45 min., then stirring was continued at the temperature for another 45 min. To this cold solution was added MeOH (20 ml), saturated NaCl solution (10 ml) and allowed the reaction mixture to warm up to r.t. and diluted with ether (200 ml), MgSO₄ (150g) was added and stirred for another 2 h. The mixture was filtered and the solid was washed twice with ether. The combined filtrates were rotavaped to afford 11.2g (78%) of the desired aldehyde.

Part C:

Preparation of 2(S)-hydroxy-cis-3-butene, 2-methoxy-2-propyl ether. To a suspension of ethyltriphenylphosphonium bromide (28g, 75.5 mmol) in THF (125 ml) was added KN (TMS)₂ (15.7g, 95%, 75 mmol) in portions at 0°C and stirred for 1 h at the temperature. This red reaction mixture was cooled to -78°C and to this was added a solution of aldehyde from Part B (11g, 75 mmol) in THF (25 ml). After the addition was completed, the resulting reaction mixture was allowed to warm up to r.t. and stirred for 16 h. To this mixture was added saturated NH₄Cl (7.5 ml) and filtered through a pad of celite with a thin layer of silica gel on the top. The solid was washed twice with ether. The combined filtrates were concentrated in vacuo to afford 11.5g of crude product. The purification of crude product by flash chromatography (silica gel, 10:1 Hexanes/EtoAc) affording 8.2g (69%) pure alkene.

Part D:

Preparation of 2(S)-hydroxy-cis-3-butene. A mixture of alkene from Part C (8.2g) and 30% aqueous acetic acid (25 ml) was stirred at r.t. for 1 hour. To this mixture was added NaHCO₃ slowly to the pH ~ 7, then extracted with ether (10 ml x 5). The combined ether solutions were dried (Na₂SO₄) and filtered. The filtrate was distilled to remove the ether to give 2.85g (64%) pure alcohol, m/e=87(M+H).

-138-

Part E:

Preparation of 2,2,3-trimethyl-hex-(trans)-4-enic acid. To a mixture of alcohol from Part D (2.5g, 29 mmol) and pyridine (2.5 ml) in CH_2Cl_2 (60 ml) was
5 added isobutyryl chloride (3.1g, 29 mmol) slowly at 0°C. The resulting mixture was stirred at r.t. for 2 hours then washed with H_2O (30 ml x 2) and sat. NaCl (25 ml). The combined organic phases were dried (Na_2SO_4),
10 concentrated to afford 4.2g (93%) ester 2(S)-hydroxy-cis-3-butenyl isobutyrate. This ester was dissolved in THF (10 ml) and was added to a 1.0M LDA soln. (13.5 ml of 2.0M LDA solution in THF and 13.5 ml of THF) slowly at -78°C. The resulting mixture was allowed to warm up to r.t. and stirred for 2 h and diluted with 5% NaOH (40
15 ml). The organic phase was separated, the aqueous phase was washed with Et_2O (10 ml). The aqueous solution was collected and acidified with 6N HCl to pH ~ 3. The mixture was extracted with ether (30 ml x 3). The combined ether layers were washed with sat. NaCl (25
20 ml), dried (Na_2SO_4) and concentrated to afford 2.5g (60%) of desired acid, $m/e=157(\text{M}+\text{H})$.

Part F:

Preparation of benzyl 2,2,3(S)-trimethyl-trans-4-hexenoate. A mixture of acid from Part E (2.5g, 25
16 mmol), BnBr (2.7g, 15.8 mmol), K_2CO_3 (2.2g, 16 mmol), NaI (2.4g) in acetone (20 ml) was heated at 75°C (oil bath) for 16 h. The acetone was stripped off and the residue was dissolved in H_2O (25 ml) and ether (35 ml). The ether layer was separated, dried (Na_2SO_4) and
30 concentrated to afford 3.7g (95%) of benzyl ester, $m/e=247(\text{M}+\text{H})$.

Part G:

Preparation of benzyl 2,2,3(R)-trimethylsuccinate. To a well-stirred mixture of KMnO_4
35 (5.4g, 34, 2 mmol), H_2O (34 ml), CH_2Cl_2 (6 ml) and benzyltriethylammonium chloride (200 mg) was added a solution of ester from Part F (2.1g, 8.54 mmol) and acetic acid (6 ml) in CH_2Cl_2 (28 ml) slowly at 0°C. The

-139-

- resulting mixture was stirred at the temperature for 2 h then r.t. for 16 h. The mixture was cooled in an ice-water bath, then this was added 6N HCl (3 ml) and solid NaHSO₃ in portions until the red color disappeared. The
- 5 clear solution was extracted with CH₂Cl₂ (30 ml x 3). The combined extracts were washed with sat. NaCl solution, dried (Na₂SO₄) and concentrated to give an oil. This oil was dissolved in Et₂O (50 ml) and to this was added sat. NaHCO₃ (50 ml). The aqueous layer was
- 10 separated and acidified with 6N HCl to pH ~ 3 then extracted with Et₂O (30 ml x 3). The combined extracts were washed with sat. NaCl solution (15 ml), dried (Na₂SO₄) and concentrated to afford 725 mg (34%) of desired acid, benzyl 2,2,3(R)-trimethylsuccinate,
- 15 m/e=251(M+H).

Example 32BPart A:

- Preparation of Butanediamide, N¹-[3-[[[(1,1-
- dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
- 20 hydroxy-1-(phenylmethyl)propyl]-2,3,3-trimethyl-[1S-
- [1R*(2S*),2S*]]-

- To a well-stirred solution of benzyl 2,2,3(R)-trimethylsuccinate (225 mg, 0.9 mmol) in DMF (1.0 ml) was added HOBt (230 mg, 1.5 mmol). The clear reaction
- 25 mixture was then cooled to 0°C, to this was added EDC (210 mg, 1.1 mmol) and stirred for 1 h at the temperature. To this cold mixture was added a powder of (350 mg, 1.0 mmol) and DMF (0.5 ml). The resulting reaction mixture was stirred for 2 h at 0°C and 16 h at
- 30 r.t. After the removal of DMF (≤ 40°C), a solution of 60% sat. NaHCO₃ (10 ml) was added. This mixture was extracted with EtOAc (10 ml x 2). The extracts were combined and washed with sat. NaHCO₃ (10 ml x 2), 5% citric acid (10 ml x 2), H₂O (10 ml), sat. NaCl (10 ml)
- 35 and dried (Na₂SO₄) then concentrated to afford 512 mg (98%) of desired product Butanoic Acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-

-140-

4-oxo, [1S-[1R*(3S*),2S*]]-benzyl ester as a white solid, m/e=582(M+H).

Part B:

A mixture of benzyl ester from Part A (480 mg, 0.825 mmol), 10% Pd/C (450 mg) in MeOH (25 ml) was hydrogenated (H₂, 50 psi) for 1/2 h at r.t. The mixture was filtered and the solid was washed with MeOH (10 ml). The collected filtrates were concentrated to afford a crude acid as a white solid. The crude acid was dissolved in Et₂O-EtOAc (10:1, 25 ml) and the solution was washed with sat. NaHCO₃ (25 ml) then 5% NaOH (10 ml). The combined aqueous layers were cooled to 0°C and acidified with concentrated HCl (CO₂) to pH ~ 1 then extracted with Et₂O-EtOAc (10:1, 25 ml x 3). The combined extracts were washed with sat. NaCl (15 ml), dried (Na₂SO₄) and concentrated to afford 307 mg (75.7%) of pure acid Butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(3S*),2S*]]-, as a white solid, m/e=491(M+H).

Part C:

Butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [1S-[1R*(3S*),2S*]]-, as a white solid, m/e=491(M+H).

To a well-stirred solution of the acid from Part B (245 mg, 0.5 mmol) in DMF (0.5 ml) was added HOBt (153 mg, 1.0 mmol) and EDC (143 mg, 0.75 mmol) at 0°C. After stirring at 0°C for 2 h, NH₄OH (0.63 ml of 28% NH₄OH, 5 mmol) was added and stirred at 0°C for 2 h, r.t. for 16 h. The removal of DMF (≤ 40°C) gave a white solid. The purification of the crude product by flash chr mat graphy (silica gel, 5% M OH/CH₂Cl₂) gave 172 mg (70%) of pure amide 12 as a white solid, m/e=491(M+H).

-141-

Example 33Preparation of methyl 2,2-dimethyl-3-methyl succinate,
(R) and (S) isomers.Part A:

5 Preparation of methyl 2,2-dimethyl-3-oxo-
butanoate. A 250 ml RB flask equipped with magnetic
stir bar and N₂ inlet was charged with 100 ml dry THF and
4.57g (180 mmol) of 95% NaH. The slurry was cooled to -
20°C and 10g (87 mmol) methyl acetoacetate was added.
10 dropwise followed by 11.3 ml (181 mmol) CH₃I. The
reaction was stirred at 0°C for 2 hours and let cool to
room temperature overnight. The reaction was filtered
to remove NaI and diluted with 125 ml Et₂O. The organic
phase was washed with 1x100 ml 5% brine, dried and
15 concentrated in vacuo to a dark golden oil that was
filtered through a 30g plug of silica gel with hexane.
Concentration in vacuo yielded 10.05g of desired methyl
ester, as a pale yellow oil, suitable for use without
further purification.

20 Part B:

Preparation of methyl 2,2-dimethyl-3-O-
(trifluoromethanesulfonate)-but-3-enoate. A 250 ml RB
flask equipped with magnetic stir bar and N₂ inlet was
charged with 80 l by THF and 5.25 ml (37.5 mmol)
25 diisopropylamine was added. The solution was cooled
to -25°C (dry ice/ethylene glycol) and 15 ml (37.5 mmol)
of 2.5 M nBuLi in hexanes was added. After 10 minutes a
solution of 5g (35 mmol) 1 in 8 ml dry THF was added.
The deep yellow solution was stirred at -20°C for 10
30 min. then 12.4g N-phenyl
bis(trifluoromethanesulfonimide) (35 mmol) was added.
The reaction was stirred @ -10°C for 2 hours,
concentrated in vacuo and partitioned between ethyl
acetate and sat. NaHCO₃. The combined organic phase was
35 washed with NaHCO₃, brine and conc. to an amber oil that
was filtered through 60g silica gel plug with 300 l 5%
ethyl acetate/hexane. Conc. in vacuo yielded 9.0g light
yell w oil that was diluted with 65 ml ethyl acetate and

-142-

washed with 2x50 ml 5% aq K_2CO_3 , 1x10 l brine, dried over Na_2SO_4 and conc. in vacuo to yield 7.5g (87%) vinyl triflate, (m/e=277(M+H)) suitable for use without further purification.

5 Part C:

Preparation of methyl 2,2-dimethyl-3-carboxyl-but-3-enoate. A 250 ml Fisher Porter bottle was charged with 7.5g (27 mmol) of compound prepared in B, 50 ml dry DMF, 360 mg (1.37 mmol) triphenyl phosphine and 155 mg (.69 mmol) $Pd(II) (OAc)_2$. The reaction mixture was purged twice with N_2 then charged with 30 psi CO . Meanwhile a solution of 20 ml dry DMF and 7.56 ml (54 mmol) NEt_3 was cooled to $0^\circ C$ to this was added 2.0g (43 mmol) of 99% formic acid. The mixture was swirled and added to the vented Fisher Porter tube. The reaction vessel was recharged to 40 psi of CO and stirred 6 hours @ room temperature. The reaction mixture was concentrated in vacuo and partitioned between 100 ml ethyl acetate and 75 ml 5% aq K_2CO_3 . The aqueous phase was washed with 1x40 l additional EA and then acidified with conc. HCl /ice. The aqueous phase was extracted with 2x70 l ethyl acetate and the organics were dried and conc. to yield 3.5g (75%) white crystals, mp $72-75^\circ C$, identified as the desired product (m/e=173(M+H)).

Part D:

Preparation of methyl 2,2-dimethyl-3-methylsuccinate, isomer #1. A steel hydrogenation vessel was charged with 510 mg (3.0 mmol) acrylic acid, from Part C, and 6 mg $Ru (acac)_2$ (R-BINAP) in 10 ml degassed MeOH. The reaction was hydrogenated at 50 psi/room temperature for 12 hours. The reaction was then filtered through celite and conc. to 500 mg clear oil which was shown to be a 93:7 mixture of isomer #1 and #2, respectively as determined by GC analysis using a 50 M β -cyclodextrin column: $150^\circ C$ - 15 min. then ramp $2^\circ C/min.$; isomer #1, 17.85 min., isomer #2, 18-20 min.

-143-

Part E:

Preparation of methyl 2,2-dimethyl-3-methylsuccinate, Isomer #2. A steel hydrogenation vessel was charged with 500 mg (2.9 mmol) acrylic acid, and 6 mg Ru(OAc) (acac)(S-BINAP) in 10 ml degassed MeOH. The reaction was hydrogenated at 50 psi/room temperature for 10 hours. The reaction was filtered through celite and concentrated in vacuo to yield 490 mg of product as a 1:99 mixture of isomers #1 and #2, respectively, as determined by chiral GC as above.

Example 34

Preparation of 3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propylamine, 1.

Part A:

To a solution of 75.0g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of 807 mL of methanol and 807 mL of tetrahydrofuran at -2°C, was added 13.17g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one hundred minutes. The solvents were removed under reduced pressure at 40°C and the residue dissolved in ethyl acetate (approx. 1L). The solution was washed sequentially with 1M potassium hydrogen sulfate, saturated sodium bicarbonate and then saturated sodium chloride solution. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced pressure. To the resulting oil was added hexane (approx. 1L) and the mixture warmed to 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3g (43% yield) of N-benzyl xycarbonyl-3(S)-amino-1-chlcro-4-phenyl-2(S)-butanol, mp 150-151°C and $M+Li^+ = 340$.

Part B:

-144-

To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at room temperature, was added 32.3g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate, filtering and stripping, one obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and MH⁺ 298.

Part C:

A solution of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (30.1g, 0.10 mol) and 165mL of isoamylamine in 150 mL of isopropyl alcohol was heated to reflux for 2.5 hours. The solution was cooled to room temperature, concentrated in vacuo and then recrystallized. The product was isolated by filtration and from ethylacetate/hexane to afford 31.7g (81%) of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]N-isoamylamine.

Part D:

A solution of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenyl butyl], N-isoamylamine in 10 ml of tetrahydrofuran was treated with tert-butylisocyanate (267 mg, 2.70 mmol) at room temperature for 5 minutes. The solvent was removed in vacuo and replaced with ethyl acetate. The ethyl acetate solution was washed with 5% citric acid, water, and brine, dried over anhydrous MgSO₄, filtered and concentrated in vacuo to give 1.19g, 97% of N-benzyloxycarbonyl-3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propylamine, MH⁺ m/z = 470.

Part E:

A solution of (37.3g, 77 mmol) of product from Part D in 100 mL of methanol was hydrogenated over 10%

-145-

palladium-on-carbon for 4 hours to afford 26.1g of the desired product.

Example 35

Preparation of Butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*, 2S*]]-

Part A:

To a solution of 102mg (0.29 mmol) of Example 34, Part E, and 70 mg (0.89 mmol) of pyridine in 2 mL of methylene chloride was added 29 mg (0.29 mmol) of succinic anhydride. After 2 hours, ethyl acetate was added and then extracted with saturated NaHCO₃. The aqueous layer was acidified, reextracted with ethyl acetate, washed with saturated brine, dried over magnesium sulfate, filtered and concentrated in vacuo to afford 78 mg (60%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino-4-oxo-, [1S-[1R*, 2S*]]-.

Part B:

This was activated with EDC and N-hydroxybenzotriazole in N,N-dimethylformamide and then reacted with ammonia to generate the desired final compound.

25

Example 36

Part A:

To a solution of 4.60g (24.7 mmol) of trans-diethyl 1,2-cyclopropanedicarboxylate in 100 mL of 50:50 v:v tetrahydrofuran/water was added 1.24g (29.6 mmol) of lithium hydroxide. After 17 hours, the tetrahydrofuran was removed in vacuo, the water layer washed with ethyl acetate, acidified with 1N hydrochloric acid and reextracted with ethyl acetate. The organic layer was dried and stripped to afford 2.1g of crude product. After recrystallization from diethyl ether/hexane and then methylene chloride/hexane one obtains 1.1g (28%) of trans-monoethyl 1,2-cyclopropanedicarboxylate, m/e = 151 (M + H).

-146-

Part B:

To a solution of 297 mg (1.87 mmol) of trans-monoethyl 1,2-cyclopropanedicarboxylate and 429 mg (2.8 mmol) N-hydroxybenzotriazole (HOBT) in 3 mL of anhydrous N,N-dimethylformamide (DMF) at 0°C was added 394 mg (2.0 mmol) of 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (EDC). After 30 min. a solution of 591 mg (1.7 mmol) of product from Part A in 2 mL DMF and 171 mg (1.69 mmol) of N-methylmorpholine (NMM) was added. After 2 hours at 0°C, the reaction was stirred at RT overnight, poured into water, extracted with ethyl acetate, washed with water, 5% aq. citric acid, sat'd NaHCO₃, brine, dried over anhydrous MgSO₄ and stripped to afford 771 mg of crude product. This was chromatographed on silica gel using 5-20% methanol/methylene chloride to afford 670 mg (80%) of cyclopropane carboxylic acid, 2-[[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-, ethyl ester; m/e = 490 (M + H).

Part C:

To a solution of 658 mg (1.32 mmol) of product from part B in 5 mL of 50:50 THF/water was added 66 mg (1.58 mmol) of lithium hydroxide. After 19 hours, the THF was removed in vacuo, the water washed with ethyl acetate, acidified and reextracted with ethyl acetate. The organic layer was dried and stripped to afford 328 mg (54%) of the corresponding acid, m/e = 462 (M + H).

Part D:

To a solution of 304 mg (0.66 mmol) of product from part C, 151 mg (0.99 mmol) HOBT in 2.2 mL DMF at 0°C was added 139 mg (0.73 mmol) EDC. After 30 min. at 0°C, 1.1 mL of conc. aqueous ammonia was added. After stirring at 0°C for 2 hours and RT for 20 hours, the reaction was poured into brine and extracted with ethyl acetate. After washing with NaHCO₃, sat'd brine, drying and stripping, one obtains 141 mg of crude product.

-147-

This was chromatographed on silica gel with 1-5% methanol/methylene chloride to afford 40 mg (13%) of the desired final product, $m/e = 561$ ($M + H$).

Example 37

- 5 Preparation of trans-but-2-enediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*, 2S*]].

Part A:

- To a solution of 137 mg (0.95 mmol) fumaric acid monoethyl ester in 1 mL of DMF at 0°C was added 183 mg (0.95 mmol) EDCI. After 15 minutes, a solution of 333 mg (0.95 mmol) of the compound of Example 34, Part E, in 1 mL DMF was added and the reaction stirred for 14 hours at RT. Ethyl acetate was added and extracted with 15 sat'd brine, 0.2 N HCl, sat'd NaHCO₃, dried and stripped to afford 0.32g of crude product. Chromatography on silica gel using 0-50% ethyl acetate/hexane afforded 0.26g (58%) of but-2-enoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-4-oxo-, [1S-[1R*, 20 2S*]]-, ethyl ester, $m/e = 476$ ($M + H$).

Part B:

- To a solution of 26.6 mg (0.56 mmol) of product from part A in 3 mL of 50:50 THF/water was added 25 34 mg (0.82 mmol) of lithium hydroxide and the reaction stirred at RT for 1 hour. The THF was removed *in vacuo*, the aqueous layer acidified with 1N HCl and extracted with ethyl acetate. The organic layer was washed with brine, dried and stripped to afford 233 mg (93%) of 30 trans-but-2-enoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-4-oxo-, [1S-[1R*, 2S*]]-, $m/e = 448$ ($M + H$).

Part C:

- 35 To a solution of 225 mg (0.50 mmol) of the product from part B in 1 mL of DMF was added 95 mg (0.50 mmol) EDC. After 15 minutes at RT, 0.50 mL of conc. aqueous ammonia was added and the reaction stirred for

-148-

15 hours. Ethyl acetate was added and washed with 0.2N HCl, brine, dried and stripped to afford 170 mg of crude product. After chromatography on silica gel using 0-40% methanol/methylene chloride, one obtains 50 mg (22%) of trans-but-3-enediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*, 2S*]-, m/e = 447 (M + H).

Example 38

10 Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl-2-methyl-, [1S-[1R*(2S*), 2S*]-.

Part A:

15 To a suspension of 24.7g (0.22 mol) of itaconic anhydride in 100 mL of anhydrous toluene at reflux under a nitrogen atmosphere was added dropwise over 30 minutes 23.9g (0.22 mol) of benzyl alcohol. The insoluble material dissolved to provide a homogeneous
20 solution which was refluxed for 1.5 hours. The solution was cooled to RT, then in an ice bath and the resulting white precipitate collected by filtration to afford 24.8g (51%) of 4-benzyl itaconate.

Part B:

25 To a solution of 2.13g (9.5 mmol) of the product from part A in 12 mL of methylene chloride at 0°C was added 4.02g (29.1 mmol) of para-methoxybenzyl alcohol, 605 mg (4.95 mmol) of N,N-dimethyl 4-aminopyridine, 128 mg of N,N-dimethyl 4-aminopyridine
30 hydrochloride salt and then 2.02g (4.7 mmol) dicyclohexylcarbodiimide (DCC). After stirring at 0°C for 1 hour and then RT for 2 hours, the precipitate was collected and discarded. The filtrate was washed with 0.5 N HCl, sat'd NaHCO₃, dried and stripped to afford
35 4.76g of crude product. This was chromatographed on silica gel using 0-50% ethyl acetate/hexane to afford 1.24g of pure 4'-methoxybenzyl-4-benzylitaconate.

-149-

Part C:

A solution of 1.24g (3.65 mmol) of product from part B and 20 mg of [(R,R)-Dipamp)cyclooctadienylrhodium] tetrafluoroborate in 30 mL of methanol was thoroughly degassed, flushed with nitrogen and then hydrogen and then stirred under 50 psig of hydrogen for 15 hours. The solution was filtered and stripped, dissolved in methylene chloride and washed with sat'd NaHCO₃, dried and stripped to afford 0.99g of a brown oil. This was then dissolved in 40 mL of methylene chloride, 3 mL of trifluoroacetic acid added and the solution stirred at RT for 3.5 hours. Water was added and separated and the organic layer extracted with sat'd NaHCO₃. The aqueous layer was acidified and reextracted with ethyl acetate, separated and the organic layer washed with brine, dried and stripped to afford 320 mg (50%) of 2(R)-methyl-4-benzylsuccinic acid.

Part D:

To a solution of 320 mg (1.44 mmol) of product from part C and 314 mg (2.05 mmol) HOBT in DMF at 0°C was added 303 mg (1.58 mmol) of EDC. After stirring for 30 minutes, a solution of 467 mg (1.34 mmol) of the product from Example 34, Part E in 4 mL of DMF was added. After stirring for 1 hour at 0°C and 14 hours at RT, ethyl acetate was added and washed with sat'd NaHCO₃, 5% aqueous citric acid, dried and stripped to afford 0.97g of crude product. This was chromatographed on silica gel using 0-10% ethyl acetate/hexane to afford 420 mg of pure butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3S*), 2S*]-, benzyl ester.

Part E:

A solution of 150 mg (0.27 mmol) of product from part D in 15 mL of methanol was hydrogenated over 10% palladium on carbon under 50 psig hydrogen for 17 hours. The reaction was filtered and stripped to afford

-150-

125 mg (100%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3S*), 2S*]]-.

5 Part F:

To a solution of 125 mg (0.27 mmol) of product from part E and 65 mg (0.42 mmol) of HOBT in 5 mL of DMF at 0°C was added 59 mg (0.31 mmol) of EDC. After 30 min. at 0°C, 1 mL of conc. aqueous ammonia was added.

- 10 After stirring at 0°C for 2 hours and RT for 15 hours, ethyl acetate was added and washed with sat'd NaHCO₃, 5% aqueous citric acid, dried and stripped to afford 90 mg of crude product. This was recrystallized from ethyl acetate/hexane to afford 40 mg (32%) of pure
- 15 butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl, [1S-[1R*(2S*), 2S*]]-.

Example 39

- 20 Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl, [1S-[1R*(2R*), 2S*]]-.

Part A:

- 25 A solution of 1.41g (4.1 mmol) of 4'-methoxybenzyl 4-benzylitaconate and 25 mg of [(S,S-Dipamp)cyclooctadienylrhodium]tetrafluoroborate in 20 mL of methanol was thoroughly degassed, flushed with nitrogen and then hydrogen and then stirred under 40
- 30 psig hydrogen for 72 hours. The solution was filtered and concentrated to provide 1.34g of a brown oil. This was dissolved in 40 mL of methylene chloride and 3 mL of trifluoroacetic acid was added. After stirring for 4 hours, water was added, separated and the organic layer
- 35 extracted with sat'd NaHCO₃. The aqueous layer was separated, reacidified, extracted with ethyl acetate which was separated, washed with brine, dried and

-151-

stripped to afford 440 mg of 2(S)-methyl-4-benzylsuccinic acid.

Part B:

To a solution of 440 mg (1.98 mmol) of the product from part A and 437 mg (2.86 mmol) of HOBT in 9 mL of DMF at 0°C was added 427 mg (2.23 mmol) of EDC. After 30 minutes at 0°C, a solution of 653 mg (1.87 mmol) of the product from Example 34, Part E, in 3 mL DMF was added. After 1 hour at 0°C and 15 hours at RT, ethyl acetate was added, extracted with sat'd NaHCO₃, 5% aqueous citric acid, dried and concentrated to afford 0.98g of crude product. Chromatography on silica gel using 0-10% ethyl acetate afforded 610 mg (59%) of pure butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)-amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3R*), 2S*], benzyl ester.

Part C:

A solution of 310 mg (0.56 mmol) of the product from part B in 20 mL of methanol was hydrogenated over 20 mg of 10% palladium on carbon under 50 psig hydrogen for 19 hours. The solution was filtered and concentrated to afford 220 mg (85%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)-amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-3-methyl-4-oxo-, [1S-[1R*(3R*), 2S*].

Part D: To a solution of 190 mg (0.41 mmol) of the product from part C and 90 mg (0.58 mmol) HOBT in 5 mL of DMF at 0°C, was added 88 mg (0.46 mmol) of EDC. After 30 minutes at 0°C, 2 mL of conc. aqueous ammonia was added. After 1 hour at 0°C and 15 hours at RT, ethyl acetate was added, washed with sat'd NaHCO₃, 5% aqueous citric acid, dried and concentrated to afford crude product. Recrystallization from ethyl acetate/hexan afforded 20 mg (11%) of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-

-152-

methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl, [1S-[1R*(2R*), 2S*]]-.

Example 40

- 5 Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)aminocarbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, [1S-[1R*(3S*), 2S*]]-.
- Part A: In a similar manner to the procedure used
10 above, p-methoxybenzyl alcohol was reacted with itaconic anhydride in refluxing toluene to provide 4-(p-methoxybenzyl)itaconate.
- Part B: To a solution of 3.30g (13.2 mmol) of the
15 product from part A in 17 mL of toluene, was added 2.08g (13.7 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene and then 2.35g (13.7 mmol) of benzyl bromide. After 2 hours, the solution was filtered and the filtrate washed with sat'd NaHCO₃, 3N HCl, brine, dried and concentrated
20 to afford 3.12g of an oil. After chromatography on silica gel using 0-5% ethyl acetate/hexane one obtains 2.19g (49%) of benzyl 4-(4-methoxybenzyl)itaconate.

Part C:

- A solution of 1.22g (3.6 mmol) of product from
25 part B and 150 mg of [(R,R-Dipamp) cyclooctadienylrhodium] tetrafluoroborate in 15 mL of methanol was thoroughly degassed, flushed with nitrogen and then hydrogen and hydrogenated under 50 psig for 16 hours. The solution was filtered and concentrated to
30 afford 1.2g of a brown oil. This was dissolved in 5 mL of methylene chloride and 5 mL of toluene and 3 mL of trifluoroacetic acid was added. After 4 hours, the solvents were removed in vacuo, the residue dissolved in methylene chloride, which was then extracted with sat'd
35 NaHCO₃. After separation, the aqueous layer was acidified, reextracted with methylene chloride which was then dried and concentrated to afford 470 mg (60%) of 3(R)-methyl-4-benzylsuccinic acid.

-153-

Part D:

To a solution of 470 mg (2.11 mmol) of product from part C and 463 mg (3.03 mmol) of HOBT in 5 mL of DMF at 0°C was added 451 mg (2.35 mmol) of EDC. After 30 min. at 0°C, a solution of 728 mg (2.08 mmol) of the product from Example 34, Part E, in 3 mL of DMF was added. After stirring at 0°C for 1 hour and 15 hours at RT, ethyl acetate was added and extracted with sat'd NaHCO₃, 5% aqueous citric acid, brine, dried and concentrated to give 930 mg of crude product chromatography on silica gel using 0-10% ethyl acetate/hexane one obtains 570 mg (50%) of butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-4-oxo-, [1S-[1R*(2S*), 2S*]-, benzyl ester.

Part E:

The product was hydrogenated in methanol using 10% palladium on carbon under 40 psig of hydrogen to afford butanoic acid, 4-[[3-[[[(1,1-dimethylethyl)amino]carbonyl]-(3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-4-oxo-, [1S-[1R*(2S*), 2S*]-.

Part F:

To a solution of 427 mg (0.92 mmol) of product from part E and 210 mg (1.37 mmol) in 3 mL of DMF at 0°C was added 196 mg (1.02 mmol) of EDC. After 30 min. at 0°C, 2 mL of conc. aqueous ammonia was added. After 1 hour at 0°C and 15 hours at RT, ethyl acetate was added and then extracted with sat'd NaHCO₃, brine, dried and concentrated to afford crude product. Recrystallization from ethyl acetate/hexane afforded 50 mg (12%) of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, [1S-[1R*(3S*), 2S*]-.

-154-

Exempl 41

Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, [1S-[1R*(3R*), 2S*]-.

This was prepared in an identical manner to the previous example except that the asymmetric hydrogenation step was done in the presence of [((S,S-dipamp)cyclooctadienyl)rhodium]-tetrafluoroborate as catalyst.

Example 42

Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*(2S*, 3R*), 2S*]], and [1S-[1R*(2R*, 3S*), 2S*]].

Part A:

To a solution of 863 mg (5.91 mmol) of meso-2,3-dimethylsuccinic acid in 7 mL of DMF at RT was added 1.13g (5.91 mmol) of EDC. After 15 minutes, a solution of 2.07g (5.91 mmol) of the product from Example 34, Part E, and 1.4 mL of pyridine in 7 mL of anhydrous methylene chloride was added. After 11 hours, ethyl acetate was added and washed with 0.2N HCl, brine, dried and concentrated to afford 2.73g (97%) of a 1:1 mixture of diastereomeric acids.

Part B:

To a solution of 1.45g (3.04 mmol) of the 1:1 mixture from part A and 613 mg (4.51 mmol) of HOBT in 10 mL of DMF at 0°C was added 635 mg (3.31 mmol) of EDC. After 30 minutes at 0°C, 5 mL of conc. aqueous ammonia was added. After 1 hour at 0°C and 14 hours at RT, ethyl acetate was added, washed with 0.2N HCl, sat'd NaHCO₃, brine, dried and concentrated to afford 0.64g (44%) of a 1:1 mixture of amides.

These were separated on a Whatman 10 micron partisil column using 8%-14% isopropanol/-methylene

-155-

chl rid . Th first isomer to elute was identified as
butanediamide, N-[3-[[[(1,1-
dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
hydroxy-1-(phenylmethyl)propyl]-, [1S-[1R*(2R*, 3S*),
5 2S*], m/e/ = 477 (M + H).

The second isomer to elute was identified as
butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]-
carbonyl](3-methylbutyl)amino]-2-hydroxy-1-
(phenylmethyl)propyl]-, [1S-[1R*(2S*, 3R*), 2S*], m/e =
10 477 (M + H).

Example 43

Preparation of pentanediamide, N-[3-[[[(1,1-
dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-
15 hydroxy-1-(phenylmethyl)propyl]-3,3-dimethyl-, [1S-[1R*,
2S*].

Part A:

To a solution of 232 mg (0.66 mmol) of the
product from Example 34, Part E, and 98 mg (1.2 mmol) of
20 pyridine in 2 mL of methylene chloride was added 95 mg
(0.66 mmol) of 3,3-dimethylglutaric anhydride at RT.
After 15 hours, ethyl acetate was added, washed with IN
HCl, brine, dried and concentrated to afford 261 mg of
crude product. Chromatography on silica gel using 5-
25 20% methanol/methylene chloride afforded 108 mg of acid,
m/e = 492 (M + H).

Part B:

To a solution of 92 mg (0.19 mmol) of product
from part A and 38 mg (0.28 mmol) HOBT in 0.5 mL DMF at
30 0°C was added 36 mg (0.19 mmol) of EDC. After 30
minutes at 0°C, 0.25 mL of conc. aqueous ammonia was
added. After 1 hour at 0°C and 16 hours at RT, ethyl
acetate was added, washed with 0.2N HCl, sat'd NaHCO₃,
brine, dried and concentrated to afford 72 mg of crude
35 product. This was passed through a one-inch column of
basic alumina with 10% methanol/methylene chloride to
afford 53 mg of desired product, m/e = 491 (M + H).

-156-

Example 44

Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2,3-dimethyl-[1S-
5 [1R*(2R*, 3S*), 2S*]] (Isomer #1) and

Preparation of butanediamide, N-[3-[[[(1,1-dimethylethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2,3-dimethyl-[1S-
10 [1R*(2R*, 3S*), 2S*]] (Isomer #2).

Part A:

To a solution of 1.47g (4.20 mmol) of the product from Example 34, Part E, and 1.4 mL of pyridine in 9 mL of methylene chloride at RT was added 538 mg
15 (4.20 mmol) of 2,2-dimethylsuccinic anhydride. After 15 hours, ethyl acetate was added and washed with 0.2N HCl, brine, dried and concentrated to afford 1.87g of crude product (approx. 3:1 mixture of isomers).

Part B:

20 To a solution of 1.85g (3.9 mmol) of crude product from part A and 887 mg (5.8 mmol) of HOBT in 10 mL of DMF at 0°C was added 809 mg (4.2 mmol) EDC. After 30 minutes at 0°C, 6 mL of conc. aqueous ammonia was added. After 1 hour at 0°C and 15 hours at RT, ethyl
25 acetate was added, washed with 0.2N HCl, sat'd NaHCO₃, brine, dried and concentrated to afford 923 mg of crude product. The two isomers were separated on a Whatman Partisil 5 column using 8-14% isopropanol/methylene chloride. The major isomer was identified as Isomer #1,
30 m/e = 477 (M + H).

The minor isomer was identified as Isomer #2, m/e = 477 (M + H).

Example 45

This example illustrates the procedure
35 utilized to prepare compounds wherein the stereochemistry about the hydroxyl group is (S).

-157-

Part A:

A solution of 3(S)-(1,1-dimethylethoxycarbonyl)amino-1,2-(R)-epoxy-4-phenylbutane (1.00g, 3.80 mmol) and isobutylamine (5.55g, 76 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was warmed to 60°C for 1 hour. The solution was cooled to room temperature and concentrated *in vacuo* and the residue recrystallized from hexane/methylene chloride to give 0.93g, 73% of [2(S), 3(S)]-N-[[[3-((1,1-dimethylethyl)carbamoyl)amino]]-2-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)amine], mp 91.3 - 93.0°C.

Part B:

The product from Part A (46.3mg, 0.14 mmol) was dissolved in a mixture of 5 mL of tetrahydrofuran and 2 mL of methylene chloride and treated with tert-butylisocyanate (136.4mg, 1.376 mmol) via syringe. The solution was stirred at room temperature for 0.5 hour and then the solvent was removed *in vacuo*. The product, TLC on SiO₂, 1:1 hexane: ethyl acetate had R_f = 0.74 and was used directly in the next step without further purification.

Part C:

The crude product from Part B was taken up in 10 mL of 4N hydrochloric acid in dioxane and stirred at room temperature for 0.25 hours. The solvent and excess hydrochloric acid was removed *in vacuo* whereupon the product crystallized. The solid was isolated by filtration washed with acetone and dried *in vacuo* to 3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino-2(S)-hydroxy-1(S)-(phenylmethyl)propylamine hydrochloride.

Part D:

A solution of N-Cbz-L-asparagine (225.5mg, 0.847 mmol) and N-hydroxybenzotriazole (182.9mg, 1.21 mmol) was dissolved in 2 mL of dimethylformamide and cooled to 0°C and then treated with EDC (170.2mg, 0.898 mmol) for 10 minutes. This mixture was then treated with 3-[[[(1,1-dimethylethyl)amino]carbonyl](2-

-158-

5 methylpropyl)amino-2(S)-hydroxy-1(S)-
(phenylmethyl)propylamine hydrochloride.
(300.0mg, 0.807 mmol) followed by N-m thylmorpholine
(90.0mg, 0.888 mmol) via syringe. The solution was
10 stirred at room temperature for 16 hours and then poured
into 20 mL of rapidly stirring 60% saturated aqueous
sodium bicarbonate solution whereupon a white
precipitate formed. The solid was isolated by
filtration, washed with saturated aqueous sodium
15 bicarbonate solution, water, 5% aqueous citric acid
solution, water and then dried in vacuo to give 319mg,
68% of butanediamide, N¹-[3-[[[(1,1-
dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2(S)-
hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-
[(benzyloxycarbonyl)amino] mp 139-141°C, MH⁺ m/z = 584.

EXAMPLE 46

The compounds of the present invention are
effective HIV protease inhibitors. Utilizing an enzyme
assay as described below, the compounds set forth in the
20 examples herein disclosed inhibited the HIV enzyme.
The preferred compounds of the present invention and
their calculated IC₅₀ (inhibiting concentration 50%,
i.e., the concentration at which the inhibitor compound
reduces enzyme activity by 50%) values are shown in
25 Table 16. The enzyme method is described below. The
substrate is 2-aminobenzoyl-Ile-Nle-Phe(p-NO₂)-Gln-
ArgNH₂. The positive control is MVT-101 (Miller, M. et
al, Science, 246, 1149 (1989)) The assay conditions are
as follows:

30 Assay buffer: 20 mM sodium phosphate, pH 6.4
20% glycerol
1 mM EDTA
1 mM DTT
0.1% CHAPS

35 The above described substrate is dissolved in
DMSO, then diluted 10 fold in assay buffer. Final
substrate concentration in the assay is 80 μM.

-159-

HIV protease is diluted in the assay buffer to a final enzyme concentration of 12.3 nanomolar, based on a molecular weight of 10,780.

The final concentration of DMSO is 14% and the final concentration of glycerol is 18%. The test compound is dissolved in DMSO and diluted in DMSO to 10x the test concentration; 10 μ l of the enzyme preparation is added, the materials mixed and then the mixture is incubated at ambient temperature for 15 minutes. The enzyme reaction is initiated by the addition of 40 μ l of substrate. The increase in fluorescence is monitored at 4 time points (0, 8, 16 and 24 minutes) at ambient temperature. Each assay is carried out in duplicate wells.

TABLE 16

Compound	IC ₅₀ (nanomolar)
1. 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl ester, [3S-(3R*,6R*,7S*)]-	3
2. 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, [3S-(3R*,6R*,7S*)]-	35
3. Butanediamide, N ¹ -[3-[[[(1,1-dimethyl-2-oxoethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]	2
4. Butanediamide, N ¹ -[3-[[[(1,1-dimethyl-2-hydroxyethyl)amino]carbonyl](3-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]	28
5. Butanediamide, N ¹ -[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]	4

-160-

TABLE 16 (Cont'd)

5	Compound	IC ₅₀ (nanomolar)
10 15	6. Butanediamide, N ¹ -[3-[[[1,1-dimethyl-2-(4-morpholinyl)ethyl]-amino]carbonyl][(4-fluorophenyl-methyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*)]-	15

Example 47

20 The effectiveness of the compounds listed in Table 9 were determined in the above-described enzyme assay and in a CEM cell assay.

 The HIV inhibition assay method of acutely infected cells is an automated tetrazolium based colorimetric assay essentially that reported by Pawles et al, J. Virol. Methods 20, 309-321 (1988). Assays were performed in 96-well tissue culture plates. CEM cells, a CD4⁺ cell line, were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetal calf serum and were then treated with polybrene (2μg/ml). An 80 μl volume of medium containing 1 x 10⁴ cells was dispensed into each well of the tissue culture plate. To each well was added a 100μl volume of test compound dissolved in tissue culture medium (or medium without test compound as a control) to achieve the desired final concentration and the cells were incubated at 37°C for 1 hour. A frozen culture of HIV-1 was diluted in culture medium to a concentration of 5 x 10⁴ TCID₅₀ per ml (TCID₅₀ = the dose of virus that infects 50% of cells in tissue culture), and a 20μL volume of the virus sample (containing 1000 TCID₅₀ of virus) was added to wells containing test compound and to wells containing only medium (infected control cells). Several wells received culture medium without virus (uninfected control cells).

-16I-

Likewise, the intrinsic toxicity of the test compound was determined by adding medium without virus to several wells containing test compound. In summary, the tissue culture plates contained the following experiments:

5				
		Cells	Drug	Virus
	1.	+	-	-
	2.	+	+	-
10	3.	+	-	+
	4.	+	+	+

In experiments 2 and 4 the final concentrations of test compounds were 1, 10, 100 and 500 $\mu\text{g/ml}$. Either azidothymidine (AZT) or dideoxyinosine (ddI) was included as a positive drug control. Test compounds were dissolved in DMSO and diluted into tissue culture medium so that the final DMSO concentration did not exceed 1.5% in any case. DMSO was added to all control wells at an appropriate concentration.

Following the addition of virus, cells were incubated at 37°C in a humidified, 5% CO₂ atmosphere for 7 days. Test compounds could be added on days 0, 2 and 5 if desired. On day 7, post-infection, the cells in each well were resuspended and a 100 μl sample of each cell suspension was removed for assay. A 20 μL volume of a 5 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each 100 μL cell suspension, and the cells were incubated for 4 hours at 27°C in a 5% CO₂ environment. During this incubation, MTT is metabolically reduced by living cells resulting in the production in the cell of a colored formazan product. To each sample was added 100 μl of 10% sodium dodecylsulfate in 0.01 N HCl to lyse the cells, and samples were incubated overnight. The absorbance at 590 nm was determined for each sample using a Molecular Devices microplate reader. Absorbance values for each

-162-

set of wells is compared to assess viral control infection, uninfected control cell response as well as test compound by cytotoxicity and antiviral efficacy.

-163-

TABLE 17

5	Compound	IC ₅₀ (nM)	EC ₅₀ (nM)
10	1. 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl ester, [3S-(3R*,6R*,7S*)]-	3	24
15	2. Butanediamide, N ¹ -[3-[[[(1,1-dimethyl-2-hydroxyethyl)amino]-carbonyl](3-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]	28	113
20	3. Butanediamide, N ¹ -[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)-amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]	4	37
30	4. Butanediamide, N ¹ -[3-[[[(1,1-dimethyl-2-(4-morpholinyl)ethyl)-amino]carbonyl] [(4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-	15	14
35			

-164-

Utilizing the procedures set forth above in the examples along with the general description, it is contemplated that the compounds listed below could be prepared and that such compounds would have activities as HIV protease inhibitors substantially similar to the activities of the compounds set forth in the examples.

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1-methylethyl) ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (phenylmethyl) ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, methyl ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1-methylethyl) ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (phenylmethyl) ester, [3S-(3R*,6R*,7S*)]-

-165-

2,5,9,11-Tetraazatrid can-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(phenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, methyl
5 ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(phenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl
10 ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(phenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1-
15 methylethyl) ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(phenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1,1-
20 dimethylethyl) ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(phenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-,
25 (phenylmethyl) ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(4-fluorophenylmethyl)-1-(2-quinolinyl)-
30 , methyl ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(cyclohexylmethyl)-1-(2-quinolinyl)-,
35 methyl ester, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-

-166-

1,4,10-trioxo-6-butyl-1-(2-quinolinyl)-, methyl ester,
[3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-
5 oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-
fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-
(2-quinolinyl)-, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-
10 oxoethyl)-7-hydroxy-12,12-dimethyl-9-(phenylmethyl)-
1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, [3S-
(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-
15 oxoethyl)-7-hydroxy-12,12-dimethyl-9-butyl-1,4,10-
trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, [3S-
(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-
20 oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-
1,4,10-trioxo-6-(4-fluorophenylmethyl)-1-(2-quinolinyl)-
, [3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-
25 oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-
1,4,10-trioxo-6-(cyclohexylmethyl)-1-(2-quinolinyl)-,
[3S-(3R*,6R*,7S*)]-

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-
30 oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-
1,4,10-trioxo-6-butyl-1-(2-quinolinyl)-, [3S-
(3R*,6R*,7S*)]-

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-
35 oxoethyl)amino]carbonyl](phenylmethyl)amino]-2-hydroxy-
1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-
, [1S-[1R*(R*),2S*]]

-167-

Butan diamid , N¹-[3-[[[(1,1-dimethyl-2-oxo thyl)amino]carbonyl](4-pyridinylmethyl)amino]-2-hydroxy-1-(phenylm thyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

5

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-hydroxyethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

10

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-hydroxyethyl)amino]carbonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

15

Butanediamide, N¹-[3-[[[(1,1-dimethyl-1-cyanoethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

20

Butanediamide, N¹-[3-[[[(1,1-dimethyl-1-cyanoethyl)amino]carbonyl](phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

25

Butanediamide, N¹-[3-[[[(1,1-dimethyl-1-cyanoethyl)amino]carbonyl](4-phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

30

Butanediamide, N¹-[3-[[[(1,1-dimethyl-1-cyanoethyl)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

35

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)amino]carbonyl](phenylmethy

-168-

amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

5 Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)amino]carbonyl](butyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

10 Butanediamide, N¹-[3-[[[(1,1-dimethyl-3-(4-morpholinyl)propyl)amino]carbonyl][(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

15 Butanediamide, N¹-[3-[[[(1,1-dimethyl-3-(4-morpholinyl)propyl)amino]carbonyl][butyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

20 Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-morpholinyl)ethyl)amino]carbonyl][(phenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

25 Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-(1-methylpiperazinyl)ethyl)amino]carbonyl][3-methylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

30 The compounds of the present invention are effective antiviral compounds and, in particular, are effective retroviral inhibitors as shown above. Thus, the subject compounds are effective HIV protease inhibitors. It is contemplated that the subject compounds will also inhibit other viruses such as HIV,
35 human T-cell leukemia virus, respiratory syncytial virus, hepatitis virus, cytomegalovirus and picornavirus.

The compounds of the present invention can be used in the form of salts derived from inorganic or

-169-

organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily and more usually 0.01 to 1 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

The amount of active ingredient that may be combined with the carrier materials to produce a single

-170-

dosage form will vary depending upon the host treated and the particular mode of administration.

It will be understood, however, that the specific dose level for any particular patient will
5 depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing
10 therapy.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically
15 acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous,
20 intramuscular, intrasternal injection, or infusion techniques.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable
25 dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable
30 vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be
35 employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

-171-

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary
5 temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be
10 admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as
15 magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions,
20 solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

25 While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents. When administered as a
30 combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the
35 invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be

-172-

within the scope and nature of the invention which are
d fin d in the appended claims.


The preceding examples can be repeated with
similar success by substituting the generically or
5 specifically described reactants and/or operating
conditions of this invention for those used in the
preceding examples.

From the foregoing description, one skilled in
the art can easily ascertain the essential
10 characteristics of this invention, and without departing
from the spirit and scope thereof, can make various
changes and modifications of the invention to adapt it
to various usages and conditions.


-173-

WHAT IS CLAIMED IS:


1. A compound represented by the formula:




15 wherein A represents R, R¹³ and radicals represented by formulas:



(A1)



(A2)



(A3)

wherein

20 R represents hydrogen and alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,

-174-

- cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, alkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminoalkylcarbonyl, aminoalkanoyl radicals, alkylaminoalkylcarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroalkyl, heterocycloalkylalkyl radicals;
- 15 R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical; t represents 0 or 1;
- R¹ represents -CH₂SO₂NH₂, CO₂CH₃, CONH₂, alkyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, allo-isoleucine, leucine, tert-leucine, phenylalanine, ornithine, alanine, threonine, allo-threonine, isoleucine, histidine, norleucine, valine, serine, aspartic acid and beta-cyano alanine side chains;
- 25 R^{1'} and R^{1''} independently represent hydrogen and radicals as defined for R¹;
- 30 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals optionally substituted with a group selected from -NO₂, -OR⁹, -SR⁹, and halogen radicals, wherein R⁹ represents hydrogen and alkyl radicals;
- 35 R³ represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;

-175-


X' represents O, C(R¹⁷) wherein R¹⁷ represents hydrogen and alkyl radicals, and N;

Y and Y' independently represent O and S;

R⁴ represents hydrogen and radicals as defined by R³;

5 B represents radicals represented by the formula:

10



15

wherein

n represents an integer of from 0 to 6, R⁷ and R^{7'} independently represent radicals as defined for R³ and amino acid side chains selected from the group consisting of valine, isoleucine, glycine, alanine, 20 allo-isoleucine, asparagine, leucine, glutamine, and t-butylglycine or R⁷ and R^{7'} together with the carbon atom to which they are attached form a cycloalkyl radical; and R⁸ represents cyano, hydroxyl, alkyl, 25 alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl and heteroaryl radicals and radicals represented by the formulas C(O)R¹⁶, CO₂R¹⁶, SO₂R¹⁶, SR¹⁶, CONR¹⁶R¹⁷, OR¹⁶, CF₃, and NR¹⁶R¹⁷ wherein R¹⁶ and R¹⁷ independently represent hydrogen and radicals as defined for R³ or 30 R¹⁶ and R¹⁷ together with a nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radicals;

R⁶ represents hydrogen and radicals as defined for R³;

35 R²⁰, R²¹, R³⁰, R³¹ and R³² represent radicals as defined for R¹, or one of R¹ and R³⁰ together with one of R³¹ and R³² and the carbon atoms to which they are attached form a cycloalkyl radical; or R³⁰ and R³² together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical; and

40 R³³ and R³⁴ independently represent hydrogen and radicals as defined for R³, or R³³ and R³⁴ together with X'


-176-

represent cycloalkyl, aryl, heterocyclyl and heteroaryl radicals, provided that when X' is O, R³⁴ is absent.

2. Compound represented by the formula:

5

10



15 wherein

R represents hydrogen and alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclioxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, alkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminoalkylcarbonyl, aminoalkanoyl radicals, alkylaminoalkylcarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroalkyl, heterocycloalkylalkyl radicals;

30

R' represents hydrogen and radicals as defined for R³, or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical;

35

R¹ represents -CH₂SO₂NH₂, CO₂CH₃, CONH₂, alkyl and cycloalkyl radicals, and amino acid side chains selected from the group of asparagine, S-methyl cysteine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, histidine, norleucine,

40

-177-


glutamine, glycine, allo-isoleucine, alanine,
threonine, isoleucine, leucine, tert-
leucine, phenylalanine, ornithine, allo-threonine,
serine, aspartic acid, beta-cyano alanine and valine
side chains;

$R^{1'}$ and $R^{1''}$ independently represent hydrogen and radicals
as defined for R^1 ;

R^2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl,
and aralkyl radicals, which radicals are optionally
substituted with a group selected from halogen
radicals and $-NO_2$, $-OR^9$ and SR^9 wherein R^9 represents
hydrogen and alkyl radicals;

R^3 represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl,
heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and
heteroaralkyl radicals;

R^4 represents hydrogen and radicals as defined by R^3 ; B
represents radicals represented by the formula:



wherein

n represents an integer of from 0 to 6, R^7 and $R^{7'}$
independently represent radicals as defined for R^3 and
amino acid side chains selected from the group
consisting of valine, isoleucine, glycine, alanine,
allo-isoleucine, asparagine, leucine, glutamine, and
t-butylglycine or R^7 and $R^{7'}$ together with the carbon
atom to which they are attached form a cycloalkyl
radical; and R^8 represents cyano, hydroxyl, alkyl,
alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl
and heteroaryl radicals and radicals represented by
the formulas $C(O)R^{16}$, CO_2R^{16} , SO_2R^{16} , SR^{16} , $CONR^{16}R^{17}$, OR^{16} ,
 CF_3 and $NR^{16}R^{17}$ wherein R^{16} and R^{17} independently

-178-

represent hydrogen and radicals as defined for R^3 or R^{16} and R^{17} together with a nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radicals.

- 5 R^6 represents hydrogen and radicals as defined for R^3 ; t represents 0 or 1; and Y and Y' independently represent 0 and S.

3. Compound of Claim 2 wherein R represents aralkoxycarbonyl and heteroaryl radicals.

- 10 4. Compound of Claim 2 wherein R represents carbobenzoxy, 2-benzofurancarbonyl and 2-quinolinylcarbonyl radicals.

5. Compound of Claim 2 wherein R represents carbobenzoxy radicals.

- 15 6. Compound of Claim 2 wherein R represents 2-quinolinylcarbonyl and 2-benzofurancarbonyl radicals.

7. Compound of Claim 2 wherein R^1 represents alkyl radicals and amino acid side chains selected from
20 the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, S-methyl cysteine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine.

8. Compound of Claim 2 wherein R^1 represents
25 methyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine and allo-threonine
30 side chains.

9. Compound of Claim 2 wherein R^1 represents methyl and t-butyl radicals.

10. Compound of Claim 2 wherein R^1 represents a t-butyl radical.

- 35 11. Compound of Claim 2 wherein R^1 represents amino acid side chains selected from asparagine, valine, alanine and isoleucine side chains.

-179-

12. Compound of Claim 2 wherein R^1 represents amino acid side chains selected from asparagine, isoleucine and valine side chains.

13. Compound of Claim 6 wherein R^1 represents an asparagine side chain.

14. Compound of Claim 2 wherein R^1 represents a t-butyl radical and R represents alkanoyl, aralkanoyl, aryloxyalkanoyl, and arylalkyloxycarbonyl radicals.

15. Compound of Claim 2 wherein R^1 represents a methyl radical when t is 1.

16. Compound of Claim 2 wherein t is 0.

17. Compound of Claim 2 wherein t is 1.

18. Compound of Claim 2 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula $-OR^9$ and $-SR^9$ wherein R^9 represents alkyl radicals.

19. Compound of Claim 2 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals.

20. Compound of Claim 2 wherein R^2 represents aralkyl radicals.

21. Compound of Claim 2 wherein R^2 represents $CH_3SCH_2CH_2-$, iso-butyl, n-butyl, benzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

22. Compound of Claim 2 wherein R^2 represents an n-butyl and iso-butyl radicals.

23. Compound of Claim 2 wherein R^2 represents benzyl and 2-naphthylmethyl radicals.

24. Compound of Claim 2 wherein R^2 represents a cyclohexylmethyl radical.

25. Compound of Claim 2 wherein R^3 , represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl and heteroaralkyl radicals.

26. Compound of Claim 25 wherein R_4 represents hydrogen.

27. Compound of Claim 25 wherein R^3 and R^4 independently represent alkyl and alkenyl radicals.

-180-

28. Compound of Claim 26 wherein R^3 and R^4 independently represent alkyl and hydroxyalkyl radicals.

29. Compound of Claim 26 wherein R^3 and R^4 independently represent alkyl, cycloalkyl and
5 cycloalkylalkyl radicals.

30. Compound of Claim 26 wherein R^7 and $R^{7'}$ independently represent alkyl and aralkyl radicals or together with the carbon atom to which they are attached form a cycloalkyl radical having from 3 to about 6
10 carbon atoms.

31. Compound of Claim 26 wherein R^7 and $R^{7'}$ independently represent methyl and ethyl radicals or R^7 and $R^{7'}$ together with the carbon atom to which they are attached represent cyclopropyl, cyclobutyl, cyclopentyl
15 and cyclohexyl radicals.

32. Compound of Claim 26 wherein R^7 and $R^{7'}$ are both methyl.

33. Compound of Claim 2 wherein R^3 represents alkyl radicals having from about 2 to about 5 carbon
20 atoms.

34. Compound of Claim 2 wherein R^3 represents n-hexyl, n-pentyl, n-propyl, i-butyl, neo-pentyl, i-amyl and n-butyl radicals.

35. Compound of Claim 2 wherein R^7 and $R^{7'}$ together with the carbon atom to which they are attached represent cyclopropyl, cyclobutyl, cyclopentyl and
25 cyclohexyl radicals.

36. Compound of Claim 2 wherein R^3 represents benzyl, para-fluorobenzyl, para-methoxybenzyl, para-methylbenzyl, and 2-naphthylmethyl radicals. 37.

Compound of Claim 32 where n is 0 and R^8 represents alkylcarbonyl, aryl, aroyl, aralkanoyl, cyano and alkoxy carbonyl.

38. Compound of Claim 37 where R^8 represents
35 methylcarbonyl, phenyl and cyano, COOH,

39. Compound of Claim 37 where R^8 represents methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl and benzyloxycarbonyl.

-181-

40. Compound of Claim 37 where R^8 represents -COOH.
41. Compound of Claim 32 where n is 1 or 2 and R^8 represents alkoxycarbonyl, hydroxycarbonyl, arylsulfonyl, alkylsulfonyl, alkylthio, hydroxyl, alkoxy, aryloxy, aryl, heteroaryl and mono- and disubstituted radicals.
42. Compound of Claim 32 where n is 1 or 2 and R^8 represents N,N-dialkylamino or N-heterocyclamine.
43. Compound of Claim 41 where n is 1 and R^8 represents methoxycarbonyl and hydroxycarbonyl.
44. Compound of Claim 41 where n is 1 and R^8 represents methylsulfonyl, methylthio and phenylsulfonyl.
45. Compound of Claim 41 where n is 1 and R^8 is hydroxy or methoxy.
46. Compound of Claim 41 where n is 1 and R^8 is phenyl or 4-pyridyl or 4-pyridyl N-oxide.
47. Compound of Claim 41 where n is 1 and R^8 is dimethylaminocarbonyl.
48. Compound of Claim 42 where R^8 represents N,N-dimethylamino, 1-piperidinyl, 4-morpholinyl, 4-(N-methyl)piperazinyl, 1-pyrrolidinyl.
49. Compound of Claim 48 where n is 1 and R^8 represents 4-morpholinyl.
50. Compound of Claim 48 where n is 2 and R^8 represents 4-morpholinyl, N,N-dimethylamino and 4-(N-methyl)piperazinyl.
51. Compound of Claim 35 where n is 0 and R^8 represents methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl and methylcarbonyl.
52. Compound of Claim 35 where n is 0 and R^8 represents methylcarbonyl.
53. Compound of Claim 2 wherein R^3 represents heteroaralkyl radicals.
54. Compound of Claim 2 wherein R^3 is a p-fluorobenzyl radical.

-182-

55. Compound of Claim 2 wherein R^3 is a 4-pyridylmethyl radical or its N-oxide derivative.

56. Compound of Claim 2 wherein R^3 represents an i-amyl radical.

5 57. Compound of Claim 35 wherein n is 1 and R^8 represents a 4-pyridyl radical.

58. Compound of Claim 2 wherein R^1 and $R^{1'}$ are both hydrogen and $R^{1''}$ represents an alkyl radical having from 1 to about 4 carbon atoms.

10 59. Compound of Claim 2 wherein R^1 and $R^{1'}$ are both hydrogen and $R^{1''}$ represents $-CH_2SO_2NH_2$, CO_2CH_3 , $CONH_2$, alkyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cystine and the sulfone and sulfoxide derivatives thereof, histidine,
15 norleucine, glutamine, glycine, allo-isoleucine, alanine, threonine, isoleucine, leucine, tert-leucine, phenylalanine, ornithine, allo-threonine and valine side chains.

20 60. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

61. A pharmaceutical composition comprising a compound of Claim 2 and a pharmaceutically acceptable carrier.

25 62. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 60.

63. Method of Claim 60 wherein the retroviral protease is HIV protease.

30 64. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 60.

65. Method of Claim 64 wherein the retroviral infection is an HIV infection.

35 66. Method for treating AIDS comprising administering an effective amount of a composition of Claim 60.

-183-

67. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 61.


68. Method of Claim 67 wherein the retroviral protease is HIV protease.

69. Method for treating a retroviral infection comprising administering an effective amount of a composition of Claim 61.

70. Method of Claim 69 wherein the retroviral infection is an HIV infection.

71. Method for treating AIDS comprising administering an effective amount of a composition of Claim 61.

72. Compound represented by the formula:



25 wherein

R' represents radicals as defined for R³;

R¹ represents -CH₂SO₂NH₂, CO₂CH₃, CONH₂, alkyl and cycloalkyl radicals and amino acid side chains selected from asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, threonine, allo-threonine, isoleucine, histidine, norleucine, valine, glutamine serine, aspartic acid and beta-cyano alanine side chains;


R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals optionally substituted with a group selected from -NO₂, -OR⁹, -SR⁹, and halogen radicals, wherein R⁹ represents hydrogen and alkyl radicals;

-184-

R^3 represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl radicals;

5 R^4 represents hydrogen and radicals as defined for R^3 ;

B represents radicals represented by the formula:



10

15

20

wherein

25 n represents an integer of from 0 to 6, R^7 and $R^{7'}$ independently represent radicals as defined for R^3 and amino acid side chains selected from the group consisting of valine, isoleucine, glycine, alanine, allo-isoleucine, asparagine, leucine, glutamine, and

30 t-butylglycine or R^7 and $R^{7'}$ together with the carbon atom to which they are attached form a cycloalkyl radical; and R^8 represents cyano, hydroxyl, alkyl, alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl and heteroaryl radicals and radicals represented by

35 the formulas $C(O)R^{16}$, CO_2R^{16} , SO_2R^{16} , SR^{16} , $CONR^{16}R^{17}$, CF_3 and $NR^{16}R^{17}$ wherein R^{16} and R^{17} independently represent hydrogen and radicals as defined for R^3 or R^{16} and R^{17} together with a nitrogen to which they are attached represent heterocycloalkyl and heterocaryl radicals;

40 R^{20} and R^{21} represent radicals as defined for R^1 ; and

Y and Y' independently represent O and S.

73. Compound of Claim 72 wherein t is O.

74. Compound of Claim 72 wherein R^1 represents hydrogen and alkyl radicals.

-185-

75. Compound of Claim 72 wherein R^1 represents alkyl radicals having from 1 to about 4 carbon atoms.

76. Compound of Claim 72 wherein R^1 represents methyl, ethyl, isopropyl and t-butyl radicals.

5 77. Compound of Claim 72 wherein R^{20} and R^{21} independently represent hydrogen and alkyl radicals.

78. Compound of Claim 72 wherein R^{20} and R^{21} independently represent hydrogen and methyl radicals.

10 79. Compound of Claim 72 wherein R^{20} is hydrogen and R^{21} is an alkyl radical.

80. Compound of Claim 72 wherein R^1 represents alkyl, aryl and aralkyl radicals.

81. Compound of Claim 72 wherein R^1 is selected from methyl and phenethyl radicals.

15 82. Compound of Claim 72 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula $-OR^9$ and $-SR^9$ wherein R^9 represents alkyl radicals.

20 83. Compound of Claim 72 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals.

84. Compound of Claim 72 wherein R^2 represents aralkyl radicals.

25 85. Compound of Claim 72 wherein R^2 represents $CH_3SCH_2CH_2-$, iso-butyl, n-butyl, benzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

86. Compound of Claim 72 wherein R^2 represents an n-butyl and iso-butyl radicals.

30 87. Compound of Claim 72 wherein R^2 represents benzyl and 2-naphthylmethyl radicals.

88. Compound of Claim 72 wherein R^2 represents a cyclohexylmethyl radical.

35 89. Compound of Claim 72 wherein R^3 , represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, aralkyl and heteroaralkyl radicals.

-186-

90. Compound of Claim 89 wherein R^4 represents hydrogen.
91. Compound of Claim 89 wherein R^3 represents alkyl and alkenyl radicals.
- 5 92. Compound of Claim 90 wherein R^3 represents alkyl and hydroxyalkyl radicals.
93. Compound of Claim 90 wherein R^3 represents alkyl, cycloalkyl and cycloalkylalkyl radicals.
- 10 94. Compound of Claim 90 wherein R^3 represents alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.
95. Compound of Claim 90 wherein R^3 represents alkyl, aryl and aralkyl radicals.
- 15 96. Compound of Claim 90 wherein R^3 represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals.
97. Compound of Claim 72 wherein R^3 represents alkyl radicals having from about 2 to about 5 carbon
20 atoms.
98. Compound of Claim 72 wherein R^3 represents n-propyl, i-butyl, n-pentyl, neo-pentyl, i-amyl, n-hexyl and n-butyl radicals.
99. Compound of Claim 72 wherein R^4 represents
25 hydrogen.
100. Compound of Claim 72 wherein R^3 represents benzyl, para-fluorobenzyl, para-methoxybenzyl, para-methylbenzyl, and 2-naphthylmethyl radicals.
- 30 101. Compound of Claim 72 wherein R^7 and $R^{7'}$ independently represent alkyl and aralkyl radicals or together with the carbon atom to which they are attached form a cycloalkyl radical having from 3 to about 6 carbon atoms.
- 35 102. Compound of Claim 72 wherein R^7 and $R^{7'}$ independently represent methyl and ethyl radicals or R^7 and $R^{7'}$ together with the carbon atom to which they are

-187-

attached represent cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals.

103. Compound of Claim 72 wherein R^7 and $R^{7'}$ are both methyl.

5 104. Compound of Claim 72 wherein R^3 represents alkyl radicals having from about 2 to about 5 carbon atoms.

105. Compound of Claim 72 wherein R^7 and $R^{7'}$ together with the carbon atom to which they are attached
10 represent cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals.

106. Compound of Claim 90 where n is 0 and R^8 represents alkylcarbonyl, aryl, aroyl, aralkanoyl, cyano and alkoxycarbonyl.

15 107. Compound of Claim 106 where R^8 represents methylcarbonyl, phenyl and cyano.

108. Compound of Claim 106 where R^8 represents methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl, benzyloxycarbonyl and COOH.

20 109. Compound of Claim 106 where R^8 represents -COOH.

110. Compound of Claim 90 where n is 1 or 2 and R^8 represents alkoxycarbonyl, hydroxycarbonyl, arylsulfonyl, alkylsulfonyl, alkylthio, hydroxyl,
25 alkoxy, aryloxy, aryl, heteroaryl and dialkylaminocarbonyl.

111. Compound of Claim 90 where n is 1 or 2 and R^8 represents N,N-dialkylamino or N-heterocyclamine.

30 112. Compound of Claim 110 where n is 1 and R^8 represents methoxycarbonyl and hydroxycarbonyl.

113. Compound of Claim 110 where n is 1 and R^8 represents methylsulfonyl, methylthio and phenylsulfonyl.

114. Compound of Claim 110 where n is 1 and R^8
35 is hydroxy or methoxy.

115. Compound of Claim 110 where n is 1 and R^8 is phenyl or 4-pyridyl or 4-pyridyl N-oxide.

-188-

116. Compound of Claim 110 where n is 1 and R⁸ is dimethylaminocarbonyl.

117. Compound of Claim 111 where R⁸ represents N,N-dimethylamino, 1-piperidinyl, 4-morpholinyl, 4-(N-methyl)piperazinyl, 1-pyrrolidinyl.

118. Compound of Claim 117 where n is 1 and R⁸ represents 4-morpholinyl.

119. Compound of Claim 117 where n is 2 and R⁸ represents 4-morpholinyl, N,N-dimethylamino and 4-(N-methyl)piperazinyl.

120. Compound of Claim 90 where n is 0 and R⁸ represents methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl and methylcarbonyl.

121. Compound of Claim 90 where n is 0 and R⁸ represents methylcarbonyl.

122. A pharmaceutical composition comprising a compound of Claim 72 and a pharmaceutically acceptable carrier.

123. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 122.

124. Method of Claim 123 wherein the retroviral protease is HIV protease.

125. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 122.

126. Method of Claim 125 wherein the retroviral infection is an HIV infection.


127. Method for treating AIDS comprising administering an effective amount of a composition of Claim 122.

128. Compound represented by the formula:

35

40

-189-



10

wherein

R^1 represents $-\text{CH}_2\text{SO}_2\text{NH}_2$, CONH_2 , CO_2CH_3 , alkyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, allo-

15 isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, threonine, allo-threonine, isoleucine, histidine, norleucine, valine, glutamine, serine, aspartic acid and beta-cyano alanineside chains;

R^2 represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals optionally substituted with a group selected from $-\text{NO}_2$, $-\text{OR}^9$, $-\text{SR}^9$, and halogen radicals, wherein R^9 represents hydrogen and alkyl radicals;

25

R^3 represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl radicals;

30

R^4 represents hydrogen and radicals as defined by R^3 ;
 t is either 0 or 1;

X' represents O, N and $\text{C}(R^{17})$ wherein R^{17} represents hydrogen and alkyl radicals;


35 R^{30} , R^{31} and R^{32} represent radicals as defined for R^1 , or one of R^1 and R^{30} together with one of R^{31} and R^{32} and the carbon atoms to which they are attached form a cycloalkyl radical; or R^{30} and R^{32} together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical;

40

-190-

R^{33} and R^{34} independently represent hydrogen and radicals as defined for R^3 , or R^{33} and R^{34} together with X' represent cycloalkyl, aryl, heterocyclyl and heteroaryl radicals, provided that when X' is O, R^{34} is absent;

B represents radicals represented by the formula:



wherein

n represents an integer of from 0 to 6, R^7 and $R^{7'}$ independently represent radicals as defined for R^3 and amino acid side chains selected from the group consisting of valine, isoleucine, glycine, alanine, allo-isoleucine, asparagine, leucine, glutamine, and t-butylglycine or R^7 and $R^{7'}$ together with the carbon atom to which they are attached form a cycloalkyl radical; and R^8 represents cyano, hydroxyl, alkyl, alkoxy, cycloalkyl, aryl, aralkyl, heterocycloalkyl and heteroaryl radicals and radicals represented by the formulas $C(O)R^{16}$, CO_2R^{16} , SO_2R^{16} , SR^{16} , $CONR^{16}R^{17}$, $-OR^{16}$, CF_3 and $NR^{16}R^{17}$ wherein R^{16} and R^{17} independently represent hydrogen and radicals as defined for R^3 or R^{16} and R^{17} together with a nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radicals; and

Y , Y' and Y'' independently represent O and S;

129. Compound of Claim 128 wherein Y , Y' and Y'' are O.

130. Compound of Claim 128 wherein t is O.

131. Compound of Claim 128 wherein R^1 , R^{31} and R^{32} are all methyl and R^{30} is hydrogen.

132. Compound of Claim 128 wherein R^1 represents hydrogen and alkyl radicals having from 1 to

-191-

about 4 carbon atoms, aralkyl radicals, hydroxyl radicals, and radicals represented by the formula $-\text{CH}_2\text{C}(\text{O})\text{R}''$ wherein R'' represents R^{38} , $-\text{NR}^{38}\text{R}^{39}$ and $\text{R}^{38}-\text{OR}$ wherein R^{38} and R^{39} independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms.

133. Compound of Claim 128 wherein R^1 represents hydrogen, methyl, benzyl, phenylpropyl, hydroxyl and radicals represented by the formula $-\text{CH}_2\text{C}(\text{O})\text{R}''$ wherein R'' represents $-\text{CH}_3$, NH_2 and $-\text{OH}$.

134. Compound of Claim 128 wherein R^1 and R^{31} are both hydrogen and R^{30} and R^{32} are both methyl.

135. Compound of claim 128 wherein R^1 and R^{30} are both hydrogen and R^{31} and R^{32} are both methyl.

136. Compound of Claim 128 wherein R^{30} , R^{31} and R^{32} are hydrogen and R^1 is methyl.

137. Compound of Claim 128 wherein R^1 and R^{31} are both hydrogen and R^{30} and R^{32} together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical.

138. Compound of Claim 128 wherein X^1 is O and R^{33} is hydrogen and R^{34} is absent.

139. Compound of Claim 128 wherein X^1 is N, R^{33} is hydrogen and R^{34} represents an arylmethyl radical.

140. Compound of Claim 128 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula $-\text{OR}^9$ and $-\text{SR}^9$ wherein R^9 represents alkyl radicals.

141. Compound of Claim 128 wherein R^2 represents alkyl, cycloalkylalkyl and aralkyl radicals.

142. Compound of Claim 128 wherein R^2 represents aralkyl radicals.

143. Compound of Claim 128 wherein R^2 represents $\text{CH}_3\text{SCH}_2\text{CH}_2-$, iso-butyl, n-butyl, p-fluorobenzyl, benzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

144. Compound of Claim 128 wherein R^2 represents an n-butyl and iso-butyl radicals.

-192-

145. Compound of Claim 128 wherein R^2 represents benzyl and 2-naphthylmethyl radicals.
146. Compound of Claim 128 wherein R^2 represents a cyclohexylmethyl radical.
- 5 147. Compound of Claim 128 wherein R^4 represents hydrogen.
148. Compound of Claim 128 wherein R^3 represents alkyl, alkenyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, 10 heterocycloalkylalkyl, aryl, aralkyl and heteroaralkyl radicals.
149. Compound of Claim 128 wherein R^3 represents alkyl and alkenyl radicals.
150. Compound of Claim 128 wherein R^3 15 represents alkyl and hydroxyalkyl radicals.
151. Compound of Claim 128 wherein R^3 represents alkyl, cycloalkyl and cycloalkylalkyl radicals.
152. Compound of Claim 128 wherein R^3 20 represents alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.
153. Compound of Claim 147 wherein R^3 represents alkyl, aryl and aralkyl radicals.
154. Compound of Claim 147 wherein R^3 25 represents alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals.
155. Compound of Claim 147 wherein R^3 represents alkyl radicals having from about 2 to about 5 30 carbon atoms.
156. Compound of Claim 147 wherein R^3 represents i-butyl, neo-pentyl, i-amyl, and n-butyl radicals.
157. Compound of Claim 147 wherein R^3 35 represents alkyl radicals having from about 2 to about 5 carbon atoms, cycloalkylalkyl radicals, aralkyl radicals, heterocycloalkylalkyl radicals and heteroaralkyl radicals.

-193-

158. Compound of Claim 147 wherein R^3 represents benzyl, para-fluorobenzyl, para-methoxybenzyl, para-methylbenzyl, 4-pyridylmethyl, and 2-naphthylmethyl radicals.
- 5 159. Compound of Claim 147 wherein R^3 is para-fluorobenzyl.
160. Compound of Claim 147 wherein R^7 and $R^{7'}$ independently represent alkyl and aralkyl radicals or together with the carbon atom to which they are attached
10 form a cycloalkyl radical having from 3 to about 6 carbon atoms.
161. Compound of Claim 147 wherein R^7 and $R^{7'}$ independently represent methyl and ethyl radicals or R^7 and $R^{7'}$ together with the carbon atom to which they are
15 attached represent cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals.
162. Compound of Claim 147 wherein R^7 and $R^{7'}$ are both methyl.
163. Compound of Claim 147 wherein R^3
20 represents alkyl radicals having from about 2 to about 5 carbon atoms.
164. Compound of Claim 147 wherein R^7 and $R^{7'}$ together with the carbon atom to which they are attached represent cyclopropyl, cyclobutyl, cyclopentyl and
25 cyclohexyl radicals.
165. Compound of Claim 147 where n is 0 and R^8 represents alkylcarbonyl, aryl, aroyl, aralkanoyl, cyano and alkoxycarbonyl.
166. Compound of Claim 147 where R^8 represents
30 methylcarbonyl, phenyl and cyano.
167. Compound of Claim 147 where R^8 represents methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl and benzyloxycarbonyl.
168. Compound of Claim 147 where R^8 represents
35 -COOH.
169. Compound of Claim 147 where n is 1 or 2 and R^8 represents alkoxycarbonyl, hydroxycarbonyl, arylsulfonyl, alkylsulfonyl, alkylthio, hydroxyl,

-194-

alkoxy, aryloxy, aryl, heteroaryl and N,N-dialkylcarbamoyl.

170. Compound of Claim 147 where n is 1 or 2 and R⁸ represents N,N-dialkylamino or N-heterocyclylamine.

171. Compound of Claim 169 where n is 1 and R⁸ represents methoxycarbonyl and hydroxycarbonyl.

172. Compound of Claim 169 where n is 1 and R⁸ represents methylsulfonyl, methylthio and phenylsulfonyl.

173. Compound of Claim 169 where n is 1 and R⁸ is hydroxy or methoxy.

174. Compound of Claim 169 where n is 1 and R⁸ is phenyl or 4-pyridyl or 4-pyridyl N-oxide.

175. Compound of Claim 169 where n is 1 and R⁸ is dimethylaminocarbonyl.

176. Compound of Claim 170 where R⁸ represents N,N-dimethylamino, 1-piperidinyl, 4-morpholinyl, 4-(N-methyl)piperazinyl, 1-pyrrolidinyl.

177. Compound of Claim 176 where n is 1 and R⁸ represents 4-morpholinyl.

178. Compound of Claim 176 where n is 2 and R⁸ represents 4-morpholinyl, N,N-dimethylamino and 4-(N-methyl)piperazinyl.

179. Compound of Claim 147 where n is 0 and R⁸ represents methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl and methylcarbonyl.

180. Compound of Claim 147 where n is 0 and R⁸ represents methylcarbonyl.

181. A pharmaceutical composition comprising a compound of Claim 128 and a pharmaceutically acceptable carrier.

182. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 181.

183. Method of Claim 182 wherein the retroviral protease is HIV protease.

-195-

184. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 181.

185. Method of Claim 184 wherein the retroviral infection is an HIV infection.

186. Method for treating AIDS comprising administering an effective amount of a composition of Claim 180.

187. A compound of Claim 1 which is:

10 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, methyl ester, [3S-(3R*,6R*,7S*)]-

15 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(3-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1,1-dimethylethyl) ester, [3S-(3R*,6R*,7S*)]-

20 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl ester, [3S-(3R*,6R*,7S*)]-

25 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-fluorophenylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1,1-dimethylethyl) ester, [3S-(3R*,6R*,7S*)]-

30

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, methyl ester, [3S-(3R*,6R*,7S*)]-

35

2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-

-196-

- 1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl ester, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1-methylethyl) ester, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1,1-dimethylethyl) ester, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (phenylmethyl) ester, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-pyridylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, ethyl ester, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(4-pyridylmethyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, (1,1-dimethylethyl) ester, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylbutyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, [3S-(3R*,6R*,7S*)]-
- 2,5,9,11-Tetraazatridecan-13-oic acid, 3-(2-amino-2-oxoethyl)-7-hydroxy-12,12-dimethyl-9-(2-methylpropyl)-1,4,10-trioxo-6-(phenylmethyl)-1-(2-quinolinyl)-, [3S-(3R*,6R*,7S*)]-

-197-

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-oxoethyl)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-oxoethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-hydroxyethyl)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-hydroxyethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1-methyl-1-cyanoethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)amino]carbonyl](4-fluorophenylmethyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1,1-dimethyl-2-(4-pyridyl)ethyl)amino]carbonyl](3-methylbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]

Butanediamide, N¹-[3-[[[(1,1-dimethyl-3-(4-morpholinyl)propyl)amino]carbonyl](4-fluor-

-198-

phenylmethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-
2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

5 Butanediamide, N¹-[3-[[[1,1-dimethyl-3-(4-
morpholinyl)propyl]amino]carbonyl][(3-methy-
lbutyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-
quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

10 Butanediamide, N¹-[3-[[[1,1-dimethyl-2-(4-
morpholinyl)ethyl]amino]carbonyl][(4-fluor-
ophenylmethyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-
2-[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

15 Butanediamide, N¹-[3-[[[1,1-dimethyl-2-(4-
morpholinyl)ethyl]amino]carbonyl][3-methylbutyl]amino]-
2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-
quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

20 Butanediamide, N¹-[3-[[[1,1-dimethyl-3-(4-(1-
methylpiperazinyl)propyl]amino]carbonyl][3-
methylbutyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-
[(2-quinolinylcarbonyl)amino]-, [1S-[1R*(R*),2S*]]-

25 Preparation of butanediamide, N-[3-[[[1,1-dimethyl-5-
(4-morpholinyl-3-oxapentyl]-amino]carbonyl][3-
methylbutyl]amino]-2-hydroxy-1-phenylmethyl)propyl]-2-
[(2-quinolinyl-carbonyl)amino]-, [1S-[1R*(R*),2S*]]-

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 91/08617

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶					
According to International Patent Classification (IPC) or to both National Classification and IPC					
Int.CI.5	C 07 D 215/48	C 07 D 295/13	C 07 C 311/46		
C 07 C 311/47	C 07 C 317/50	C 07 C 323/60	C 07 C 275/14		
II. FIELDS SEARCHED					
Minimum Documentation Searched ⁷					
Classification System		Classification Symbols			
Int.CI.5		C 07 C C 07 D C 07 K			
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸					
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹					
Category [°]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²			Relevant to Claim No. ¹³	
X	GB,A,2184730 (SQUIBB) 1 July 1987, see claims (cited in the application)			1-61	
X	EP,A,0264795 (MERCK) 27 April 1988, see claims (cited in the application)			1-61	
X	GB,A,2200115 (SANDOZ) 27 July 1988, see claims (cited in the application)			1-61	
X	US,H, 725 (E.M. GORDON) 2 January 1990, see whole document (cited in the application)			1-61	
	--- -/-				
<p>[°] Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>					
IV. CERTIFICATION					
Date of the Actual Completion of the International Search			Date of Mailing of this International Search Report		
02-03-1992			- 3. 04. 92		
International Searching Authority			Signature of Authorized Officer		
EUROPEAN PATENT OFFICE			Marie Pez		

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	<p>The EMBO Journal, vol. 8, no. 8, 1989, (Oxford, GB), A. SALI et al.: "High resolution X-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor: the analysis of the inhibitor binding and description of the rigid shift in the enzyme", pages 2179-2188, see page 2180, column 1, formula</p> <p>-----</p>	1

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers ** because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 62-71, 123-127, 182-186 are directed to a method of treatment of the human /animal body, the search has been carried out and based on the alleged effects of the compounds

2. ☐ Claim numbers because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

3. ☐ Claim numbers because they are dependant claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ supplemental sheet(2)

**** Claims searched incompletely: 1-186**

The use of terms such as heteroaryl and heterocyclyl are in contradiction to the requirements of Art. 6 PCT. The search was performed on the basis of those claims which are clear and concise and of those examples in the description which are complete and correct.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9108617
SA 54381

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/03/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 2184730	01-07-87	DE-A- 3643977	02-07-87
		FR-A- 2592048	26-06-87
		JP-A- 62164658	21-07-87
		US-A- 4757050	12-07-88
EP-A- 0264795	27-04-88	DE-A- 3635907	28-04-88
		AU-A- 7982387	28-04-88
		JP-A- 63112548	17-05-88
		ZA-A- 8707950	26-04-88
GB-A- 2200115	27-07-88	AU-A- 1037588	01-09-88
		BE-A- 1002212	16-10-90
		CH-A- 676988	28-03-91
		DE-A- 3800591	04-08-88
		FR-A- 2609716	22-07-88
		JP-A- 1019053	23-01-89
		LU-A- 87110	23-08-88
		NL-A- 8800100	16-08-88
		SE-A- 8800169	22-07-88
US-H- 725	02-01-90	None	